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 Abstract  
 
Recombinant human P450s are important in preclinical studies to discover possible 
interactions between drugs when taking medicines. Drugs may be either inhibitors or 
substrates for P450s. Some P450s also play a major role in cancer and other diseases.  
 
Recombinant P450s offer better activity, availability and consistency than primary 
hepatocytes. In this thesis, a recombinant P450 expression system in yeast was 
developed with the aim of providing a cost-effective way of producing human P450 
enzymes upon the yeast’s endoplasmic reticulum (ER). These ER-bound P450s are 
usually referred to as microsomal P450s.  
 
A yeast expression system was used to co-express several human P450s and their 
reductases, essential for P450 activities. Episomal and chromosomally integrating 
plasmids with auxotrophic markers were used to build the system. Gene expression was 
by either GAL1 promoter (galactose inducible) or ADH2 promoter (ethanol inducible).  
High level P450 expressions and activities were optimised by the effect of different 
growth media. It was found that by using different media conditions for recombinant 
protein expression, P450 activities could be improved.  
 
Efforts were made to produce P450 proteins in fermentors. For these larger-scale 
cultures, a cheaper, cost effective alternative to lyticase-mediated cell wall lysis was 
developed; it involves mechanical cell disruption- without degrading the microsomes. 
For large volumes, fractionation of microsomes by ultracentrifugation was unfeasible so 
a procedure was established that allows precipitation using polyethylene glycol (PEG).  
 
Recombinant P450s are extremely temperature-sensitive. They are stable only at minus 
80°C and rapidly lose activity at room temperature. Lyophilisation is known to extend 
the shelf-life of recombinant proteins. Although lyophilisation is a harsh procedure 
which could shear the P450 proteins, from the microsomal membranes, it was found it 
could stabilise P450 activity so that the enzymes could be kept at room temperatures for 
weeks. The process was extensively optimised using a variety of different buffers and 
lyophilisation conditions and it was confirmed that:  
 
(a) Recombinant microsomal P450s produced from yeast, insect and bacterial cells 
could be stabilised using lyophilisation; 
  
(b) The lyophilised P450s could be plated out in 96-well microtitre plates and the 
plates could be kept at ambient temperature (+21°C) for weeks without losing 
activity, indicating that the process was robust; 
 
(c) The lyophilised enzymes and un-lyophilised samples behaved in the same way 
regarding their, potency towards known inhibitors, in fluorometric/ mass 
spectrometry assays and shipment to overseas destinations for P450 activity 
testing. 
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 List of abbreviations and useful terms 
 
Abs  Absorbance of light 
ADE2 Pertaining to a particular gene or enzyme in the adenine anabolism 
pathway that when knocked out produces an auxotrophic requirement for 
plasmid selection. 
ADH  Pertaining to the alcohol dehydrogenase gene or protein. 
AEBSF A protease inhibitor used to prevent P450 degradation. 
AMMC Gentest substrate for CYP2D6, 3-[2-(N,N-Diethyl-N-
methylammonium)ethyl]-7-methoxy-4-methylcoumarin 
APCI-ESI Atmospheric-pressure chemical ionization-electrospray ionization 
method for mass spectrometry. 
b5  A protein that may donate an electron to a P450. 
b5 reductase  A redox partner of b5. 
BD (Gentest) Becton Dickinson, a major supplier of medical objects and biologicals. 
bp  Base pair, two complementary opposing nucleotides from each DNA 
strand that are connected by hydrogen bonds. 
Buffer A/ Sorbitol buffer A sorbitol buffer used for preparing microsomes. 
Buffer B A sorbitol buffer used for yeast lytic enzyme and sonication. 
Buffer C A glycerol buffer for storage of microsomes at -80°C.  
CO  Carbon monoxide gas. 
CEC  3-Cyano-7-ethoxycoumarin, substrate for CYP1A2. 
CPR  Cytochrome P450 reductase. 
CYP  Cytochrome P450. 
DBF  Dibenzylfluorescein a CYP2C8 substrate 
DBOMF An Invitrogen substrate for CYP3A4. 
DTT   Dithiothreitol, used to stabilise proteins.  
DHAP  Dihydrooxyacetone phosphate. 
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 DO  Dissolved oxygen in a solution. 
EDTA  Ethylene diamine tetra acetic acid.  
EOMCC An Invitrogen 2D6 substrate 
EROD  Ethoxyresorufin, A CYP1 family substrate.  
FMN Flavin mononucleotide, a prosthetic group of oxidoreductase proteins, 
enzymes that transfer electrons. 
G3P  Glycerol-3-phosphate. 
G6PDH  Glucose-6-phosphate dehydrogenase, part of P450 artificial regenerating 
system.  
G6P  Glucose-6-phosphate  
GAL Pertaining to the galactose metabolism gene, promoter region or 
transcription factor.  
GAPDH Glyceraldehyde 3-phosphate dehydrogenase. 
HIS3 Pertaining to a particular gene or enzyme in the histidine anabolism 
pathway that when knocked out produces an auxotrophic requirement for 
plasmid selection. 
HRD   Human P450 reductase.  
KPSI  Thousdands of pounds per square inch. 
LB   Luria-Bertani, bacterial media.  
LEU2 Pertaining to a particular gene or enzyme in the lucine anabolism 
pathway that when knocked out produces an auxotrophic requirement for 
plasmid selection. 
LEU2d LEU2 gene with a defective promoter to encourage increased copy 
number of the plasmid that bears it.  
LCMS A combination of high performance liquid chromatography and mass 
spectrometry. 
NAD+ β-Nicotinamide adenine dinucleotide, redox agent, oxidising agent, 
accepts electrons to become reduced.  
NADH β-Nicotinamide adenine dinucleotide, redox agent, reducing agent 
donates electrons. 
5 
 
 NADP  β-Nicotinamide adenine dinucleotide phosphate, redox agent, accepts 
electrons to become reduced.  
NADPH β-Nicotinamide adenine dinucleotide phosphate, redox agent, reducing 
agent donates electrons. 
NAD(P)H A designation meaning either NADH or NADPH. 
nm  Nanometres, wavelength.  
OD   Optical density.  
P450 An enzyme that was thought of as a Pigment that absorbed strongly in 
the 450 nm wavelength region. 
PAH  Polyaromatic hydrocarbons. 
Reductase An enzyme that supplies electrons to another protein. 
RF(L)U  Relative fluorescence (light) units, a dimensionless and arbitrary but 
proportional amount of light emission detected.    
rpm  Revolutions per minute.  
S9 fraction Cell lysate with large organelles and debris removed   
SD  A kind of yeast minimal media. 
SOC  A bacterial media used in plasmid transformations 
Solution A  Part of the artificial P450 regenerating system containing the enzyme 
substrate and NADP. 
Solution B Part of the artificial P450 regenerating system containing the enzyme for 
solution A. 
SW6  A minimal broth of YNB, glucose and casamino acids. 
TRP1  Pertaining to a particular gene or enzyme in the tryptophan anabolism 
pathway that when knocked out produces an auxotrophic requirement for 
plasmid selection. 
TEMED  N,N,N’,N’,-tetramethylethylenediamine, for the polymerisation of 
acrylamide gels.    
U   A Unit of enzyme activity. 
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 URA3  Pertaining to a particular gene or enzyme in the uracil anabolism 
pathway that when knocked out produces an auxotrophic requirement for 
plasmid selection. 
YNB  Yeast nitrogen base, mainly an ammonium salt. 
YPG  A yeast media with yeast extract, peptone and glycerol. 
YRD   Pertaining to the yeast’s P450 reductase 
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 Chapter 1  Introduction  
1.0  Statement of purpose 
 
The purpose of this research was to:  
i. Produce different human cytochrome P450 (CYP) enzymes, bound to 
microsomal membranes, using a yeast (Saccharomyces cerevisiae) expression 
system; 
ii. Characterise the produced P450 enzymes for their concentrations and activities; 
iii. Attempt to reduce the time spent for production of microsome-bound P450 
enzymes and, hence, reduce overall costs; 
iv. Investigate if the fragile microsome-bound P450 (CYP) enzymes were at all 
capable of retaining activity after lyophilisation and if the process allowed any 
degree of temperature-stability; P450s are well known for (a) being stable only 
at minus 80°C (-80°C) and (b) rapidly losing activity at ambient temperature, 
+21°C.  
 
1.1  A brief overview of cytochrome P450s 
 
Cytochrome P450s (CYPs) are enzymes that are found across different biological 
kingdoms and are of great interest because of their: 
 Use in the modification/removal of xenobiotics, which are exogenous chemicals 
harmful to humans; 
 Involvement in the turnover of compounds endogenous to the human body and 
which are crucial for human existence; 
 Use in the development of new medicines for treatment of human disease; 
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  Use as biomarkers for gauging pollution and possible environmental 
bioremediation; 
 Involvement in the genesis of human diseases; 
 Possible use in biotransformation reactions, which are invaluable in the 
synthesis of high-value chemicals, mimicking the pathways followed by nature. 
It has been mentioned that P450s may have been important for development of life on 
Earth in response to environments that contained toxic molecules (Hasler et al., 1999).  
Humans are exposed to natural compounds, foods, medicinal plants, medicines and 
pollution. These contain compounds that are lipophilic and so will not exit the body 
without conversion to soluble hydrophilic substances and further conjugations that 
allow easy excretion. The processes of excretion involve Phase I solubilisation reactions 
which are mediated by P450 enzymes; Phase II metabolism involves conjugation of the 
solubilised substances to an ionized group that facilitate excretion (Rang, Ritter and 
Dale, 1999).  
It is still unclear why there are so many different kinds of cytochrome P450s within 
most species. The rice plant (Oryza sativa), for example, has 356 P450s and 99 P450 
pseudogenes (Nelson et al., 2004). Most plants have 400-500 P450s. Under laboratory-
based experimental conditions, many human P450s demonstrate cross reactivity with a 
wide range of substrates and inhibitors. It is difficult to understand why a particular 
organism may have so many enzymes with overlapping reactions. However, affinity for 
specific substrates and the IC50 values of inhibition using specific compounds vary 
greatly indicating that there must be subtle differences in their modes of action (Donato 
et al., 2004).  
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 In humans, many P450s are tissue-specific and often require their genes to be induced 
implying that they are not constitutively expressed.  
 
1.2  Biochemistry of cytochrome P450s 
 
Generally, electron transport chains use cytochromes and their interactions with 
NAD(P)H and similar molecules to generate energy (Madigan et al., 2002). These haem 
proteins not only assist in the generation of hydrogen ions but can also transport gases 
within organisms allowing the development of complex life forms (Sandman, 1985). 
The iron chelated to the porphyrin ring is used for electron transport.  
A porphyrin is a ringed group of four pyrroles that forms a macrocycle, Figure 1.1. The 
metal ion of iron, in a 2+ or 3+ state, sits at the centre of the ring and chelates with the 
lone pairs of electrons present on the nitrogen atoms of the four pyrroles 
(Krishnamurthy et al., 2007) to form haem, which acts as a cofactor for the P450 
enzymes.  
Interaction of a haem with the cytochrome P450s is mediated by chelation of the Fe3+ to 
the ‘S’ of the –SH (thiol) group of a specific cysteine (an amino acid) contained in the 
P450. This is depicted in Figure 1.2 (Rabe et al., 2008). 
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 Figure 1.1. The Porphyrin macrocycle.  
 
  
Figure 1.1.  The porphyrin ring consists of a group of four pyrroles which form a macrocycle. This goes 
on to form the haem group through coordination of Fe3+ iron with the four nitrogen atoms of the four 
pyrroles. 
 
Figure 1.2. A haem group interacts with P450s through coordination 
of the iron to the sulphur of a specific cysteine amino acid 
residue present in all P450s.  
 
 
Figure 1.2. The porphyrin ring contains four pyrroles. Iron in the Fe3+ (Fe III) state chelates with the ‘N’ 
atom of the four pyrroles of the porphyrin ring to form haem which ultimately binds to a P450 to form a 
haem-protein. As an example of how a haem-protein (haem-P450) is formed, the haem group is held in 
place via hydrogen bonds; in the case of CYP2D6 (P450-2D6), the hydrogen bonds are formed by 
interactions of CYP2D6’s amino acid residues Arg-101, Arg-132, Arg-444 (arginine being a dibasic 
amino acid), Trp-128 (a pyrrole-containing amino acid), His-437 (an imidazole-containing amino acid) 
with the –COOH moieties of the haem macrocycle. However, chelation through formation of a 
‘coordination’ bond occurs only when the haem Fe3+ chelates with the –SH (thiol group) of the cysteine 
residue 443 in CYP2D6. Similar interactions with cysteine thiols occur in all P450s.  
 
N
H
N
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 In eukaryotic cells, P450s are normally membrane bound. When P450s are removed 
from their membranes their activity is diminished or completely lost (Smith et al., 
1974). The N-terminal amino acids of P450s are hydrophobic and therefore can embed 
themselves in lipid membranes, normally upon the smooth endoplasmic reticulum, an 
intracellular compartment that exists in all eukaryotic cells. The P450 activity is 
dependent on both lipids and proteins present in the endoplasmic reticular (ER) 
membranes. Because of this, it has been postulated that ER’s lipid components and their 
proteins have co-evolved together (Simons, 2010). In the laboratory, isolating the 
fragile ER membranes, embedded with recombinant P450 proteins (known as 
microsomal P450s), is quite a challenge. The microsomes must be isolated from the cell 
lysates and separated from the soluble cellular fractions and other intracellular 
organelles.  
The observation that haem proteins possess carbon monoxide (CO) gas-binding 
properties led to the precursor of the assay that is currently used to quantify P450 
concentrations, present in recombinant and human liver microsomes, in the laboratory. 
In the late nineteenth century, Haldane & Smith (1896) had demonstrated that inhalation 
of small known amounts of CO gas, from bags, allowed estimation of blood 
haemoglobin levels. This observation was confirmed in 1919 by Salvesen (Salvesen, 
1919).  
Spectrophotometric developments in the 1950s (Chance & Legallais, 1951) allowed 
high quality spectral data to be obtained and created the premise for the discovery by 
Martin Klingenberg of “the presence of a new CO binding pigment” (Klingenberg, 
1958). At the same time, David Garfinkel made a very similar discovery (Garfinkel, 
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 1958). Klingenberg observed an absorbance peak of a pigment at the wavelength of 450 
nm (Pigment 450; hence, the name P450) in rat liver microsomes. Garfinkel obtained 
identical results using pig liver microsomes. Klingenberg had thought the pigment was a 
single cytochrome similar to cytochrome b5. A few years later, Omura and Sato 
published their paper describing “the nature and function” of the new pigment (Omura 
& Sato, 1962). 
Cytochrome P450s’ role as functional proteins that could be useful for drug metabolism 
studies was revealed three years later by Cooper et al (1965). They demonstrated that 
several different chemical reactions performed by rat and cow microsomes, on various 
drug compounds, were mediated only by CO-binding pigments which absorbed light.  
 
1.3  Evolution of cytochrome P450s 
 
In 1989, only sixteen P450s were known (Guengerich, 1989). During the 1980s, the 
idea emerged that all P450 genes diverged from an ancestral gene about 2 billion years 
ago with the P450 reductase (i.e. an enzymatic protein essential for P450 enzyme 
activity) possibly being a bridging product (Nerbert et al., 1989). It was also suggested 
that the few mitochondrial P450s that exist in mammalian livers originated earlier, in 
evolution, than the microsomal ones. The role of the few mitochondrial P450s in 
mammals is specifically in the syntheses of endogenous steroidal molecules. They are 
reduced (i.e. activated) by the iron-sulphur protein, adrenodoxin. Plants do not have 
P450s in their mitochondria. Therefore, it would seem that a significant evolutionary 
event occurred after animals and plants diverged (Omura, 2006).  
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 It is thought that the diverse role of microsomal P450s may have somehow evolved 
through the microsomal redox partner (i.e. microsomal P450 reductase) that has such a 
low specificity; it is the only protein responsible for the activation of numerous (>50) 
P450s that exist in all mammals (Nelson & Strobel, 1987).  
The P450 reductase is conserved across mammals although it may not be perfectly 
conserved across all species. Despite this, a P450 reductase from one species has been 
shown to provide electrons to P450s of another; for example, the yeast P450 reductase 
can activate human P450s in the absence of the human P450 reductase.  
In most bacterial cells, P450s exist as fusion proteins, usually an N-terminal P450 being 
fused to the C-terminal reductase (Lah et al., 2008).  
 
1.4  Diversity of cytochrome P450s 
 
Figure 1.3 depicts the diversity of the human P450s and Table 1.1 portrays the number 
of genes that exist in different species in different taxonomic groups (Nelson, 2009).  
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 Figure 1.3.  A phylogenetic tree of human P450s (Omura, 2006). 
 
 
Figure 1.3. There are 57 human P450 genes that have been arranged into 15 gene families; amongst them 
there are 7 mitochondrial genes; there are also 58 human pseudogenes within these groups (Nelson, 
2003). 
 
Table 1.1.  Numbers of P450s which have been discovered per taxonomic 
group (Nelson, 2009). 
 
Taxonomic Group Number of P450s   
(% of total P450s 
discovered) 
Number of P450 
Families 
Number of P450 
Subfamilies 
Insects 1,675  (14.8) 59 338 
Animals (not 
insects) 
1,607 (14.2) 69 169 
Plants 4,266  (37.8) 126 464 
Fungi 2,570 (22.8) 459 1011 
Protists 247 (2.2) 62 119 
Bacteria 905 (8.0) 196 409 
Archaea 229 (0.2) 12 14 
Virus (Mimivirus) 2 (0.02) 2 2 
Total 11,294 985 2,526 
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 Nature has produced vast numbers of P450s. It should be noted that the number of 
P450s listed in Table 1.1 is perhaps influenced by the research interests of scientific 
investigators, majority of whom prefer certain organisms over others. 
 
1.5  Naming of cytochrome P450 genes and their polymorphs 
 
Previously researchers had named cytochrome P450s (CYPs) ad hoc, as they were being 
discovered. Hence, there were assortments of names which gave rise to a lot of 
confusion. Matters became further confused when a variety of polymorphisms were 
discovered in the P450 genes (Anzenbacher & Anzenbacherova, 2001). Because of this, 
the human cytochrome P450 allele nomenclature committee has now coordinated the 
naming of P450 genes and their polymorphisms.  
Polymorphisms in P450 genes that have emerged do not always result in a diseased 
state. However, the changes at the genetic level have implications. For example, 
CYP2A13 is expressed in the respiratory tract and metabolises carcinogens in 
cigarette/cigar smoke to less toxic compounds but certain polymorphisms in its gene 
result in reduced function of the CYP2A13 enzyme (Cauffiez et al., 2004).  
Moreover, too much or unwanted P450 activity may also pose a problem. Excessive 
P450 activity leading to activation of pro-carcinogens by CYP1 family enzymes is 
implicated in several human cancers (Su et al., 2009). 
 
23 
 
 1.6  Induction of P450s 
 
Many human P450s are tissue-specific.  Most of them are not expressed constitutively 
because to do so would either cause a burden to the human body or lead to disease. 
Human P450s are normally expressed only in the presence of a specific substrate or a 
synthetic compound that mimics the natural substrate; Table 1.2 (Anzenbacher & 
Anzenbacherova, 2001). 
Table 1.2.  Human P450s and their common inducers and substrates along 
with information on their location within the body 
(Anzenbacher & Anzenbacherova, 2001). 
 
CYP Localisation Typical Substrate Typical Inducers 
1A1 Lung, liver, brain, GIT, lymphocytes & heart PAH PAH and dioxins 
1A2 Liver Aromatic amines, PAH & caffeine 
PAH, ß-naphthoflavone 
& smoking 
1B1 
Skin, brain, heart, lung, 
placenta, liver, kidney, 
GIT & spleen 
PAH Dioxin 
2A6 Liver Coumarin & steroids Barbituates & dexamethasone 
2B1/2 Brain Morphine Nicotine 
2B6 Liver & heart Nicotine Barbituates 
2C8 Liver & kidney Retinoids & taxol Unknown 
2C9/10 Liver Tolbutamide & diclofenac 
Barbiturates & 
rifampicin 
2C19 Liver & heart (S)-mephenytoin, omeprazole & diazepam 
Barbituates & 
rifampicin 
2D6 Liver, brain & heart Antidepressants & ß-blockers Unknown 
2E1 
Liver, lung brain 
endothelium, heart, 
bone marrow 
Ethanol, nitrosamines & 
acetaminophen Ethanol & starvation 
2F Lung Coumarins Unknown 
3A4/5 
Liver, GIT, kidney, 
lung, brain, 
endothelium, placenta 
& lymphocytes 
Calcium channel 
blockers, cyclosporine, 
acetaminophen, taxol & 
steroids 
Steroids & barbiturates 
3A7 Foetus, placenta & liver Similar to 3A4/5 Steroids & barbiturates 
4A9/11 Kidney Fatty acids Clofibrate 
4B1 Lung & placenta Unknown Unknown 
4F2/3 Kidney Arachidonic acid derivatives Unknown 
P450 genes exist in every tissue of the human body; however, the human liver is the key tissue for major 
P450 activity.  PAH, polyaromatic hydrocarbons; GIT, gastrointestinal tract. 
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1.7  P450 mediated drug-drug interactions (DDI) 
 
Different possible scenarios of P450-mediated interaction between two drugs A and B 
can be envisaged, a few of which have been listed below: 
(1) Drug A inhibits P450 enzyme X which metabolises drug B resulting in the latter 
being incapable of being excreted from the body and resulting in toxic effects. 
(2) Drug A suppresses the transcription of the P450 X gene which would result in 
P450 enzyme X not being made; thus, drug B which ought to be metabolised by 
P450 enzyme X cannot undergo excretion from the body resulting in toxic 
effects. 
(3) Drug B induces P450 enzyme Y which metabolises drug A that results in the 
latter being metabolised far quicker than desired which would result in the 
prescription of a higher dosage of drug A for it be efficacious.  
(4) Drug A acting as a ligand for the activation of receptors that also act as 
transcription factors; they activate (or suppress) the transcription of P450 gene X 
which codes for the P450 enzyme X which is responsible for the metabolism of 
drug B; in the case of activation, more drug would have to be prescribed and, in 
the case of suppression, less.  
(5) Drug A enhances the activity of P450 enzyme X through increased translation 
that leads to increased formation of toxic metabolites of drug B which the 
body’s excretion system cannot cope with.  
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 In a study of 265 approved drugs it was found that 119 of them were cytochrome P450 
inducers and 83 were suppressors at the gene expression level (Lee et al., 2006). 
Current drug approval guidelines clearly state that, before approval of any drug for 
therapeutic use, P450 inhibition profiles must be submitted. All approved drugs inhibit 
one or the other major P450 enzymes: 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5, 
3A7. As indicated above, in this Section, use of certain combination of drugs can give 
rise to low efficacy and, conversely, can be overly effective leading to fatalities.  
The problem of drug-drug interaction (DDI) pertains not only to conventional drugs. 
There has been concern around the interaction of herbal medicines with 
pharmaceuticals. Use of St. John’s Wort (a CYP3A4 inducer) together with the 
immunosuppressant, cyclosporine, may cause insufficient plasma levels of 
cyclosporine. Smoking can also increase metabolism of the asthma drug theophylline by 
significantly enhancing hepatic clearance via induction of CYP1A enzymes (Schrenk, 
1998).   
 
1.8  The cytochrome P450–mediated hydroxylation cycle 
 
Cytochrome P450 (CYP) enzymes can perform a variety of complex reactions. 
However, the most common chemical reaction that probably all P450 enzymes perform 
is hydroxylation (Guallar et al., 2003). This process requires molecular oxygen, CPR 
(the cytochrome P450 reductase), cytochrome b5 and the b5 reductase. Molecular 
oxygen, O2, is utilised via a dismutation reaction (that involves both oxidation and 
reduction) and results in the formation of water and reactive oxygen species (ROS) at 
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 the same time. The ROS participates in hydroxylation, inserting an atom from 
molecular oxygen on to an unreactive (i.e. inert) carbon atom which could be part of 
either an aliphatic –C—H or an unsaturated/aromatic =C—H bond.  
Figure 1.4 depicts the hydroxylation of camphor using the bacterial P450cam, the 
specific cytochrome P450 that metabolises camphor.  
 
Figure 1.4.  Metabolism of camphor, a simplified version (Guallar et al., 
2003). 
 
 
Figure 1.4.  P450-mediated-hydroxylation of the substrate, camphor. The flat layer of ring structures 
consist of the porphyrin rings, the larger solid red central sphere is iron. The smaller red and two white 
spheres in (1) depict water, the two red spheres in (3) is molecular oxygen, and the red small sphere in (4) 
is singlet oxygen. The substrate, camphor, is denoted by R3-CH. Coordination of the P450 to Fe3+ via a 
thiolate which is being contributed by the –SH of a cysteine in the P450. In multicellular organisms the 
first and, possibly, the second electron is provided by a P450 reductase. The second may also sometimes 
be provided by the cytochrome b5/ b5 reductase system. 
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 1) The P450 is bound to the ferric iron Fe (III) of the porphyrin macrocycle in the 
resting state with water bound and no net charge. Binding of P450 to the iron 
occurs via the sulfhydryl/thiol (—SH) group of a cysteine residue in the P450.  
2) The non-covalent binding of the camphor (C10H16O), the substrate, occurs with 
loss of water. The process allows the complex to receive an electron from 
NADPH via P450 reductase which reduces the ferric iron Fe (III) to the ferrous Fe 
(II) state. This causes a structural shift in the porphyrin ring.   
3) This new complex receives molecular oxygen which binds to the complex; it is 
termed as a “ferric superoxo” moiety. 
4) A second electron is donated via NAD(P)H by either cytochrome b5 or P450 
reductase. This electron reacts with already bound oxygen forming a negatively-
charged distal oxygen. It results in changes in the bond between the two oxygen 
atoms, from a double to a single bond, to provide a stable electron configuration. 
The proximal oxygen then takes an electron from ferrous iron to make the iron 
more positively charged, as Fe (III). This double negatively-charged complex 
attracts a proton as a positively-charged hydrogen ion to the distal oxygen which 
has an extra electron. This produces a hydroxyl group (–OH) group. 
5) The single negatively-charged complex attracts another positively-charged 
hydrogen ion into its vicinity which allows the complex to substitute itself away 
from the hydroxyl group to be released as water. The complex is called an 
oxyferryl moiety with a Fe (IV), the iron being even more positively charged. 
Since the remaining oxygen requires an electron to fill its outer shell, it forms a 
double bond with Fe (IV).  
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 6) With the iron moving towards a more positive state it has enough energy to split 
the stable double bond between two oxygen atoms. The free oxygen atom acts as 
a free radical, with 2 electrons missing from its outer shell, and inserts itself into 
the substrate, between the C—H bond, to gain electrons; thus, substrate 
hydroxylation occurs.   
7) With the interaction over and the complex neutrally charged, the substrate has less 
affinity for the active site.  
Using such hydroxylation cycles, P450s can oxidise a diverse range of complex 
substrates varying from ethylene (28.05 MW) to cyclosporine (1202.61 MW) (Kent et 
al., 2001). 
 
1.9  Drug Metabolism & Elimination 
 
It was shown in Table 1.2 that cytochrome P450s (CYPs) perform their roles in a range 
of tissues. However, the liver is the primary organ of drug metabolism. It contains the 
major P450s of interest to pharmaceutical companies, CYP3A4 being the most 
important, Table 1.3.  
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 Table 1.3.  Details of the predominant P450s in the human liver 
(Anzenbacher & Anzenbacherova, 2001).  
 
CYP 
Relative 
content in 
the liver 
(%) 
Expression 
variability in 
fold 
differences 
Estimated 
fraction of 
drugs 
metabolised (%) 
Drugs that act as 
substrates 
1A1 1 100 < 1 % None known 
1A2 12 40 4 % Caffeine 
2A6 4 30 < 1 % None known 
2B6 1 50 < 1 % None known 
2C9/2C10/2C19 20 20 11 % Diclofenac (2C9) (S)-mephenytoin (2C19) 
2D6 4 1000 30 % Sparteine, debrisoquine & dextromethorphan 
2E1 6 20 2 Chlorzoxazone 
3A4 30 60 52 
Nifedipine, 
erythromycin, 
alprazolam & 
dexrometorphan 
The key P450s involved in drug metabolism occur in the liver in varying amounts. Certain P450s are 
highly induced by certain drugs. CYPs 3A4 and 2D6 are of major interest to the pharmaceutical industry. 
“Not known” denotes that there is no relevant pharmaceutical drug which has been found, as of yet, to be 
a substrate for the enzyme’s liver activity, using analytical tools like Liquid Chromatography/Mass 
Spectrometry. 
 
Usually, a drug approved for therapeutic use exits the body in a more soluble (polar) 
form after being metabolised by a P450 enzyme. As described earlier, drug metabolism 
is split into Phase I and II reactions. In Phase I, a hydroxylation reaction creates 
compounds that are more reactive and provides a molecular attachment point for 
molecules such as glucuronide allowing conjugation (a form of esterification) in Phase 
II. The enzyme UDP-glucuronyl transferase removes glucuronide from a carrier 
molecule and then transfers the glucuronide to the drug that has been hydroxylated (i.e. 
metabolised) by a P450. The glucuronide has a carboxyl group (COOH) which is 
involved in esterification and three polar –OH groups which improve the water 
solubility of the resultant conjugate (Rang et al., 1999).  
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 Other types of Phase II conjugations of hydroxylated drugs, formed via Phase I P450 
metabolism, involve reactions that lead to sulphation, methylation, acetylation and 
glycylation of the hydroxylated product.  
 
1.10  Cytochrome P450 (CYP) Modifications 
 
Joo et al (1999) have documented P450 mutations in a bacterial P450 that allow 
peroxide shunt, a partial bypass mechanism in the normal P450 cycle facilitating far 
easier hydroxylation reactions using hydrogen peroxide than with molecular oxygen. 
This bypass mechanism does not require the presence of P450 reductase or other 
chemical cofactors for P450 activity. The authors used alterations in specific amino 
acids to increase P450 activity 20-fold and were also able to co-express P450s with 
horseradish peroxidase (HRP) which converts the products of the P450 reaction into 
fluorescent compounds making them amenable for screening by digital imaging. This 
allowed rapid assessment of the best constructs through screening of numerous clones 
using whole cells without having to process them into microsomes, saving time and 
money.  
Unfortunately however, it is nearly impossible to rationally alter known human P450 
enzyme activities for further screening, using HRP activity, because 3D structures of 
most human P450 enzymes are not known in fine detail. If they were to be available, it 
may allow creation of novel P450 enzymes that could be used for catalysis of intricate 
bio-organic syntheses that are “difficult to perform using standard organic chemistry” 
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 (Rabe et al., 2008), with the possibility of opening up limitless opportunities for 
biotransformation reactions.  
It has been observed that site-directed mutagenesis at or near the active site can yield 
new functionality in P450s. However, a minor change may also interfere with the whole 
tertiary structure (Domanski & Halpert, 2001). This problem could possibly be 
overcome if the relationship between homologous P450 proteins and their substrate 
specificity could be mapped and then legitimate predictions as to what changes a protein 
could bear without totally distorting its tertiary structure. As crystal structures of P450s 
are more widely available, site-directed mutagenesis as a tool to produce novel P450s 
could be a distinct possibility sometime in the future.  
From the crystal structure of CYP2D6 (Figure 1.5), Rowland et al (2006) inferred that 
the negatively-charged amino acids Asp-301 and Glu-216 are the main determinants of 
substrate and inhibitor binding. This was confirmed by substitution of one or both the 
negatively-charged amino acids (Aspartic Acid and Glutamic Acid) with a neutral 
amino acid, Alanine. This caused reduction or loss of activity. It has been suggested that 
Glu-216 at the top of the active site cavity acts as a “recognition residue” attracting 
basic molecules into the active site before “ushering” them towards Asp-301, which is 
within the active site, for any reaction on a substrate to occur. It was noted that Phe-120 
aligned the substrate into the correct spatial position within the active site. The authors 
also confirmed that the reductase binding region is in CYP2D6’s C-terminus which is 
rich in dibasic amino acids; a mutation in this region from strongly basic Arginine-440 
to less basic Histidine caused total inactivity. 
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 Figure 1.5. CYP2D6 structure (Rowland et al., 2006). 
 
 
Figure 1.5. The 3D structure of CYP2D6 protein has been represented as red helical domains, each one 
alphabetised for reference; green ß sheets numerically referenced. These domains are joined by blue loops 
which have flexible structures. The haem group in black and grey is centrally located. 
 
1.11 A brief background to cytochrome P450s (CYPs) in the yeast, 
Saccharomyces cerevisiae  
 
The yeast Saccharomyces cerevisiae has three P450 genes: CYP51F1, CYP56A1 and 
CYP61A1 (Nelson, 2004). The three genes are essential for yeast’s basic existence. 
They code for mitochondrial enzymes and have highly specific functions that contribute 
to the yeast cells’ structure. They are not involved in the removal of toxic compounds.  
Amongst all P450 gene families, the CYP51 family of enzymes is the most widely 
distributed across fungi (Lepesheva & Waterman, 2004). The CYP51 gene codes for the 
enzyme, sterol 14-demethylase, which is important for sterol biosynthesis.  
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 CYP61 family of genes codes for sterol desaturases. They are involved specifically in 
ergosterol biosynthesis (Nelson, 1999). 
The CYP56 family of genes is involved in spore wall formation (Nelson, 1999). 
 
1.12 Usefulness of yeast, Saccharomyces cerevisiae, in the 
production of human P450s 
 
The yeast Saccharomyces cerevisiae, which is as cheap to grow as bacterial cells, has 
the potential to be an excellent host for expression of human P450s. The full yeast 
genome has been sequenced and its proteins are well characterised and compared with 
human proteins, providing a well-defined environment for the expression of foreign 
proteins (Kellis et al., 2003). Moreover, it is a eukaryote and therefore has similar 
intracellular organelles as human cells. One of these organelles consists of the 
endoplasmic reticular membranes to which P450s are naturally bound in human cells. 
An added attraction of yeast, as a possible eukaryotic host, is that the human P450s, 
when expressed in yeast, are unlikely to be contaminated with significant endogenous 
P450s that may corrupt an assay for the human enzymes. Hence, yeast-produced P450-
bearing microsomes, if it were to be possible to obtain, could be used for screening of 
potential inhibitors and substrates of human P450 enzymes.  
The human P450 reductase (hRD), the enzyme essential for human cytochrome P450 
(CYP) activity, closely resembles the rat, rabbit, pig and trout primary protein 
sequences. Although sequence homology between yeast and human P450 reductases is 
only about 33%, surprisingly, the yeast P450 reductase has the ability to activate human 
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 P450s. This because the FAD, FMN and NADPH binding regions are highly conserved 
amongst different species allowing S. cerevisiae’s endogenous P450 reductase (yRD) to 
be capable of donating electrons to human P450s (CYPs), in the absence of hRD (Odea 
et al., 1985).  
 
1.13  A background to the growth of yeast strains harbouring 
human P450 genes 
 
Transformation, growth and expression of yeast cells are on a par, in terms of cost, time 
and complexity, with bacterial systems. Commercial yeast strains containing multiple 
auxotrophic mutations may allow up to 5 genes to be cloned into the yeast cell offering 
different possibilities of co-expressing multiple proteins. When an auxotrophic marker 
is not utilised, the requirement for the missing marker gene is bypassed by adding a 
relatively cheap supplement to the growth media.  
The yeast auxotrophic markers stem from the knockout of genes in the yeast’s anabolic 
pathway that are essential for growth in minimal growth media. The individual gene 
knockouts remove the ability to manufacture within yeast, for example, (a) an amino 
acid such as leucine, histidine or tryptophan, and (b) a nucleic acid or nucleic acid 
precursor such as uracil or adenine. These are nutrients that are essential for yeast’s cell 
growth.  
Not all auxotrophic markers are ‘equal’ implying that introducing the same gene 
expression cassette at different markers may cause uniquely different burdens to the 
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 cell, depending on the relative importance of the marker in the pathway that leads to the 
synthesis of an amino acid or a nucleic acid (Amberg et al., 2005).  
For regulated expression of heterologous proteins in yeast, two key promoters have 
often been used to drive the transcription of heterologous genes. One of the promoters 
that is induced by the addition of galactose is the GAL1 or GAL10 promoters. The other 
promoters from yeast’s ADH1 or ADH2 genes, are induced by ethanol. In this thesis, an 
ethanol-inducible 573bp fragment of the ADH2 promoter is used, instead of the 
published 300bp ADH2 promoter sequence to enhance heterologous protein expression. 
The GAL1 promoter that has been used has also undergone modifications with the aim 
of enhancing heterologous protein expression. It has been seen in our laboratory that the 
variants of the ADH2 and GAL1 promoter indeed provide better inducibility and 
expression of foreign proteins in yeast (unpublished observations). Ethanol-inducibility 
of the ADH2 promoter can occur when glucose is gradually exhausted in the media and 
converted to ethanol, whereas the GAL1 promoter is induced immediately in the 
presence of galactose.  
The first expression of a cytochrome P450, in yeast, was published in 1985 using the 
constitutive GAPDH promoter (Odea et al., 1985). Later, a paper was published with 
the aim of maximising expression of P450s in yeast (Urban et al., 1990) using the 
indicible GAL1/GAL10 promoters. It described that the expressed P450, CYP1A1, in 
the presence of endogenous yeast P450 reductase (yRD), had poor activity. The P450 
activity could be increased by overexpressing yRD up to 5-fold, either from a 
chromosomal locus or from a multi-copy plasmid; yRD gene expression, in both cases, 
were driven by the GAL10 promoter. The paper also stated cryptically that “... a 
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 maximal expression in yeast for a given mammalian P450 activity was not necessarily 
achieved by maximal P450 expression”.  
A 1995 paper (Pompon et al., 1995) claimed the development of a third generation 
yeast expression system which also used the galactose-inducible promoter. The authors 
tried to split the burdens of exponential growth and expression. They used an 
intermediate phase of ethanol addition to the medium before switch from glucose to 
galactose. This method yielded several hundred nano-moles of P450 per litre of culture 
but the enzymes were poorly active. It appears that the absence of enough yeast P450 
reductase was the factor that limited activity. This led to the evaluation of a production 
system that co-expressed human P450 reductase with a human P450. It was found that 
expressing the human P450 reductase was much more difficult than the yeast’s P450 
reductase and the improvement of activity was minimal.  
 
1.14  Difficulties with Yeast expression 
 
To maintain a steady utilisation of glucose, microbes are adapted to sensing glucose 
levels and they respond according to the level of gene expression (Johnston, 1999). 
Saccharomyces cerevisiae is an atypical eukaryotic microbe. It is able to switch 
between respiration and fermentation depending on glucose concentrations. After 
sensing glucose, respiratory enzymes, such as (a) electron transport chain cytochromes 
and (b) enzymes that allow the use of other carbon sources (like sucrose, maltose and 
galactose), are repressed. Genes encoding glucose transporters and glycolytic enzymes 
are also expressed.  
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 1 to 2% glucose is usually added to the media when growing yeast in the laboratory. 
This allows for the production of reasonable biomass. The switching between 
fermentation and respiration adds extra complexities to optimisation of biomass and 
expression times.  
Another related problem with yeast is petite formation where mitochondria are either 
damaged or missing. It can be caused by the stresses placed upon cells by expression of 
foreign proteins (Yaffe, 1991). Cells can appear to be normal when grown in a glucose 
rich environment. However, without the oxidative pathways the non-fermentable carbon 
sources, like galactose, cannot be utilised (Goldring et al., 1971). Both the rhoº and rho– 
petites, which are intolerant of oxidative stress, are undesirable for the expression of 
heterologous proteins that need a non-fermentable carbon source for full-blown 
expression (Jamieson, 1998).  
A problem with the fermentative process of growth is that, during glucose fermentation 
and production of ethanol, excess NADH is produced. Glycolysis occurs, with or 
without oxygen, in the cytosol, converting glucose to pyruvate. In an oxidative 
environment the pyruvate produced may enter the mitochondrial Krebs cycle. However, 
during fermentation of petites, pyruvate formation leads to an excess of pyruvate and 
NADH that cannot be used. Excess pyruvate in the cell is likely to cause osmotic stress 
whereas excess NADH can lead to the redox pool running out of NAD. To fix this, 
some balance would have to be restored through (a) conversion of pyruvate to 
acetaldehyde via loss of CO2 and (b) NADH consumptive conversion to ethanol formed 
by alcohol dehydrogenase 1 (ADH1); the formed ethanol can cross membranes freely 
reducing osmotic stress (Constenoble et al., 2000).  
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 A problem can occur if the excess NADP that could be used to supply the electron 
transport chain cannot cross the mitochondrial membrane, after fermentation is over. 
The cell employs the glycerol phosphate shuttle, which during fermentation acts as a 
redox buffer. During respiration, the process can be taken further, shuttling reducing 
power into the mitochondria in the electron transport chain. This is done by the 
conversion of the by-product dihydroxyacetone phosphate (DHAP), formed during 
glycolysis, to glycerol-3-phosphate (G3P) via reduction by glycerol 3-phosphate 
dehydrogenase (GPDH) by the way of NADP conversion to NAD. G3P can pass into 
the mitochondria and is reversed backwards in the same way to DHAP to yield NADH 
for electron transport. Once G3P becomes excessive it is converted by glycerol 3-
phosphatase to glycerol. 
Even though glycerol is a non-fermentable carbon source it ends up being produced for 
redox balance. It protects the cells from hyper-osmotic stress caused by high levels of 
solutes in the media by attempting to match the osmotic pressure to the external 
surroundings of the cell and therefore protecting proteins and membranes from damage 
(Michnick et al, 1997; Kuroda et al., 1994; Remize et al., 1999).  
All the above factors, which have influence on the growth of yeast, could be further 
explored for optimal expression of proteins in yeast.   
 
1.15  Biotransformation reactions in yeast with P450s 
 
Yeast cells expressing active P450 enzymes and P450 reductases could be potential 
cellular factories for biotransformation reactions of chemicals. As an example, an 
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 Arabidopsis P450 reductase, when expressed in a CYP61 gene-knockout yeast strain, 
interfered with the synthesis of ergosterol, forcing the cells to produce the intermediate 
ergosta-5-enol as a cheap precursor for the mass production of several different steroidal 
hormones (Kelly & Kelly, 2003). As ergosta-5-enol can replace ergosterol in the yeast 
membrane, the cells behave normally. By further modifying the cells by introducing 
different mammalian P450s into the cell, different steroids were produced. This 
demonstrates that yeast cells could be modified to undergo tailor-made 
biotransformations which may allow production of medicines with intricate 
stereochemistry, at very low cost.   
 
1.16 Lyophilisation/ stabilisation 
 
Certain purified commercial enzymes, such as glucose-6-phosphate dehydrogenase, are 
often supplied as dried formulations. This allows shipping at ambient temperature and 
retention of stability. The P450 enzymes cannot be purified because they are active only 
when they are bound to endoplasmic reticular membranes. Hence, no one has yet 
conceived of supplying active membrane-bound P450 enzymes as dried products. 
Commercial suppliers of P450s require their products to be stored –80ºC and in buffers 
with high solute concentrations. Depending on the supplier, buffers contain mixtures of 
glycerol, sucrose, glucose, Tris-EDTA, phosphates and protease inhibitors. They are 
shipped on dry ice. Maintenance of the cold chain is inconvenient, adds costs and makes 
most applications difficult, if not impossible.  
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 For preservation over years, proteins are usually stored in buffers which do not have 
much water, lack oxygen, and are kept at very low temperatures (minus 20°C to minus 
80°C). Preservation in the natural environment in the cold is quite well known (Sallon et 
al., 2008). To avoid degradation of protein, inhibitors of proteases are often added.  
Lyophilisation is a process that also allows preservation. Lyophilised Salmonella 
vaccines maintain very high levels of viability after years of storage at +4ºC (Khan et 
al., 2007). Attempts have also been made to lyophilise mammalian cells but not with 
great success.  
From efforts to lyophilise cells and soluble proteins, it may seem an obvious step to 
attempt to lyophilise microsomes (i.e. membrane-bound proteins). Whilst microsomes 
have been lyophilised, since their discovery, as a means of storage, it is clear that this 
was used only as a technique for preserving large quantities of animal tissue 
homogenates for later structural analysis. There was a drive to examine why the stability 
of drug metabolising enzymes, obtained from animal tissues, had so many variables 
(Kamataki & Kitagawa, 1974; Aikawa et al., 1976). It was shown that microsomes from 
animal livers were best stored as a lyophilised pellet rather than in solution and that 
lyophilised S9 fractions were more stable than lyophilised microsomes. There was a 
significant difference in the stability of microsomes from different animals when tested 
over a month. It was not clear why this was so but it is possible that differing protein 
concentrations of the liver preparations affected stability (Tanaka et al., 1991).  
In the past decade, commercial suppliers have improved P450 products to provide them 
more as standardised entities with some characterised stability data. However, 
instability seen during long-term storage and during assays has been brought into focus 
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 by multiple publications (Bernhardt, 2006; Chefson & Auclair, 2006; Urlacher & Eiben, 
2006).  
Soluble enzymes, upon lyophilisation, lose activity. It is thought that the dehydration of 
the protein causes a conformational change that is not reversible when rehydrated, 
although sugars have been usually used as cryo-protectants to prevent loss of activity 
(Chefson et al., 2007). Chefson expressed CYP3A4 in a yeast expression system and 
lyophilised the P450s. However, purified proteins (shorn of membranes) were 
lyophilised, not 3A4-containing microsomes. These had minimal or no biological 
activity. It has been shown, that in order for the P450 and P450 reductase proteins to 
retain activity, they must remain attached to the membranes and also retain the haem 
group. 
Nardid, Dyubko and Repina (1997) stated that just freezing and thawing microsomes 
may cause irreversible conformational changes. This work was conducted with purified 
P450s from rabbit liver microsomes which were allowed to associate with artificial 
membranes.  
Pearce et al (1996) have stated that intact human liver microsomes can tolerate only up 
to 10 cycles of freeze-thaw without significant changes. Interestingly, in non-processed 
livers stored at minus 80°C, P450 reductase and key P450 activities diminish up to 40% 
after only one month.  
In summary, the general stability of P450s, before and after lyophilisation, has been 
found to be poor. The idea that useful levels of P450 activity may be recovered from 
lyophilised microsomes seemed unlikely but it was still thought to be worthy of further 
42 
 
 investigations with recombinant P450-bound microsomes with the aim of allowing the 
development of new and exciting applications in drug discovery. 
 
  
43 
 
 Chapter 2  Materials and Methods  
 
2.1  PCR using the Qiagen Proofstart kit  
 
Qiagen Proofstart kit, catalogue number, 202203.  
Invitrogen Custom Primers were used. Primer annealing temperature was calculated as 
((G+C)*41)-675)/ (Σ All bases A+T+G+C) + 61.8) = °C. 
Control was template substituted for an equal volume of ultrapure water.  
Final volume of 50 µl using 0.2 ml PCR tubes (Stratagene, 401425). 
• Ultrapure water     26 µl 
• 10x Proofstart buffer    5 µl 
• 5x Q buffer     10 µl 
• Forward primer, 0.5 µg.µl-1   2 µl 
• Reverse primer, 0.5 µg.µl-1   2 µl 
• dNTPs, 20mM    3 µl 
• Qiagen proofstart taq polymerase  1 µl 
 
The template was either:  
1. A small loopful of cells, 
2. Previously cloned DNA, 5 ng.µl-1,   
3. Human cDNA liver library, 1 µg.µl-1 , 1 µl 
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 PCR steps; 
• 95˚C for 5 min, 
• 95˚C for 45 seconds to melt the strands, 
• 55˚C (calculated individually) for primer annealing for 90 seconds, 
• 72˚C for 3 min to elongate the strands, 
• 30 cycles of the above 3 steps, 72˚C for 10 min, 
• 4˚C held. 
After PCR, the reaction was run on a 1% (w/v) agarose-TAE gel, and relevant bands 
were excised from the gel using a Qiagen gel-extraction kit.  
2.2 Agarose gel electrophoresis of DNA 
 
1% (w/v) agarose gels in TAE with 1 µl of 10 mg.ml-1 of ethidium bromide was used 
with the Bio-Rad, Mini-Sub Cell GT and the gels were run at 100 Volts for typically 45 
min. Images were captured using the Bio-Rad, XRS Chemidoc system. 
Reagents 
 
• Agarose, Gibco, Catalogue number 15510-027, 
• 10x or 50x TAE Gel running buffer, pH 8.3, 
• Final 1x concentration of 0.4 M Tris-acetate, Fisher, BPE152-1, 
• Final 1x concentration of 20 mM Glacial acetic acid, Sigma, 320099,  
• Final 1x concentration of 10 mM EDTA, Gibco, 15706-021.  
 
• 10 mg.ml-1 Ethidium bromide in ultrapure water, Sigma-Aldrich, Catalogue 
number E7637.  
 
10x loading buffer in 100 ml of ultrapure water.  
• 50 ml of 50% (v/v) Glycerol, Fisher, G/0650/17. 
• 2 g Ficoll, Sigma, F-2637. 
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 • 10 ml of 50 mM EDTA pH 8, Gibco, 1570-6-021. 
• 0.5 g of Bromophenol blue, Sigma, 114391. 
 
DNA ladders from New England Biolabs, 1 Kb, N3232 and 100 bp, N3231.    
 
2.3  Qiagen Gel-extraction kit 
 
Using the standard supplied protocol, DNA was purified from agarose gels with the aid 
of the Qiagen gel extraction kit (Qiagen, 28604). The DNA was eluted in 30 µl of TE at 
pH 8.0. 
Reagents 
 
• 10x TE buffer at pH 8.0.   
• Final 1x concentration of 100 mM Tris, Fisher BPE152-1. 
• Final 1x concentration of 10 mM EDTA, Gibco, 15706-021. 
• Made up in ultrapure water. 
 
2.4  Restriction digests using NEB and Roche enzymes  
 
Standard supplied protocols were used.  
A typical reaction was:  
• 2 µg of DNA fragment, 
• 0.2 µl of BamHI 10 U.µl-1, 
• 0.2 µl of Xba1 10 U.µl-1, 
• 1 µl of 10x buffer B, 
• 6.6 µl of ultrapure water. 
If BSA was required, 0.1 µl of the supplied 100x stock was added.  
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 2.5  T4 DNA ligase reactions for DNA molecules using 
commercial kits from NEB and Roche 
 
Standard supplied protocols were used. Control reactions were also performed with 
either no ligase or no DNA fragment. 
NEB Kit, catalogue number M0202S.  
• Ultrapure water 12 µl 
• 10x Buffer  2 µl 
• Plasmid/Vector 1 µl 
• Insert fragment 4 µl 
• T4 Ligase  1 µl 
 
Roche Kit, catalogue number 716359. 
• Ultrapure water 7.75 µl 
• 10x Buffer  1.5 µl 
• Plasmid/Vector 1 µl 
• Insert fragment 4 µl 
• Ligase   0.75 µl 
Reactions were incubated overnight at +16°C in a water bath in a cold room or kept at 
+4°C over 48h. 
If required, enzymes were heat inactivated before transformation. Where appropriate, 
the ligation products were run on a 1% (w/v) TAE-agarose gel to check efficiency of 
ligation and then gel-extracted using the Qiagen gel-extraction kit.  
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 2.6  Bacterial competent cell transformation 
 
Competent E. coli DH5α cells were sourced from Invitrogen (18265017). The plasmids 
used were amplified in DH5α before transformation into yeast. Selection was via 
ampicillin resistance.  
Competent cells were thawed on ice for 10 min. 
• 7.5 µl of purified plasmid (10-20 ng) or ligation mixes were added to the cells 
and placed on ice for 10 min.  
• The samples were heat shocked at 42ºC for 90 seconds.  
• 1 ml of SOC medium (Sigma, S1797) was added to the cells followed by 
incubation at 37ºC for 1h.   
• Cells were concentrated at 13,000 rpm (15,700g) for 1 min allowing the removal 
of 800 µl of supernatant. Cells were re-suspended in 200 μl, and 100 μl of cells 
were plated out on to two LB agar plates with ampicillin at 100 μg.ml-1 of agar.  
• Agar plates were incubated overnight at 37ºC. 
• Transformants were grown in 10 ml cultures of LB broth with 100 μg.ml-1 of 
ampicillin at 37˚C, 180 rpm.  
• Glycerol stocks were produced and stored at -80˚C.   
• Plasmids were checked using restriction enzyme digestions. See section 2.4. 
 
Reagents 
• LB broth 25 g.L-1 in ultrapure water, Difco, 244620. 
• LB agar 20 g.L-1 in ultrapure water, Difco, 244520.  
• A 100 mg.ml-1 stock of ampicillin (Fisher, BPE1760-5) in ultrapure water with a 
final concentration in the media of 100 μg.ml-1.  
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 2.7  Isolation of plasmids from E. coli using the Qiagen Midi prep 
 kit (25 ml cultures) 
 
Standard supplied protocols were used, depending on the amount of DNA required. The 
Midi preparation (Qiagen, 12143) for 100 μg of plasmids was normally sufficient. 
Glycerol stocks for each clone were made if no previous stocks existed.  
Each DNA pellet was dissolved based on its size, in a volume of TE (pH 8.0).  
Plasmid concentrations were measured by adding 10 μl of plasmids to 1 ml of ultrapure 
water in a quartz cuvette (14-385-914A).  
Plasmid concentration in μg.μl-1 = OD at 260 nm x dilution factor x 0.05,  
Plasmid purity = OD at 260 nm/OD at 280 nm. 
If the plasmid concentration was too low then the plasmids were concentrated into a 
smaller volume using a Qiagen gel-extraction spin column. Plasmids could then be re-
suspended in a suitable smaller volume. 
 
2.8  Transformation of integrating or episomal plasmids in 
Yeast, DMSO method 
 
• A 10 ml yeast culture was grown in YPD broth, at 30°C, shaking at 220 rpm 
overnight. Auxotrophic supplements were added at 8.3 µl of stock per 1 ml of 
media. 
• 1.5 ml of the culture was centrifuged for 20 seconds at 13,000 rpm (15,700g) in 
a microfuge. The supernatant was poured off retaining the pellet. 
• 100 μg of salmon sperm DNA from a 2 mg.ml-1 stock (50 μl) was added to the 
pellet. After thawing from –20˚C, the salmon sperm DNA was heat-treated at 
95˚C for 5 min.  
• The solution and pellet were mixed well.  
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 • Variable step*: (* for integrating plasmids, normally the linearized P450 
Reductase, 4-6 μg of DNA was added.; for episomal plasmids, normally 
encoding P450 genes, 0.5-1 μg of DNA was added).  
• The solution was vortexed. 
• 500 µl of PEG solution for yeast transformation was added.  
• 55 µl of pure molecular grade DMSO (Sigma, D5879) was added.  
• Incubated in a Thermomixer for 15 min at 25°C, 400 rpm. 
• The samples were heat-shocked for 15 min at 42°C. After 10 min of heat-
shocking, 60 µl of pure molecular grade ethanol (Sigma, E7023) was added. 
• Cells were centrifuged at 8000 rpm (5900g) in microfuge for 1 min. 
• Cells were washed twice in 500 µl in TE, pH 7.5, using above centrifuge 
settings. 
• Cells were re-suspended in 200 µl TE, pH 7.5.  
• Agar plates were spread in duplicate using 100 µl of each plate on SD-Minimal 
agar plates containing the appropriate auxotrophic supplements at 8.3 µl per 1 
ml of agar and incubated at 30°C for 3-4 days. 
Since yeast cells are capable of growing with damaged or missing mitochondria, growth 
on a glycerol media was used to deselect these petites. 
• Several individual colonies were transferred on to a glycerol agar (YPG) at 30°C 
for 3-4 days to deselect petite strains. 
• 3 individual colonies were picked directly from the yeast glycerol agar and 
transferred back upon SD-Minimal agar to maintain plasmid selection. 
• Colonies were then picked and grown in 10 ml cultures of YPD broth at 30˚C in 
a shaking incubator at 220 rpm.  
• Glycerol stocks were produced from individual colonies for -80°C storage. 
Reagents 
 
PEG solution for yeast transformation, final concentrations in ultrapure water 
• 40% (w/v) PEG-3350 MW, Sigma, P4338, 
• 0.1 M Lithium acetate, pH 7.5, Sigma, L4158, 
• 10 mM Tris, pH 7.5, Fisher, BPE152-1, 
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 • 1 mM EDTA, pH 7.5, Gibco, 1570-6-021.  
 
Salmon sperm (Sigma, D1626) 
• 200 mg of salmon sperm in 100 ml of TE, pH 8.  
• DNA was pipetted up and down.  
• Left overnight in a 4°C cold room with vigorous magnetic stirring.  
• Aliquoted and stored at -20°C.  
• Heated to 99°C in a thermomixer for 5 min before use. 
 
S-Minimal agar, in 500 ml, in ultrapure water  
• 3.35 g of YNB, Difco, 291940, 
• 10 g of Glucose, Sigma, G5400, 
• 7.5 g of Agar, Oxoid, LP0013, 
• 1 pellet of Sodium hydroxide as supplied by Fisher, BP359-500. 
 
YPG agar, in 500 ml, in ultrapure water 
• 5 g of Yeast Extract, Oxoid, LP0085,  
• 10 of Peptone, Oxoid, LP0021, 
• 15 ml of Glycerol, Fisher, G/065/17,  
• 10 g of Agar Oxoid, LP0013. 
 
YPD broth 25 g.L-1, Difco, 242810. 
 
 
51 
 
 2.9  Growth and expression of P450s in Yeast Strains using YPGE 
media for galactose promoter clones 
 
Strains were grown from glycerol stocks and grown on SD-Minimal agar with the 
required supplements at 30ºC for 3 days. 
Growth of strains, Day 1 
 
A 50 ml flask was inoculated with 10 ml of modified SD-Minimal broth with the 
required supplements. 83 μl of stock solution was added for each required supplement 
(adenine 125 μl) and 100 μl of Casamino acids stock solution. The starting OD at 600 
nm (OD600) was measured and the cells incubated at 30ºC for 16h at 220 rpm. 
 
Growth of strains, Day 2 
 
OD600 was measured. Once the culture reached approximately 6 ODs, it was placed at 
+4ºC to cool. This culture was then used to inoculate a 100 ml YPGE culture in a 500 
ml flask; see Table 2.1 for inoculum volume for OD600 ranges. 
Table 2.1.  Inoculum volume for OD600 ranges. 
 
Ranges of OD at 600 nm Inoculum volume in ml 
4.5 – 5.5 1.5 
6 – 6.7 1.2 
7 0.8 
7+ 0.5 
 
830 μl of stock solutions were added for each required supplement (adenine being an 
exception, 1250 μl). The starting OD600 was measured and the cells incubated at 30ºC 
for 16 to 24h at 220 rpm. 
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 Expression of strains, Day 3 
 
The OD600 of the 100 ml culture was measured. Once the culture reached over 5 ODs at 
600 nm, it was placed at +4°C to cool. 
10 ml of 20% (w/v) filter-sterilised galactose solution was added, for induction. 415 μl 
of stock solutions of each required supplement was added (adenine 625 μl). The OD600 
was measured and the cells incubated at 30ºC for 14 to 24h at 220 rpm. 
 
Harvest of strains, Day 4 
 
OD600 was measured for the 100 ml culture. Once the culture reached over 17 ODs at 
600 nm, then it was placed at +4°C to cool. The cultures were transferred to centrifuge 
buckets and centrifuged at 3620 rpm (2828g), in a Sorvall Legend RT, for 12 min at 
4°C. 
The supernatant was poured away and the pellet was re-suspended gently in 100 ml of 
Sorbitol buffer A. The process was repeated twice more at the same settings. 
The pellet weight was recorded and the pellet stored at –80°C. 
Reagents  
 
SD Minimal Agar (500 ml) 
• 3.35 g YNB, Difco, 291940, 
• 10 g Glucose Sigma, G5400, 
• 7.5 g Agar, Oxoid, LP0013, 
• 1 Pellet of Sodium hydroxide as supplied by Fisher, BP359-500. 
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Casamino acids  
Stock concentration 1 g.10 ml-1 of Casein hydrolysate, N-Z-Case, Sigma, C-7585 
SD Minimal broth (1 Litre) 
• 6.7 g YNB Difco, 291940, 
• 40 ml of 50% (w/v) glucose, Sigma, G5400. 
Additions 
• Adenine Stock concentration 5 mg.ml-1 Sigma, A3159, 
• Histidine Stock concentration 2.4 mg.ml-1 Sigma, H8125, 
• Leucine Stock concentration 1.8 mg.ml-1 Sigma, L-8000, 
• Tryptophan Stock concentration 4.8 mg.ml-1 Sigma, T0254, Filter sterilised, 
• Uracil Stock concentration 2.4 mg.ml-1 Sigma, U1128. 
 
YPGE broth (1 Litre) 
• 900 ml of ultrapure water 
• Yeast Extract 10 g, Oxoid, LP0085,  
• Bactopeptone 10 g, Oxoid, LP0021.  
The components were autoclaved except where detailed. Components below were 
added after autoclaving 
• 10 ml 50% (w/v) Glucose solution, Sigma, G5400, 
• 30 ml, 100% Ethanol, Sigma, E7023, 
Final volume adjusted to 1 Litre with sterile ultrapure water. 
Galactose  
10 ml of 20% (w/v) Galactose, 20 g.100 ml-1 and filter sterilised, Fisher, 150610010. 
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Sorbitol buffer A  
• 162.5 ml of 4 M Sorbitol solution, Melford, MB1015, 
• 10 ml of 1M Tris pH 7.5, Fisher, BPE152-1, 
• 200 μl of 0.5 M EDTA pH 8, Gibco 1570-6-021, 
• 827.3 ml of sterile ultrapure water. 
 
2.10 Growth and expression of P450s from Yeast Strains, using 
YP media for ADH2 promoter clones 
 
Strains were grown from glycerol stocks on SD-Minimal agar with the required 
supplements (see Section 2.8) at 30ºC for 3 days. 
Growth of strains, Day 1 
 
A 50 ml flask was inoculated with 10 ml of modified SD-Minimal broth with the 
required supplements. 83 μl of stock solution was added (adenine 125 μl) and 100 μl of 
Casamino acids stock solution was added. The start OD600 was measured and the cells 
incubated at 30ºC for 16h at 220 rpm. 
Growth of strains, Day 2 
 
OD600 was measured for the 10 ml culture. Once the culture reached approximately 5 to 
10 ODs, it was used for inoculating a 100 ml YP culture in a 500 ml flask; see Table 
2.2, for inoculum volume of OD600 ranges. 
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Table 2.2  Inoculum volume for OD600 ranges. 
 
Ranges of OD at 600 nm Inoculum volume in ml 
4.5 – 5.5 1.5 
6 – 6.7 1.2 
7 0.8 
7 to 10 0.5 
 
830 μl of stock solutions were added (adenine 1250 μl). The starting OD600 was 
measured and the cells incubated at 30ºC for 16 to 24h at 220 rpm. 
Harvest of strains, Day 3 
 
OD600 was measured for the 100 ml culture. Once the culture reached over 12-21 OD600, 
it was cooled, and harvested. The cultures were centrifuged at 3620 rpm (2828g), in the 
Sorvall Legend RT, for 12 min at 4ºC. 
The supernatant was poured away and the pellet re-suspended gently in 100 ml of 
Sorbitol buffer A. The process was repeated twice more, at the same settings. 
The pellet weight was recorded and the pellet stored at –80ºC. 
Reagents  
 
See Section 2.9.  
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 2.11  Lyticase treatments 
 
The cell pellets from expressions were removed from -80°C storage. Depending on size, 
pellets were kept on ice for 10 min followed by 10 min at room temperature.  
Sorbitol buffer B, at room temperature, was added (2.5 ml per 100 ml culture) to the cell 
pellet. The sorbitol buffer B contained the protease inhibitor 1 mM AEBSF, and 0.1 
mM DTT.  
The pellet was gently re-suspended and transferred to a 50 ml conical flask and 
incubated at 30°C in an orbital-shaking incubator at 90 rpm. 
Spheroplasts were produced by adding lyticase. The amount of lyticase (ICN 
Biomedicals, 152270) added was calculated as below,  
(Final culture OD 600 nm X Total culture volume in ml X 75) / 2000 = mg of lyticase 
added to the 50 ml flask of re-suspended cells. 
The OD600 was observed by removal of a few µl to track the lysis process as a decrease 
in OD600. Then the spheroplasts were poured into pre-chilled 50 ml centrifuge tubes and 
1 ml sorbitol buffer B was used to wash out the remains from the flask. The 
spheroplasts were pelleted, in the Sorvall Legend RT, at 3500 rpm (2643g) for 10 min at 
+4°C. 
The following steps were performed in a cold room on ice. The pellet from 400 ml of 
original culture was re-suspended in 5 ml of sorbitol buffer A which contained 1 mM 
AEBSF and 0.1 mM of DTT. The pellet was gently re-suspended using a glass rod and 
pipetted up and down with a 10 ml pipette. 
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 The spheroplasts were sonicated for 10 seconds; this was done eight times with 3 min 
gaps, in-between using the sonicator (UP50H, Dr Hiescher); settings cycle 1 at 30% 
amplitude. 
The cells were centrifuged again at 3500 rpm (2643g) for 10 min at +4°C. The 
supernatant was transferred to Beckman JA17 tubes and centrifuged at 10,000 rpm 
(13,776g) for 10 min at +4°C. This was repeated with fresh tubes, 3 times.  
The supernatant was ultracentrifuged in the type 70 Ti rotor at 45,000 (208,429g) for 90 
min at +4°C. Finally, the microsomal pellet surface was washed twice using 500 µl of 
buffer C. The pellet was removed from the tube with micro-spatulas and placed into a 
glass homogeniser with a PTFE (Teflon) pestle. The microsomes were homogenised in 
as small as possible volume of Buffer C, aliquoted and stored at -80°C.   
 
2.12  Bradford assay of the total microsomal protein content  
 
The supplied microplate protocol was used. The BioRad Bradford Assay Dye reagent 
concentrate (Cat No 500-0006) and the Biotek Synergy HT plate reader with standard 
flat bottomed, clear 96 well plates (Appleton Woods, 9017) were used for determining 
protein concentrations. 
BSA Stock 
A bovine serum albumin (BSA) stock solution (Bio-Rad Protein Assay Standard II, 
500-0007) was diluted in water and the solution was aliquoted and stored at –21°C. The 
assay measured end-point absorbance at 595 nm. 
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 2.13  CO-difference binding assay 
 
Absorbance was measured in microsomal samples between 400-500 nm to calculate the 
P450 content. This was performed using the Shimadzu UV2401PC dual-beam 
spectrophotometer relative to a base-line of the microsomal sample before CO was 
added and with reference to a cuvette containing only buffer. 
900 μl of 100 mM phosphate buffer pH 7.4 with 20% (v/v) glycerol was added to two 
cuvettes. 5 mg of sodium hydrosulphite (i.e. sodium bisulphite; Sigma, S-1256) was 
added and the sample was mixed gently by inversion and left for 1 min. 1.5 mg of 
microsomal protein was added and gently mixed by inversion and held for 1 min. The 
volume should be adjusted with buffer to a 1 ml final volume.  
Samples were set to zero, followed by reading of the spectral baseline. 
A 50 litre CO lecture bottle (Sigma, 29,5116) was used with a fine control two-stage 
BOC regulator ending in a glass Pasteur pipette to deliver CO. The cuvette’s solution 
was bubbled with CO at the base of the cuvette, at the rate of 1 bubble per second for 60 
seconds. The pipette was removed and the sample held for a 1 min. The sample was set 
to zero followed by the spectral reading. 
Calculations 
• The extinction coefficient at 450 nm for these samples was 91 mM-1.cm-1. 
• The extinction coefficient at 420 nm (misfolded P450) = 110 mM-1.cm-1. 
• ((Absorbance at 450 - absorbance at 490) / 91) * 1000 = P450 content in nM.ml-
1 in the diluted sample. 
• (P450 nM.ml-1 * dilution factor)/ total protein = Specific Content in nM.mg-1  
• Dilution factor was total volume / volume of microsomes used for assay. 
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 Reagents 
 
Potassium phosphate buffer  
• A solution of 1 M (174.18 g.L-1) K2HPO4 (Anhydrous, Dibasic) was produced, 
Sigma, P-8281.  
• A solution of 1 M (136.06 g.L-1) KH2PO4 (Anhydrous, Monobasic) was 
produced, Sigma, P-5379. 
• 100 mM Potassium phosphate buffer at pH 7.4 with 20% (v/v) glycerol. 
• 80.2 ml of 1 M K2HPO4 (Dibasic) and 19.8 ml of 1 M KH2PO4 (Monobasic) 
were mixed together and 400 ml of 50% (v/v) glycerol and was then topped up 
to 1 litre with ultrapure water. 
50% (v/v) glycerol, Fisher, Cat No. G/0650/17; autoclaved and stored at room 
temperature. 
 
2.14  P450 fluorescent activity assays 
 
P450 activity was measured by conversion of a substrate into a product and that the 
product was fluorescent with a light intensity directly proportional to the concentration 
of the enzyme. These assays were performed in 96-well plates and analysed using the 
Biotek Synergy HT plate reader. Substrates were presumed to be light-sensitive, hence 
covered with foil and kept at -20ºC.  
Coumarin (Sigma, Fluka, 28150) 
3 mM stock solution in water, diluted to 50 µM solution in water on the day of use. 
7-Ethoxy-3-cyanocoumarin (CEC, Sigma, C2612) 
10 mM stock solution in pure acetonitrile (Fisher, A/0638/17), diluted to 1.23 mM in 
1% (v/v) acetonitrile on the day of use. 
7-Ethoxyresorufin (7-ER, Sigma, E3763) 
1 mM stock solution in pure DMSO (Sigma, D5879), diluted to 0.1 mM in 1% (v/v) 
DMSO on the day of use. 
60 
 
 Dibenzylfluorescien (DBF, Sigma D7191) 
2 mM stock solution in pure acetonitrile, diluted to a 0.1 mM working solution in 1% 
(v/v) acetonitrile on the day of use. 
3-[2-(N,N-Diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC, 
BD Gentest, 451705) 
10 mM stock solution in pure acetonitrile, diluted to 25 µM working solution in 1% 
(v/v) acetonitrile on the day of use.  
Vivid EOMCC (Invitrogen, P3024) 
2 µM stock solution in pure acetonitrile, used directly. 
Vivid DBOMF (Invitrogen, P2974) 
2 µM stock solution in pure acetonitrile, used directly. 
Regenerating System 
The regenerating system was stored at –20ºC. The system was stored as two 
components, solutions A and B, to aid stability. 
Regenerating System-Solution A 
65.42 mM Magnesium Chloride solution containing 26.13 mM NADP+ and 65.77 mM 
of Glucose-6-Phosphate.  
Regenerating System-Solution B 
5 mM Tribasic sodium citrate solution contain 40 Units per ml of glucose-6-phosphate 
dehydrogenase was then added.  
Alternative Solution A (A1) for CYP2A6 and CYP2D6 with AMMC 
65.42 mM magnesium chloride solution containing 1.31 mM NADP+ and 65.77 mM of 
glucose-6-phosphate. 
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 Reaction conditions and dilution of the P450s 
The P450s were diluted in solutions described in Table 2.3, parts A and B. P450s were 
diluted to give the correct amount of P450 in pmol in a 10 µl volume per reaction well. 
After this, 90 µl of reaction mix was added. 
Table 2.3A.  Reaction conditions for each P450, part A. 
 
Enzyme Substrate Product Excitation 
(Bandwidth) 
Emission 
(Bandwidth) 
CYP1A1 7-ER Resorufin 530 nm (25 nm) 590 nm (20 nm) 
CYP1A2 CEC CHC 409 nm (20 nm) 460 nm (40 nm) 
CYP1B1 7-ER Resorufin 530 nm (25 nm) 590 nm (20 nm) 
CYP2A6 Coumarin 7-HC 400 nm (20 nm) 460 nm (40 nm) 
CYP3A4 DBOMF Green Standard 485 nm (20 nm) 530 nm (25 nm) 
CYP2C8 DBF Fluorescein 485 nm (20 nm) 538 nm (25 nm) 
CYP2D6 EOMCC Blue Standard 400 nm (20 nm) 460 nm (40 nm) 
CYP2D6 AMMC AHMC 400 nm (20 nm) 460 nm (40 nm) 
CYP2E1 EOMCC Blue Standard 400 nm (20 nm) 460 nm (40 nm) 
 
Table 2.3B.  Reaction conditions for each P450 per well, part B. 
 
[Final Substrate] [CYP per reaction] [NADP+] Potassium Phosphate Buffer, pH 7.4 
5 µM 1.5 pmol 1.3 mM 100 mM 
16 µM 1.0 pmol 1.3 mM 100 mM 
5 µM 1.5 pmol 1.3 mM 100 mM 
3 µM 1.0 pmol 0.065 mM 100 mM, Tris pH 7.5 
2 µM 1.0 pmol 1.3 mM 100 mM 
1 µM 4.0 pmol 1.3 mM 50 mM 
10 µM 2.5 pmol 1.3 mM 100 mM 
1.5 µM 2.5 pmol 0.065 mM 100 mM 
10 µM 2.5 pmol 1.3 mM 200 mM 
Glucose-6-phosphate 3.3 mM, G-6-P dehydrogenase 0.04 Units and MgCl2 3.3 mM were used throughout 
as part of the regenerating system. 
The reactions were rapidly mixed and the kinetic reaction followed. 
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 2.17  Detection of proteins using Western blotting 
 
This method used a vertical one-dimensional Bio-Rad Mini Trans Blot Gel System with 
the Bio-Rad Mini-Protean 3 system and an acrylamide gel to separate proteins relative 
to their molecular weights. This was followed by semi-dry blotting. After blotting, 
membranes were probed with antibodies as required.  
The secondary antibodies were HRP-conjugates and were used with luminol detection 
in conjunction with the Bio-Rad XRS Chemidoc system. 
Samples were prepared as 1.5 - 3 μg of total microsomal protein per well.  
• Microsomes were thawed on ice.  
• Samples containing 100 μg of microsomes were prepared, 
• Water was added to make up to 400 μl after addition of the volume of 
microsomes which was variable.  
• 6x SDS Buffer 66.7 μl 
• Total Volume 400 μl 
Samples heated to 99°C in a thermomixer for 5 min. 
6 µl or 12 µl of samples contained 1.5 or 3 μg of total cellular protein, respectively. 
10 µl of protein markers (ladders) with major bands at 75 and 50 KDa (Bio-Rad, 161-
0373) were used. Negative control microsomes (in-house clone YW41, containing no 
P450 gene), and relevant positive controls from BD Gentest were used.  
Casting gel  
Resolving gels of 1.5 mm thickness were cast using water-saturated butanol 
solution(Sigma, B-1417) applied on top.  
Resolving gel composition for 2 gels 
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 • 17.8 ml of ultrapure water, 
• 11.25 ml of 1.5 M Tris, pH 8.8, Fisher, BPE152-1, 
• 15.1 ml of 30% Acrylamide/bis solution 29:1 Bio-Rad, 161-0156.  
• 450 µl of 10% (w/v) SDS, Gibco, 15711-021 
• 225 µl of 10% (w/v) Ammonium persulphate (APS), Sigma, A3678.   
• 22.5 µl of TEMED, Gibco, 15713-019. 
Once set, a stacking gel was applied on top, and comb added. 
Stacking gel 
• 7.5 ml of ultrapure water, 
• 3.15 ml of 0.5 M Tris, pH 6.8, 
• 1.875 ml of 30% Acrylamide/bis solution 29:1, 
• 125 µl of 10% (w/v) SDS,   
• 51 µl of 10% (w/v) APS, 
• 13.5 µl of TEMED.  
Samples were run at 90 Volts through the stacking gel and 110 Volts through the 
resolving gel for 120 min 
Gels were removed from the tank system and cut to a relevant size.  
A semi-dry blotter (Phase) was used for protein transfer. Three large rectangles of filter 
paper (Whatman, 3030 335; 16.4 cm by 11 cm) were soaked in cathode buffer until 
saturated and placed upon the metal base plate. The gel (8.2 cm by 5.5 cm) was then 
placed on top and smoothed out after soaking in cathode buffer.  
A gel-sized Immobilon-P, PVDF membrane (Millipore, IPVH20200) was cut and 
briefly dipped in methanol (Sigma, 154903) and transferred to anode II buffer for 2 min. 
The membrane was placed upon the gel and air bubbles removed. 
64 
 
 Three gel-sized pieces of filter paper, also saturated in anode buffer II, were applied on 
top and rolled flat. A further 3 pieces of filter paper of the same size, saturated in anode 
buffer I, were rolled on top. 
The semi-dry blotter was run at 0.8 mAmps per cm2 of each gel for about 75 to 90 min 
for a 1.5 mm gel thickness (Bio-Rad, Power Pac 200). 
After blotting, the membrane was removed with forceps and soaked in a trough 
containing PBS, 0.2% (v/v) Tween. Then the membrane was placed upon a plate rocker 
for 10 min at a low speed sufficient to cause gentle agitation. All the following steps 
were carried out at room temperature and using a plate rocker.    
• The PBS, Tween solution was poured off and 10 ml of 10% (w/v) powdered 
milk was added and agitated for 1h. 
• Next the milk was removed, a 15 min wash with PBS 0.2% (v/v) tween was 
carried out as 3, 5 min washes. 
• Following this step, primary antibodies as (1:1000 volume for volume) were 
applied to the blot as a 25 ml solution of 1% (w/v) milk in PBS 0.2% (v/v) 
Tween. Antibodies were incubated for 1h at room temperature or 4ºC overnight. 
• The blot was washed 3 times with PBS 0.2% (v/v) Tween for 10 min.  
• Next the blot was incubated in 25 ml of a secondary antibody solution made as 
above except at 1:2000 antibody dilution for 1h. 
• Then the blot was washed in twice in PBS 0.2% (v/v) Tween for 5 min then 
again for 5 min in PBS with 0.01% (v/v) Tween, again in PBS for 5 min and 
finally very briefly washed in ultrapure water. 
• Next an ECL kit (Santa Cruz, sc-2048) was used mixing 2.5 ml of solution A 
and B together. This was added to the membrane carefully and wrapped in cling 
film. 
• Bands were detected by the Bio-Rad XRS Chemidoc using the 
chemiluminescence settings.  
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 Reagents 
 
6x Sample buffer, 25 ml  
• 17.5 ml of 0.5 M Tris, pH 6.8, Fisher, BPE152-1,  
• 7.5 ml of Glycerol, Fisher, G/0650/17, 
• 2.5 g of SDS, Gibco, 15711-021, 
• 2.3 g of DTT, Melford, MB1015, 
• 3 mg of Bromophenol blue, Sigma, 114391. 
 
5x Running buffer  
• 75.5 g Tris, Fisher, BPE152-1, 
• 360 g Glycine, Gibco, 15709-017,  
• 25 g SDS, Gibco, 15711-021, 
• Ultrapure water up to 5 litres. 
 
Anode Buffer I per litre, pH 10.4 
• 36.3 g Tris, Fisher, BPE152-1,  
• 100 ml Methanol, Sigma, 154903,  
• Ultrapure water up to 1 litre. 
Anode Buffer II per litre, pH 10.4  
• 3.03 g Tris, Fisher, BPE152-1,   
• 100 ml Methanol, Sigma, 154903,  
• Ultrapure water up to 1 litre. 
Cathode Buffer per litre, pH 9.4 
• 5.2 g of aminocaproic acid, Sigma, A2504, 
• 3.03 g Tris base, Fisher, BPE152-1,   
• 100 ml Methanol, Sigma, 154903, 
• Ultrapure water up to 1 litre. 
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 Blocking Solution 5% 
• 2.5 g Dried milk powder (Bio-Rad, 170-6404) in 50 ml of PBS or PBS Tween 
PBS 
• 1 Tablet added to 200 ml ultrapure water, Sigma, P4417-100TAB.  
PBS Tween 20 0.2% 
2 ml of tween in 1 litre of PBS, Sigma, P2287. 
For details of the antibodies used, see Table 2.4, Antibodies used for Western blot.  
 
Table 2.4.  Antibodies used for Western blot. 
 
P450 Primary Antibody Raised against 
Raised 
in 
Secondary 
Antibody 
Raised 
in 
Positive 
control 
CYP 
1A2 
Gentest 1A1, 
458124 
Rat CYP1A1 Goat Santa Cruz, sc2304 Donkey 
Gentest 
1A2,  
456203 
CYP 
2D6 
Gentest 2D6, 
458246 
Human 
CYP2D6 Mouse 
Santa Cruz, 
sc2302 Goat 
Gentest 
2D6, 
456217 
CYP 
2E1 
Gentest 2E1, 
458216 
Rat CYP2E1 Goat Santa Cruz, sc2302 Goat 
Gentest 
2E1, 
456206 
CYP 
2A6 
Gentest 2A6, 
458106 
Human 
CYP2A6 Mouse 
Santa Cruz, 
sc2302 
Goat 
Gentest 
2A6, 
456254 
CYP 
2C8 
Abcam 2C8, 
AB22596 
Human 
Synthetic 
Peptide 
Rabbit 
Santa Cruz, 
sc2301 
Goat 
Gentest 
2C8, 
456252 
CYP 
3A4 
Gentest 3A, 
458254 
HLM fraction Mouse Santa Cruz, sc2302 Goat 
Gentest 
3A4, 
456202 
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 2.18  Growth of Yeast Fermentation Seed Cultures 
 
Strains were grown from glycerol stocks to agar to 10 ml cultures to 100 ml seed 
cultures.  
Growth of Strains from Glycerol Stocks  
Strains were streaked out from glycerol stocks and grown on SD-Minimal agar with the 
required supplements at 30ºC for 3 days. 
Growth of Strains  
A 50 ml flask was inoculated with 10 ml of yeast seed SD-Minimal broth and required 
supplements at 83 μl of stock solutions (adenine 125 μl) per flask. Also 100 μl of 10% 
(w/v) Casamino acids stock solution was added.  
Starting OD600 was measured. OD measurements were performed using the WPA 
Biowave CO800 Cell Density Meter and standard disposable plastic microcuvettes 
(Fisher, FB55147). 
Cells were incubated at 30ºC for around 14 to 16h at 220 rpm, Sanyo Orbisafe TS. 
Growth of Strains (Time, 24h) 
The OD600 of the 10 ml culture was measured. Once the culture reached 6 to 8 ODs, it 
was placed at +4ºC to cool. This culture was then used to inoculate a 100 ml yeast seed 
broth in a 500 ml flask. This was made in the same way as above; see Table 2.5 for 
inoculum volume.  
Table 2.5.  Inoculum volume for OD at 600 nm ranges.  
Ranges of OD at 600 nm Inoculum volume in ml 
4.5 – 5.5 1.5 
6 – 6.7 1.2 
7 0.8 
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830 μl of stock solutions was added for each required supplement (adenine 1250 μl) to 
each flask. Also 1 ml of 10% (w/v) Casamino acids was added. Starting OD600 was 
measured. Cells were incubated at 30ºC for approximately 16h at 220 rpm. 
Growth of Strains (Time, 48h) 
The OD at 600 nm was measured from the 100 ml culture. Once the culture reached 
approximately 6 to 8 ODs at 600 nm, it was placed at +4ºC to cool. This culture was 
sufficient to inoculate a 10 litre fermentor. 
Reagents, Media and Chemicals 
SD-Min Agar (500 ml) 
• 3.35 g YNB, Difco, 291940, 
• 10 g of D-(+)-Glucose, Sigma, G5400,  
• 7.5 g of Agar, Oxoid, LP0013, 
• 1 pellet of Sodium Hydroxide as supplied by Fisher, BP359-500. 
Autoclaved under standard conditions, 121ºC for 20 min. 
SD Min broth (1 Litre) 
• 6.7 g of YNB, Difco, 291940, 
• 40 ml of a pre-autoclaved 50% (w/v) Glucose solution using the above glucose. 
Autoclaved under standard conditions, 121ºC for 20 min. 
Yeast Seed broth (also known as SW6 media)  
Yeast seed broth was transferred from SD-Minimal broth by the addition of Casamino 
acids stock, as below at 10 μl.ml-1. Stock concentration was 1 g.10ml-1 in ultrapure 
water, filter sterilised with a 0.2 μm filter and stored at +4ºC (Sartorius Minisart Cat No. 
16534, Appleton Woods). 
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Casamino acids stock  
Casein Hydrolysate, N-Z-Case, Sigma, Cat No. C-7585.  
Auxotrophic supplements  
• Adenine stock concentration 2.5 g.500ml-1, Sigma, A3159, 
• L-Histidine stock concentration 1.2 g.500ml-1, Sigma, H-8125, 
• L-Leucine stock concentration 3.6 g.500ml-1, Sigma, L-8000, 
• L-Tryptophan stock concentration 2.4 g.500ml-1, T0254, 
• Uracil stock concentration. U-1128. 1.2 g.500ml-1, U1128.  
 
2.19  Fermentor Protocol for the Growth of a GAL1 Promoter 
Driven Expression in Yeast 
 
This method used the New Brunswick Scientific Bioflow 110, 10 litre and 1 litre water-
jacketed vessels with four feed pumps, temperature probe, oxygen probe, pH probe, 
antifoam probe, gas on/off controller and gas flow regulator. Turbidity probes were also 
added (Solvias, OFS-125-297HA). Compressed air was from a Jun-Air laboratory 
compressor and chilled water for the vessel jackets and condensers from a Grant, 
RC1400G chiller. 
Preparation of 10 litre or 1 litre Vessel for Autoclaving  
All parts were well cleaned with ultrapure water to remove cleaning detergents.  
Media was weighed dry into the fermentor and topped up with ultrapure water. 600 ml 
was used for 1 litre fermentation and 6 litres for 10 litre fermentation.   
Before autoclaving pH probes were calibrated using standard pH 7.0 and pH 4.0 
calibration solutions by connecting to the fermentor controller system.  
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 Probes were autoclaved in situ, filters (Corning, 0.2 µm, 50 mm diameter, Appleton 
Woods, 431227) were protected with foil. A port was left loose for venting pressure. 
A validated autoclave cycle was found to ensure 121°C for 20 min, the run times for a 
150 litre top-loader (Priorclave) autoclave was found to be 121°C for 115 min for the 10 
litre vessel. 121°C for 60 min was sufficient for the 1 litre. 
Preparing the fermentor to start batch fermentation (Time, 24h) 
The coolant system was set to run at 12°C and the vessel temperature was set to 30°C 
two hours prior to starting the fermentor run. The filtered compressed air, parallel 
supply, was sparged at 5 litres per min for the 10 litre fermentor and 2.5 litres per min 
for the 1 litre fermentor.  
One hour prior to the start time 40 ml of a 50% (w/v) glucose solution was added (400 
ml for 10 litre fermentation).  
Auxotrophic supplements were added in the following amounts. 
• 15 ml of double strength adenine. (150 ml for 10 litre fermentation), 
• 16.9 ml of histidine, leucine, tryptophan or uracil. (169 ml for 10 litre 
fermentation).  
100 µl of antifoam (Sigma antifoam 204, A8311), 1 ml for 10 litre fermentation was 
finally added. 
The pH was adjusted to 6.6 by adding a 5 M NaOH solution with agitation at 500 rpm. 
Dissolved oxygen (DO) was adjusted after addition of antifoam. To calibrate the DO 
probe, the air flow was set to 10 litres per min and the impeller speed set to 500 rpm and 
this was set as 100%.  
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 To start the run, the airflow was set to either 5 litres per min for the 10 litre fermentor 
(2.5 litres per min for the 1 litre) and the agitation maintained at 500 rpm. 
When the experiment was ready to start, between 80 ml-120 ml (10 litre fermentor) of 
yeast seed broth culture was added.   
Automatic Nutrient Feed, (Time, 48h) 
After 12h of fermentation the program delivered (at 10 ml per min) the following feed. 
For the 10 litre fermentor this comprised of 
• 300 ml of 50% (w/v) Glucose, Sigma, G5400,  
• 300 ml of ethanol, BP grade, Fisher, E/0650DF/25, 
• 150 ml of double strength Adenine, 
• 169 ml of Histidine, Leucine, Tryptophan or Uracil. 
Induction (Time, 48h)  
After 11h of further fermentation, 300 g of galactose (Fisher, 150610010) was added as 
a thick suspension with one of the other liquid additions. The galactose was added 
slowly to avoid osmotic shock. For the 10 litre fermentor this comprised of,    
• 150 ml of double strength adenine, 
• 169 ml of histidine, leucine, tryptophan or uracil,  
• 200 ml of absolute ethanol, 
• 1 ml of antifoam. 
Harvest (Time, 72h) 
After 36h, the fermentation was stopped. 
The system was set to +4°C and agitation reduced to 50 rpm. Air flow was reduced to 
one litre per min. The culture was pumped into cold buckets and centrifuged at 4500 
rpm, (4495g) for 20 min at +4°C, using the Sorvall Legend RT.  
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 The cell pellets were washed three times with sorbitol buffer A (see section 2.9). Each 
time the pellet was gently re-suspended. Pellets were weighed and were stored dry for 
short periods at –80°C.  
Fermentor Media Components and Chemicals 
• YP Media, 
• 200 g of Yeast Extract, Oxoid, LP0085, 
• 200 g of Peptone, Oxoid, LP0021.  
Additions 
• D-(+)-Glucose min 99% GC 50% (w/v) solution, Sigma, G5400,  
• Ethanol, Sigma, E7023, 
• D-(+)-Galactose 99+% Fisher, 150610010,  
• 5 g.500ml-1 (1 x) Adenine, Sigma, A3159,  
• 1.2 g.500ml-1 L-Histidine, Sigma, H-8125,  
• 3.6 g.500ml-1 L-Leucine, Sigma, L-8000,  
• 2.4 g.500ml-1L-Tryptophan, Sigma, T0254,  
• 1.2 g.500ml-1 Uracil Sigma, U-1128,   
• 5 M Sodium Hydroxide solution, Fisher, BP359-500, 
• Antifoam 204, Sigma, A8311. 
 
2.20  Microsome Preparation from 10 Litre Fermentation 
 Cultures Using the Constant Systems Cell Disruptor 
 
Pellets were removed from –80°C and kept on ice for 30 min, then at room temperature 
for 30 min. Sorbitol buffer A at +4ºC (see section 2.9) was added on top of the pellet in 
each bucket at the ratio of 1 ml per g of wet weight of pellet. Next the buckets were 
placed on a slow rocker until the pellets were fully defrosted.  
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 After stirring, the pellet was re-suspended gently with a pipette. Buffer A also contained 
0.275 mM DTT and 2.75 mM of AEBSF to stabilise the P450s and prevent protease 
activity.  
The cells were disrupted using the Constant Systems Basic Z model with a continuous 
jacketed processing head connected to a chiller at +4°C.  
A chilled bucket was placed at the machine outlet to collect the lysate. The pressure was 
set to 20 KPSI. The lysate was then centrifuged at 4600 rpm (4495g) for 20 min at +4°C 
using the Sorvall Legend RT.  
The lysate supernatant was poured into fresh buckets and centrifuged repeatedly (as 
above) until the remains of unbroken cells were removed. 
Large scale production method 
Supernatants were further processed with a High-Speed Beckman Coulter centrifuge 
Avanti J-20XP, JLA10.5 rotor at 10,000 rpm (18,600g) for 20 min at 4°C. This removed 
cell debris, nuclei, peroxisomes, lysosomes and mitochondria. This step was repeated 
into clean-cooled buckets until no significant pellet was produced. The product of this 
step is known as S9 fractions which were poured into fresh buckets and centrifuged at 
10,000 rpm (18,600g), for about 21h at +4°C in the JLA10.5 rotor. This step was to 
pellet the microsomal fraction of the cell.  
The following steps were all performed on ice in a cold room.  
• The supernatants containing the soluble cytosolic fraction were removed and the 
surface of the pellets was washed twice with 10 ml of microsome buffer C. 
• The pellets were transferred into a 30 ml glass homogeniser with PTFE pestle 
(Fisher, FB56769). A minimal amount of microsome Buffer C was added 
depending on size of pellet to allow initial homogenisation. The volume was 
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 enough to homogenise with no clumping of pellet. The batches of homogenised 
microsomes were pooled together and were gently pipetted up and down. 
• Microsomes were aliquoted into 50 ml tubes and stored at –80°C. A few 
separate small volumes were kept for assaying.  
• After assaying they were thawed on ice and diluted to 1 nmol of P450 per ml 
and stored in small volumes at -80ºC. 
Reagents 
• 4 M (728.68 g.L-1) D-Sorbitol, Melford, 50807, 
• 1 M (121.14 g.L-1) Tris, pH 7.5 Fisher, BPE152-1, 
• 0.5 M (186.12 g.L-1) EDTA, pH 8, Gibco, 15706-021, 
• 50% (v/v), Glycerol, Fisher, G/0650/17. 
Sorbitol buffer A  
• 162.5 ml of 4 M Sorbitol final concentration 0.65 M, Melford, MB1015, 
• 10 ml of 1 M Tris pH 7.5, final concentration 10 mM. Fisher, BPE152-1, 
• 200 µl of 0.5 M EDTA pH 8.0, final concentration 0.1 mM, Gibco, 1570-6-021,  
• Final volume was to 1 litre with ultrapure water. 
Buffer C 
• 1 ml of 1M Tris, pH 7.5 final concentration 10 mM, Fisher, BPE152-1, 
• 200 µl (0.5 M EDTA pH 8.0) final concentration 1.0 mM, Gibco, 1570-6-021, 
• 40 ml of 50% (v/v) Glycerol final concentration 20% Fisher, G/0650/17, 
• Topped up to 100 ml with ultrapure water. 
100 mM AEBSF (4-(2-Aminoethyl)-benzenesulfonyl fluoride, HCl) Protease Inhibitor 
Working Solution  
• 239.7 mg of AEBSF in 10 ml of ultrapure water. Melford, MB2003.  
DL-Dithiothreitol (DTT) Working Solution (100 mM) 
• 154.2 mg in 10 ml of ultrapure water. Melford, MB1015. 
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 2.21  PEG and Calcium chloride precipitation 
 
PEG precipitation 
The samples were processed to the S9 fraction (after high speed centrifugation, see 
section 2.11). The volume of S9 fraction in ml was multiplied by 3.75. This value gave 
the amount of cold TES buffer to add in ml. Next, the volume of cold 5 M sodium 
chloride solution was calculated in ml by dividing of the TES volume required by 40.  
After this, the volume of ice cold PEG was calculated in ml by multiplication of the 
volume of 5 M NaCl required by 10 for the amount of ice cold PEG 3350 50% (w/v) to 
be added. This was added drop-wise, left for 20 min, and centrifuged in the Beckman 
JA17 rotor, 9,400 rpm (12,000g) at +4 for 10 min; microsomal pellets were produced 
and processed using glass homogenisers.  
Calcium chloride precipitation 
The samples were processed to the S9 fraction. The volume of S9 fraction in was used 
to calculate the amount of calcium chloride to add to the S9 fraction to the volume so 
that the final concentration was 18 mM CaCl2. The samples were kept at +4°C for 30 
min. The microsomes were then centrifuged in the Beckman JA17 rotor, 10,800 rpm 
(16,000g) for 15 min and microsomal pellets were produced and processed using glass 
homogenisers. 
Reagents 
 
• 10 ml of 1 M Tris pH 7.5, BPE152-1,  
• 400 µl of 0.5 M EDTA, pH8.0, Gibco, 1570-6-012, 
• 30 ml of  4 M Sorbitol, Melford, MB1015, 
• Topped up to 200 ml with ultrapure water, 
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 • 50% (w/v) PEG 3350 made up in ultrapure water, Sigma, P4338,  
• 5 M Sodium chloride in ultrapure water, Sigma, S-3014,  
• 2 M Calcium chloride in ultrapure water, Sigma, C1016. 
 
2.22  LC-MS procedure for detection of CYP2D6 
dextromethorphan metabolism using lyophilised samples 
 
Dextromethorphan hydrobromide (MW 370.3), (Sigma, D9684-5g) is converted by 
CYP2D6 to dextrorphan (MW 356.3) by the dextromethorphan O-demethylase reaction 
mediated by CYP2D6. From this, CYP2D6 activity may be measured. 
Sample preparation 
Dextromethorphan hydrobromide substrate was made as a 10 mM stock in pure ethanol. 
Working stocks were diluted in ultrapure water to 100 µM. 1.25 µl was further diluted 
in ultrapure water to 10 µl (1/8 dilution) to give a 12.5 µM solution. From this, 1 µl was 
added to a 100 µl reaction (1/10) making the final concentration 125 nM. 
100 µl reactions were mixed in glass tubes, Fisher, FB71810. Volumes per reaction, 
• 400 mM Potassium Phosphate, pH 7.6 50 µl,  
• Ultrapure water    25 µl, 
• Solution A      10 µl, 
• Solution B     2 µl, 
• 3 pmol of CYP2D6 microsomes  3 µl, 
• Substrate      10 µl. 
Tubes were incubated for 10, 20 and 30 min at 30°C in a thermomixer at 200 rpm. 
Solutions A and B were identical to the ones described in the P450 fluorescent activity 
assays; see section 2.14. 
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 Reactions were stopped by adding 100 µl of 0.05% (w/v) formic acid in acetonitrile and 
kept on ice for 10 min. 
Tubes were centrifuged in an Eppendorf 5702R at 17°C, 4400 rpm (3000g) for 15 min. 
The supernatant was removed for analysis, pipetted into standard brown HPLC vials 
with septum lids and placed in the 4°C auto-sampler. 20 µl injection volumes were 
used. 
 
2.23 HPLC-Mass Spectrometry settings 
 
The Agilent HPLC 1100, LC/MSD SL with multimode head machine was used.  
LC-MS settings 
• m/z 258 analyte, 272 substrate- fragmentor-240, APCI-ESI, 
• Range 100-1000 -fragmentor-240, APCI-ESI, 
• Spray chamber dry gas flow rate 12 L.min-1, 
• Capillary voltage 5400, 
• Nebuliser pressure 50 PSI,  
• Corona current 1 Amp, 
• Dry gas temperature 300°C, 
• Charge voltage 1000, 
• Vaporiser temperature 200°C. 
 
The HPLC column was an Agilent eclipse XDB Zorbax C18 (993967-902) kept at 
30°C.  
Two solvents were used as the flow rate of 1 ml.min-1 with a maximum pressure of 400 
PSI. Table 2.9 shows solvent gradient during a typical HPLC/MS run, 
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 • A 0.05% (w/v) formic acid (Fluka, 94318) in ultrapure water. 
• B 0.05% (w/v) formic acid in acetonitrile (Fisher, A/0638/17). 
 
Table 2.6.  Solvent gradient during HPLC/MS run. 
 
Time in min % Solvent A % Solvent B 
0 90 10 
2 90 10 
14 10 90 
17 10 90 
Post 17, Stop and wash 
through 90 10 
 
Typical column retention times were substrate 8.51 min and analyte (i.e. metabolite) 
6.71 min. 
 
2.24  Method for determination of IC50  
 
1 pmol (1µl) of yeast CYP1A2, 2 pmol (2 µl) of yeast CYP2D6 and 1 pmol (1µl) of 
yeast CYP3A4 in a buffer mix containing 100 mM potassium phosphate buffer and 20% 
(w/v) sucrose (total volume 10 µl) were aliquoted into wells of microtitre plates then 
lyophilised. After lyophilisation, plates were kept for 21 days at 21°C. The wells were 
re-hydrated with 10 µl with ultrapure water. 
Yeast (prepared during the course of work conducted for this thesis) and insect cell 
derived microsomes obtained from Gentest, both of which had been stored at -80°C, 
were used as controls for testing the activities of the lyophilised microsomes. The plate 
layouts included 6 inhibitor concentrations to be tested in quadruplicate with further 
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 wells used for the positive control (i.e. wells containing uninhibited P450s plus solvent, 
which showed 0% inhibition) and a negative control (i.e. wells containing reactions that 
were stopped before P450 was added, which showed 100% inhibition).   
Furafylline (Sigma Q-3625), a published CYP1A2 inhibitor, was used at a final well 
concentration of between 3125 µM and 0.0305 µM of furafylline and ~0.5% DMSO. 
Quinidine (Sigma Q-3625), a published CYP2D6 inhibitor, was used at a final well 
concentration of between 3.4 µM and 0.00017 µM and ~0.5% DMSO. 
Ketoconazole (Sigma K-1003), a known CYP3A4 inhibitor, was used at a final well 
concentration of between 1.95 µM and 0.061 µM and ~0.5% DMSO. 
Inhibitors were pre-incubated with the P450s for 20 min at 21°C in 100 mM potassium 
phosphate buffer at pH7.4. The reaction was initiated with standard regenerating system 
components A and B with the substrates: CEC for CYP1A2, EOMCC for CYP2D6 and 
DBF for CYP3A4. After 10 min at 30°C the reactions were stopped with 20% 0.5M 
Tris base (pH not altered) with 80% acetonitrile and analysed for end point RFLUs.   
 
2.25  Lyophilisation reagents 
 
Below is a list of equipment and reagents used in the process. 
• Glass ampoules, SLS, VIA1000, 
• Heto Drywinner lyophilisation machine, CT/DW60E, 
• BOC-Edwards vacuum pump, RV5,  
• Twin jet ampoule sealer, Adelphi manufacturing, 6002100, 6002120 and 
6002110,  
• Bioteck Synergy HT plate reader with KC4 software version 3.9, revision 12, 
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 • A list of various commercial P450 used throughout the work follows, 
• Glycerol, Fisher, G/0650/17, 
• Mannose, Sigma, M6020, 
• Trehalose, Sigma, T9531, 
• Maltose, Sigma, M5885, 
• Sucrose, Sigma S0389, 
• Galactose, Sigma, G6404, 
• Raffinose, Sigma, R-0514, 
• Sorbitol, Melford, MB1015,  
• Glucose, Sigma, G5400.  
 
BD Gentest, Supersomes (Insect cell derived) 
• CYP1A1, 456211, 
• CYP1A2, 456203, 
• CYP1B1, 456220, 
• CYP2A6, 45254, 
• CYP2C8, 456252, 
• CYP2D6, 456217, 
• CYP2E1, 456206, 
• CYP3A4, 456202, 
• CYP2D6, 455117 Lympoblastoid derived. 
 
Cypex (Bacterial cell derived) 
• CYP2D6, CYP/EZ007, 
• CYP1A2, CYP/EZ001, 
• CYP2E1, CYP/EZ036, 
• CYP3A4, CYP/EZ005. 
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 Invitrogen (Insect cell derived) 
• CYP1A2, P2797, 
• CYP2E1, P2948, 
• CYP2D6, P2283, 
• CYP3A4, P2377. 
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 Chapter 3. Construction and characterisation of 
plasmids, optimisation of media 
components  
 
3.1  Creating promoter driven P450 reductase constructs with 
an auxotrophic marker for chromosomal integration 
 
A galactose-inducible (GAL1) promoter fragment, Gal1MS (GAL1 promoter with 
contiguous c-myc tag and SUC2 terminator) with SacI and XhoI ends was isolated from 
plasmid pBGAL1MS (Figure 3.1). This 3942 base pair plasmid contained a ColE1 
origin of replication and an ampicillin marker. The ~1 Kbp GAL1 promoter-c-myc tag-
SUC2 terminator fragment was isolated.   
Figure 3.1  Plasmid Map of pBGAL1MS. 
 
 
This is a bacterial vector with the β-lactamase gene as ampicillin resistant marker (Amp-r). It has been 
used to amplify the GAL1p-SUC2t cassette for further sub-cloning in yeast integrating vectors so that a 
P450 reductase gene could be cloned under the control of the galactose-inducible GAL1 promoter.  
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 pRS403 (ATCC, #87477) is a yeast integrating plasmid of 4456 base pairs with a ColE1 
origin of replication, bacterial ampicillin resistance gene and the yeast HIS3 gene as a 
yeast selection marker. The plasmid was linearised at the multi-cloning site by digesting 
with SacI and XhoI. A linear fragment of approximately 4.4 Kbp was isolated, Figure 
3.2.  
Figure 3.2  SacI and XhoI digested pRS403. 
 
This is a 1% agarose-TAE gel. Lane 1, the pRS403 plasmid (ATCC, 87477) digested with SacI and XhoI 
to allow ligation of the GAL1-SUCt cassette from pBGAL1MS. Lane 2, a DNA ladder with the main 
DNA markers highlighted in base pairs (bps). 
 
 
The fragments from pBGAL1MS and the linearised plasmid pRS403 were ligated using 
T4 DNA ligase. Six different bacterial clones from the transformation were amplified in 
small bacterial cultures and the DNA obtained was analysed using restriction enzyme 
digests. The DNA from the clones was digested with SacI and XhoI to confirm that they 
yielded the expected fragments, 4365bp (Vector) and 1069bp (Insert, GAL1p-SUC2t), 
Figure 3.3. All six clones were correct. One correct clone was designated 
YIHisGAL1MS, the plasmid map for which is shown in Figure 3.4.  
 
1636 
2036 
1018 
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3054 
4072 
1 2 
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 Figure 3.3  SacI-XhoI digest of YIHisGAL1MS. 
 
This is a 1% agarose-TAE gel. Lanes 1 to 6, pRS403 vector (upper band) and GAL1p-SUCt insert (lower 
band), that had been isolated from pBGAL1MS. The digest shows correct ligation to form the plasmid, 
YIHisGAL1MS. Lane 7, main DNA markers shown in base pairs (bps). 
 
Figure 3.4. Plasmid Map of YIHisGAL1MS.  
 
YIHisGAL1MS plasmid is a shuttle vector that can be amplified in bacterial cells and can be used for 
integration into a particular chromosomal locus (where the HIS3 gene resides) of the yeast, S. cerevisiae. 
The plasmid was later used to clone P450 reductase genes between the BamHI-XbaI restriction sites.  
 
Next, a BamHI-XbaI fragment of the human cytochrome P450 reductase gene (hRD) 
and a BglII-XbaI yeast reductase (yRD) fragment were cloned into the new 
YIHisGAL1MS plasmid so that the two reductase genes could be driven by the GAL1 
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 promoter. The hRD fragment was isolated from a human liver cDNA library and the 
yRD fragment was isolated from a yeast genomic library, using the polymerase chain 
reaction (PCR) and a proof-reading Taq polymerase. YIHisGAL1MS plasmid was cut 
with (BamHI-XbaI) and then ligated together with the hRD and yRD fragments (BamHI 
and BglII restriction sites having compatible overhangs) to create the new integrating 
plasmids YIHisGAL1MS/hRD (Figure 3.5) and YIHisGAL1MS/yRD (Figure 3.6). The 
two plasmids were further amplified in E. coli so that they could be used for integration 
in yeast.  
Figure 3.5.  YIHisGAL1MS/hRD. 
 
The human reductase gene (hRDStop) was inserted into the YIHisGAL1MS plasmid to form the new 
plasmid YIHisGAL1M/hRD. This plasmid was used for integration of the hRD expression cassette, 
driven by the galactose-inducible GAL1 promoter, into yeast’s HIS3 chromosomal locus.   
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 Figure 3.6  YIHisGAL1MS/yRD. 
 
The yeast reductase gene (yea_P450 reductase) was inserted into the YIHisGAL1MS plasmid to form the 
new plasmid YIHisGAL1M/yRD.  This plasmid was used for integration of the yRD expression cassette, 
driven by the galactose-inducible GAL1 promoter, into yeast’s HIS3 chromosomal locus.   
 
A SalI-XbaI digest of the YIHisGAL1MS/hRD and YIHisGAL1MS/yRD plasmids 
excised the reductase genes from the plasmid and this was confirmed by gel 
electrophoresis, Figure 3.7.  
YIHisGal1MS/yRD
7501 bps
1000
2000
3000
4000
5000
6000
7000
Esp 3I 51
Bsa BI 557
Dra I 569
Nde I 693
Bal I 709
Bbs I 783
Hin dIII 808
Dra I 813
Bst XI 886
Bgl II 899
Bgl II 959
Hin dIII 995
Nhe I 1008
Bcl I 1052
Asp 718I 1122 ++
Afl III 1203 ++
Afl III 1293
Nae I 1748
Ngo MIV 1748
Fsp I 1900
Pvu I 1920
Pvu II 1950
2076
Asp 718I
Kpn I
Apa I
Ava I
Str I
Xho I
Hin cII
Sal I
Bsp DI
Cla I
Hin dIII
Eco RV
Eco RI
2124
Bbs I 2392
Bbs I 2416
Ase I 2620
Sna BI 2877 ++
Bst XI 3049 ++
Nde I 3160
Hin cII 3192
Bbs I 3201
Axy I 3242
Eco 81I 3242
Eco RI 3282
Mun I 3585
Sca I 3709
Bst EII 3720
Bst XI 3745HI 3824Bam
I 3915Mun
I 4062Ege
I 4062Nar
I 4266Mun
cII 4284Hin
I 4284Hpa
I 4321Swa
I 4322Dra
HI 4420Bsp++
I 4434Kpn++
XI 4597Bst++
cII 4772Hin++
I 4911Bbs
XI 5080Bst
I 5223Sac
I 5391Ase
II 5443Pvu
I 5450Ase
III 5621Afl
HI 6341Bsp
I 6378Dra
I 6397Dra
I 6685Ase
I 6734Fsp
I 6881Pvu
I 6992Sca
I 7089Dra
HI 7349Bsp
HI 7454Bsp
3I 7498Esp
T7p
T3p
HIS3
f1ori
GAL1p
yea_P450 reductase
M
S
ColE1ori
Amp-r
87 
 
 Figure 3.7  SalI-XbaI digest of YIHisGAL1MS/hRD and 
YIHisGAL1MS/yRD.  
 
Lanes 1 to 3, YIHisGAL1MS/hRD and lanes 4 to 6, YIHisGAL1MS/yRD, digested with SalI-BamHI 
which yields two bands to confirm correct ligation. The upper band is the plasmid and the lower the P450 
reductase insert. This 1% agarose-TAE gel has the DNA ladder, in lane 7; the sizes of the main DNA 
markers are highlighted. 
 
The YIHisGAL1MS/hRD and YIHisGAL1MS/yRD plasmids were used separately for 
integrations into the yeast strain W303Matα which lacks a functional copy of the HIS3 
gene. Both plasmids were linearised at the NheI restriction site which is within the HIS3 
gene. The sites for linearization are shown in Figures 3.8 and 3.9. Upon homologous 
recombination, the linearised plasmid should provide a functional, repaired copy of the 
HIS3 gene. 
After linearization with NheI, the linearized DNA was isolated for integration into yeast, 
Figure 3.10.  
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 Figure 3.8  Map showing where NheI linearises the plasmid 
YIHisGAL1MS/hRD. 
 
 
The YIHisGAL1MS/hRD plasmid required linearisation at the NheI site (shown with a red arrow) to 
allow chromosomal integration to occur at the HIS3 site.  
 
Figure 3.9  Map showing where NheI linearises the plasmid 
YIHisGAL1MS/yRD. 
 
 
The YIHisGAL1MS/yRD plasmid required linearisation at the NheI site (shown with a red arrow) to 
allow chromosomal integration to occur at yeast’s HIS3 chromosomal locus.  
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 Figure 3.10 YIHisGAL1MS/hRD and YIHisGAL1MS/yRD NheI 
linearisation. 
 
Lanes 1 and 2, Plasmids YIHisGAL1MS/hRD and YIHisGAL1MS/yRD linearised with the restriction 
enzyme NheI. The linearized DNA fragments were isolated and purified for further integration into yeast. 
This is a 1% agarose-TAE gel, with the DNA ladder in lane 3; the main DNA markers are highlighted on 
the side. 
 
Later, an integrative vector encoding the human cytochrome b5 gene was constructed 
which would allow integration in yeast’s TRP1 locus. The methods used to construct the 
plasmid were similar to that used for the construction of the reductase gene encoding 
HIS3 integrating plasmids. The cytochrome b5 gene was also under the control of the 
GAL1 promoter. Besides his3 and trp1, the yeast strain W303Matα contains three other 
auxotrophic markers. They are ade2, leu2 and ura3. A URA3 bearing yeast episomal 
plasmid was used to create derivatives that encode different P450 genes. These 
plasmids complement the ura3 auxotroph. The two reductase genes have also been 
cloned in ADE2 and LEU2-bearing yeast integrating plasmids in order to determine if 
the two reductase genes placed in different chromosomal loci would express the 
reductase proteins differentially.  
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 The P450 and reductase genes were cloned in episomal and integrative plasmids that 
contained a diverse range of promoters. Different promoter bearing plasmids were 
created essentially through exchange of promoters. Besides the GAL1 promoter driven 
constructs, plasmids bearing the ethanol-inducible ADH2 promoter have widely been 
used in this thesis.  
All the human P450 genes were isolated from a cDNA library derived from a human 
liver using PCR and a proof-reading Taq polymerase.  
 
3.2  Creating a P450 episomal plasmid  
 
Various transformations using episomal P450 plasmids were made searching for clones 
with high expression levels.  
Using a human liver cDNA library as the PCR template, the 1506bp BamHI-XbaI 
fragment of the human CYP2D6 gene was amplified using the following two primers: 
• Forward primer, 5’-ATG GAT CCA AAA TGG GGC TAG AAG CAC TGG 
TGC CC-3’ (OBC016A); it has an AAA sequence, which is thought to enhance 
gene expression in yeast, between the BamHI restriction site (underlined) and 
the ATG start site (bold letters), and 
• Reverse primer, 5’-CTA GTC TAG ACT AGC GGG GCA CAG CAC AAA 
GC-3’ (2D6STOP) which contains the XbaI site (underlined).  
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 Figure 3.11 shows amplification of the human CYP2D6 gene from the human liver 
cDNA library. Figure 3.12 shows isolation of the restriction enzyme digested human 
CYP2D6 gene fragment which is ready for cloning in a vector of choice.  
Figure 3.11 PCR to isolate the CYP2D6 gene from a human liver 
cDNA library. 
 
Lane 1, the CYP2D6 gene was amplified by PCR from a human liver cDNA library so that the amplified 
fragment contains the required restriction sites. This is a 1% agarose-TAE gel which has the DNA ladder 
in lane 2; the 1636bp DNA marker is highlighted on the side. 
 
Figure 3.12  Restriction of CYP2D6 gene PCR product with BamHI and 
XbaI. 
 
Lane 1, the BamHI-XbaI digested CYP2D6 gene fragment was isolate and purified for cloning into 
episomal vectors. This is a 1% agarose-TAE gel which has the DNA ladder in lane 2; the 1636bp DNA 
marker is highlighted on the side.  
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The BamHI-XbaI digested human CYP2D6 gene, from Figure 3.12, was ligated to a 
2964bp pBluKS+ plasmid, also digested with BamHI and XbaI, to create the 4455bp 
plasmid which was designated pBluKS/BamHI-XbaI/3A-CYP2D6 (Figure 3.13).  
 
Figure 3.13  pBluKS/BamHI-XbaI/3A-CYP2D6. 
 
The BamHI-XbaI restricted CYP2D6 PCR product was ligated into the vector pBlueKS(+) in its multi-
cloning site. The resultant clones were selected in bacterial cells in the presence of ampicillin (for 
selection of ampicillin-resistant clones) and X-Gal/IPTG blue/white screening (for confirming that the 
CYP2D6 gene had indeed disrupted the lacZ gene on the parent plasmid). 
 
The plasmid was checked with a BamHI-XbaI restriction digest which yielded a 2952 
base pair vector fragment, as seen below the 3054 base pair DNA ladder marker with a 
very faint ~1500 base pair CYP2D6 fragment just beneath the 1636 base pair marker; 
see Figure 3.14.  
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Alw NI 1847
Bst EII 1898
Eag I 1918
Pvu II 1958
Pst I 1961
Afl III 1972
Nar I 1987
Srf I 2050
Sma I 2051
Nar I 2098
2180
BamHI
Sma I
Pst I
Eco RI
Eco RV
Hin dIII
Bsp DI
Cla I
Hin cII
Sal I
Xho I
Apa I
Asp 718I
Kpn I
2246
I 2414Ase
II 2466Pvu
I 2473Ase
I 2521Sap
III 2644Afl
NI 3055Alw
HI 3364Bsp
I 3401Dra
I 3420Dra
I 3708Ase
I 3757Fsp
I 3904Pvu
I 4015Sca
I 4112Dra
HI 4372Bsp
''lacZ
h_CYP2D6
lacZ'
ColE1ori
Amp-r
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 Figure 3.14 BamHI-XbaI digest of pBluKS/BamHI-XbaI/3A-CYP2D6. 
 
Lanes 1 and 2, the pBluescript plasmids were digested to show that it contained the CYP2D6 gene insert. 
This is a 1% agarose-TAE gel which has the DNA ladder lane in 3; the main DNA markers are 
highlighted on the side. The vector is visible at 3054bp but the CYP2D6 gene fragment was very faint.  
 
The pBluKS/BamHI-XbaI/3A-CYP2D6 plasmid and the pSYE224 (a yeast shuttle 
vector with the URA3 marker, a partial 2µ sequence and the Gal1p-CYC1t promoter-
terminator cassette) were both separately digested with BamHI and XbaI. The products 
were ligated, amplified in bacterial cells, and plasmid DNA was purified. The new 
plasmid was designated pSYE224/hCYP2D6 (Figure 3.15) and it was used to transform 
different W303Matα yeast strains which harboured different P450 reductases for 
expression with active human CYP2D6 enzyme. 
 
 
 
 
1 2 3 
1636 
2036 
3054 
4072 
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 Figure 3.15  The episomal plasmid, pSYE224/hCYP2D6. 
Plasmid Map showing restriction sites that occur only once. 
  
The BamHI-XbaI human CYP2D6 gene fragment (h_CYP2D6) isolated from the plasmid 
pBluKS/BamHI-XbaI/3A-CYP2D6 was ligated to the pSYE224 plasmid digested with BamHI and XbaI. 
The resultant plasmid was designated pSYE224/hCYP2D6. This episomal plasmid with a uracil marker 
(URA3) was amplified in E. coli for the plasmid to be transformed in yeast so that CYP2D6 protein could 
be expressed. The CYP2D6 gene fragment was under the control of a galactose-inducible promoter 
(Gal1p) with a terminator from a cytochrome C gene (CYC1t). The 2 micron origin of replication from 
yeast (2µ_ori) controls plasmid copy number in yeast.  
 
The BamHI-XbaI human CYP2D6 gene fragment was similarly cloned in the episomal plasmid pSYE263, 
to allow ADH2 promoter-driven expression of CYP2D6. 
 
 
A diagnostic for correct ligation of CYP2D6 gene to the vector was carried out via 
digestion with BamHI and XbaI, Figure 3.16. The CYP2D6 gene fragment was around 
the size of the 1517bp DNA marker; the vector backbone was above. Lanes one to six 
are six clones from the same transformation procedure.  
 
pSYE224/hCYP2D6
7321 bps
1000
2000
3000
4000
5000
6000
7000
Mlu I 75
Bsp 1407I 82
Xba I 261
Sac I 399
Sph I 429
Tth 111I 648
Bss HII 1389
Eag I 1499
Srf I 1631
Sma I 1632
Xma I 1632
Bal I 1715
BamHI 1758
Age I 2141
Eco RI 2439
Hin dIII 2451
Swa I 2795
Sna BI 3100
I 3745Hpa
I 4151Nru
I 4338Nhe
I 4544Sbf
3I 5195Esp
CYC1T
h_CYP2D6
GAL1P
f1 ori
2u_ori
URA3
Amp-R
ColE1ori
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 Figure 3.16   BamH1 and Xba1 digest of pSYE224/2D6. 
 
 
Lanes 1 to 6, the DNA isolated from the clones, obtained from the ligation of CYP2D6 gene to pSYE224, 
were digested to show correct ligation. Analysis of all six clones confirmed the formation of the plasmid, 
pSYE224/2D6. The upper band is the plasmid backbone and the lower, CYP2D6. This is a 1% agarose-
TAE gel which has the DNA ladder in lane 7; the 1517bp marker highlighted on the side.  
 
The episomal plasmid used contained only a 1471bp region of the yeast 2-micron (2µ) 
sequence which contains the autonomous replication sequence (ARS), origin of 
replication and the REP3 segregation element (STB).  
In the 2µ plasmid, the REP3 element co-expresses with two other genes (REP1 and 
REP2) which form a complex that controls segregation to daughter cells. As the host 
yeast strain already contains an endogenous, full 2µ plasmid (cir+), the minimal 1471bp 
Ori-STB sequence allows only replication in yeast without allowing recombination with 
the endogenous 2µ plasmid. However, the regulation of the copy number of the 
episomal plasmid is probably still provided by the endogenous 2µ plasmid.  
Similarly, five other episomal plasmids encoding the human CYP1A2, CYP2A6, 
CYP2C8, CYP2E1 and CYP3A4, all being driven by the yeast GAL1 promoter, were 
created. Their plasmid maps are shown below (Figures 3.17, 3.18, 3.19, 3.20, 3.21). 
1517 
1 2 3 4 5 6 7 
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 3.3.  Maps of CYP gene-encoding GAL1 promoter-driven episomal 
plasmids 
Figure 3.17 The episomal plasmid, pSYE224/hCYP1A2. 
Plasmid Map showing restriction sites that occur only once. 
 
The BamHI-XhoI human CYP1A2 gene fragment (h_CYP1A2) isolated from the plasmid 
pBluKS/BamHI-XhoI/6A-CYP1A2 was ligated to the pSYE224 plasmid digested with BamHI and XhoI. 
The resultant plasmid was designated pSYE224/CYP1A2. This episomal plasmid with a uracil marker 
(URA3) was amplified in E. coli for the plasmid to be transformed in yeast so that CYP1A2 protein could 
be expressed. The CYP1A2 gene fragment was under the control of a galactose-inducible promoter 
(Gal1p) with a terminator from a cytochrome C gene (CYC1t). The 2 micron origin of replication from 
yeast (2µ_ori) controls plasmid copy number in yeast. 
 
The BamHI-XhoI human CYP1A2 gene fragment was similarly cloned in the episomal plasmid pSYE263, 
to allow ADH2 promoter-driven expression of CYP1A2. 
 
  
pSYE224/h_CYP1A2
7399 bps
1000
2000
3000
4000
5000
6000
7000
Mlu I 75
Bsp 1407I 82
Xba I 261
Sph I 268
Str I 273
Xho I 273
Sal I 360
Bgl II 425
Pvu II 735
Tth 111I 864
Bcl I 1310
Bbe I 1415
Ege I 1415
Kas I 1415
Nar I 1415
BamHI 1836
Eco RI 2517
Hin dIII 2529
Swa I 2873
Sna BI 3178
I 3823Hpa
I 4229Nru
I 4416Nhe
I 4557Nde
I 4622Sbf
I 5019Apa
3I 5273Esp
CYC1T
h_CYP1A2
GAL1p
f1 ori
2u_ori
URA3
Amp r
ColE1ori
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 Figure 3.18 The episomal plasmid, pSYE224/hCYP2A6. 
Plasmid Map showing restriction sites that occur only once. 
 
The BglII-XhoI human CYP2A6 gene fragment (h_CYP2A6) isolated from the plasmid pSP73/BglII-
XhoI/6A- CYP2A6 was ligated to the pSYE224 plasmid digested with BamHI and XhoI. The resultant 
plasmid was designated pSYE224/CYP2A6. This episomal plasmid with a uracil marker (URA3) was 
amplified in E. coli for the plasmid to be transformed in yeast so that CYP2A6 protein could be 
expressed. The CYP2A6 gene fragment was under the control of a galactose-inducible promoter (Gal1p) 
with a terminator from a cytochrome C gene (CYC1t). The 2 micron origin of replication from yeast 
(2µ_ori) controls plasmid copy number in yeast. 
 
The BglII-XhoI human CYP2A6 gene fragment was similarly cloned in the episomal plasmid pSYE263, to 
allow ADH2 promoter-driven expression of CYP2A6. 
 
 
  
pSYE224/CYP2A6
7333 bps
1000
2000
3000
4000
5000
6000
7000
Mlu I 75
Xba I 261
Str I 273
Xho I 273
Sac I 417
Bal I 428
BamHI 982
Bbe I 1266
Ege I 1266
Kas I 1266
Nar I 1266
Bss HII 1393
Tth 111I 1434
Pvu II 1617
Age I 2153
Eco RI 2451
Hin dIII 2463
Swa I 2807
Sna BI 3112
I 3757Hpa
I 4163Nru
I 4350Nhe
I 4491Nde
I 4556Sbf
I 4784Nco
CYC1T
h_CYP2A6
GAL1p
f1ori
2u_ori
URA3
Amp-R
ColE1ori
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Figure 3.19 The episomal plasmid, pSYE224/hCYP2C8. 
Plasmid Map showing restriction sites that occur only once. 
 
The SpeI-XhoI human CYP2C8 gene fragment (h_CYP28) isolated from the plasmid pBluKS+/SpeI-
XhoI/6A- CYP2C8 was ligated to the pSYE224 plasmid digested with SpeI and XhoI. The resultant 
plasmid was designated pSYE224/CYP28. This episomal plasmid with a uracil marker (URA3) was 
amplified in E. coli for the plasmid to be transformed in yeast so that CYP28 protein could be expressed. 
The CYP2C8 gene fragment was under the control of a galactose-inducible promoter (Gal1p) with a 
terminator from a cytochrome C gene (CYC1t). The 2 micron origin of replication from yeast (2µ_ori) 
controls plasmid copy number in yeast. 
 
The SpeI-XhoI human CYP2C8 gene fragment was similarly cloned in the episomal plasmid pSYE263, to 
allow ADH2 promoter-driven expression of CYP2C8. 
 
  
pSYE224/CYP2C8
7324 bps
1000
2000
3000
4000
5000
6000
7000
Mlu I 75
Bsp 1407I 82
Str I 273
Xho I 273
Bgl II 296
Bal I 520
Tth 111I 666
Spe I 1755
Hin dIII 2454
Swa I 2798
Sna BI 3103I 4154Nru
I 4341Nhe
I 4482Nde
I 4547Sbf
I 4944Apa
3I 5198Esp
HI 6424Bsp
CYC1T
h_CYP2C8
GAL1p
f1ori
2u_ori
URA3
Amp-R
ColE1ori
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Figure 3.20 The episomal plasmid, pSYE224/hCYP2E1. 
Plasmid Map showing restriction sites that occur only once. 
 
The BglII-XhoI human CYP2E1 gene fragment (h_CYP2E1) isolated from the plasmid pSP73/BglII-
XhoI/6A- CYP2E1 was ligated to the pSYE224 plasmid digested with BamHI and XhoI. The resultant 
plasmid was designated pSYE224/CYP2E1. This episomal plasmid with a uracil marker (URA3) was 
amplified in E. coli for the plasmid to be transformed in yeast so that CYP2E1 protein could be 
expressed. The CYP2E1 gene fragment was under the control of a galactose-inducible promoter (Gal1p) 
with a terminator from a cytochrome C gene (CYC1t). The 2 micron origin of replication from yeast 
(2µ_ori) controls plasmid copy number in yeast. 
 
The BglII-XhoI human CYP2E1 gene fragment was similarly cloned in the episomal plasmid pSYE263, to 
allow ADH2 promoter-driven expression of CYP2E1. 
 
  
pSYE224/CYP2E1
7330 bps
1000
2000
3000
4000
5000
6000
7000
Mlu I 75
Xba I 261
Sph I 268
Str I 273
Xho I 273
Sma I 971
Xma I 971
Bss HII 1235
BamHI 1319
Pvu II 1672
Age I 2150
Eco RI 2448
Hin dIII 2460
Swa I 2804
Sna BI 3109
I 3754Hpa
I 4160Nru
I 4347Nhe
I 4488Nde
I 4553Sbf
I 4781Nco
I 4950Apa
3I 5204Esp
CYC1T
h_CYP2E1
GAL1p
f1ori
2u_ori
URA3
Amp-R
ColE1ori
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Figure 3.21 The episomal plasmid, pSYE224/hCYP3A4. 
Plasmid Map showing restriction sites that occur only once. 
 
The BglII-XbaI human CYP3A4 gene fragment (h_CYP3A4) isolated from the plasmid pSP73/BglII-
XbaI/6A- CYP3A4 was ligated to the pSYE224 plasmid digested with BamHI and XhoI. The resultant 
plasmid was designated pSYE224/CYP3A4. This episomal plasmid with a uracil marker (URA3) was 
amplified in E. coli for the plasmid to be transformed in yeast so that CYP3A4 protein could be 
expressed. The CYP3A4 gene fragment was under the control of a galactose-inducible promoter (Gal1p) 
with a terminator from a cytochrome C gene (CYC1t). The 2 micron origin of replication from yeast 
(2µ_ori) controls plasmid copy number in yeast. 
 
The BglII-XbaI human CYP3A4 gene fragment was similarly cloned in the episomal plasmid pSYE263, to 
allow ADH2 promoter-driven expression of CYP3A4. 
 
3.4  Western Blots 
 
Western blots were performed to confirm the presence of specific P450s. Tables and 
Western Blots 3.1 to 3.6 are linked to the expression of the CYP1A2, CYP2A6, 
pSYE224/CYP3A4
7339 bps
1000
2000
3000
4000
5000
6000
7000
Mlu I 75
Bsp 1407I 82
Xba I 261
Mun I 668
Sac I 891
Pvu II 954
BamHI 1123
Bsa BI 1384
Age I 2159
Swa I 2813
Sna BI 3118
Ava I 3466I 3763Hpa
I 4169Nru
I 4356Nhe
I 4497Nde
I 4562Sbf
3I 5213Esp
CYC1T
h_CYP3A4
GAL1p
f1ori
2u_ori
URA3
Amp-R
ColE1ori
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 CYP2C8, CYP2D6, CYP2E1 and CYP3A4 proteins, respectively. Since microsomes do 
not contain housekeeping proteins, CYP expression levels from different constructs 
were compared using equal amounts of microsomal protein.  
For all Western blots, total proteins from microsomal samples were transferred from a 
10% SDS-polyacrylamide gel. Each lane contains 3µg of total protein that had been 
prepared from microsomes using the cell disruption method. For all CYP expressions, 
cells were grown in the non-selective, YP medium, in shake flasks.  
In the case of CYP expression driven by the ADH2 promoter, the carbon source was 
glucose and expression was induced with the exhaustion of glucose.  
For GAL1 promoter driven CYP expression, the promoter was induced by the addition 
of galactose.  
All the CYPs were expressed in yeast from a URA3–based episomal plasmid. The CYP 
proteins were co-expressed with two different P450 reductases:  
(a) ΔhRDmyc (ΔhRDM) which represent a human P450 reductase (hRD) variant 
which lacks first N- terminal 24 amino acids of hRD but contains an additional 
11 amino acids from the c-myc tag at its C-terminus.  
(b) The yeast reductase (yRD) represents the wild type reductase.  
Both the reductase gene expression cassettes, ΔhRDM and yRD, were integrated into 
yeast’s LEU2 chromosomal locus. The empty strain (W303Matα) which neither 
contained a CYP-bearing plasmid nor a P450 reductase was used as a negative control.  
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 Western Blot 3.1 shows the presence of CYP1A2, in the 55KDa region, in all yeast 
microsomal samples that contained the human CYP1A2 protein.  
Table and Western Blot 3.1  CYP1A2.  
 
Lane P450 Promoters Reductase Strain Reference Other Information 
2 - - - YW41 Untransformed Negative Control 
3 1A2 ADH2 ΔhRDM YY43 LEU2 P450 reductase 
4 1A2 ADH2 Yeast reductase (yRD) YAC50 
LEU2 P450 
reductase 
5 1A2 GAL1 ΔhRDM YAG09 LEU2 P450 reductase 
6 1A2 GAL1 Yeast reductase (yRD) YAF76 
LEU2 P450 
reductase 
7 1A2 - - - Gentest Positive Control 
 
2            3           4           5           6            7 
The Figure shows Western blot of total proteins from microsomal samples. Lanes 3-6, yeast CYP1A2-
bearing microsomes; lane 2, the negative control (microsomes from an empty strain); lane 7, insect 
CYP1A2-bearing microsomes (obtained from Gentest).  
 
Western Blot 3.2 shows the presence of CYP2A6, in the 55KDa region, in all yeast 
microsomal samples that contained the human CYP2A6 protein. 
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 Table and Western Blot 3.2  CYP2A6.  
 
Lane P450 Promoters Reductase Strain Reference Other Information 
2 - - - YW41 Untransformed Negative Control 
3 2A6 ADH2 ΔhRDM YAD48 LEU2 P450 reductase 
4 2A6 ADH2 yRD YAD53 LEU2 P450 reductase 
5 2A6 GAL1 ΔhRDM YAG33 LEU2 P450 reductase 
6 2A6 GAL1 yRD YAG17 LEU2 P450 reductase 
7 2A6 - - - Gentest Positive Control 
 
2           3            4           5          6            7 
The Figure shows Western blot of total proteins from microsomal samples. Lanes 3-6, yeast CYP2A6-
bearing microsomes; lane 2, the negative control (microsomes from an empty strain); lane 7, insect 
CYP2A6-bearing microsomes (obtained from Gentest).  
 
Western Blot 3.3 shows the presence of CYP2C8, in the 55KDa region, in all yeast 
microsomal samples that contained the human CYP2C8 protein. 
Table and Western Blot 3.3  CYP2C8.  
Lane P450 Promoters Reductase Strain Reference Other Information 
2 - - - YW41 Negative Control 
3 2C8 ADH2 ΔhRDM YAC11 LEU2 P450 reductase 
4 2C8 ADH2 yRD YAC16 LEU2 P450 reductase 
5 2C8 GAL1 ΔhRDM YAG37 LEU2 P450 reductase 
6 2C8 GAL1 yRD YAG21 LEU2 P450 reductase 
7 2C8 - - - Gentest Positive Control  
 
2         3          4           5           6            7 
The Figure shows Western blot of total proteins from microsomal samples. Lanes 3-6, yeast CYP2C8-
bearing microsomes; lane 2, the negative control (microsomes from an empty strain); lane 7, insect 
CYP2C8-bearing microsomes (obtained from Gentest).  
Western Blot 3.4 shows the presence of CYP2D6, in the 55KDa region, in all yeast 
microsomal samples that contained the human CYP2D6 protein. 
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 Table and Western Blot 3.4  CYP2D6.  
Lane P450 Promoters Reductase Strain Reference Other Information 
2 - - - YW41 Negative Control 
3 2D6 ADH2 ΔhRDM YY51 LEU2 P450 reductase 
4 2D6 ADH2 yRD YAC52 LEU2 P450 reductase 
5 2D6 GAL1 ΔhRDM YAG13 LEU2 P450 reductase 
6 2D6 GAL1 yRD YAG01 LEU2 P450 reductase 
7 2D6 - - - Gentest Positive Control 
 
2            3           4          5           6            7 
 
 
 5         6 
The Figure shows Western blot of total proteins from microsomal samples. Lanes 3-6, yeast CYP2D6-
bearing microsomes; lane 2, the negative control (microsomes from an empty strain); lane 7, insect 
CYP2D6-bearing microsomes (obtained from Gentest). Proteins in lanes 5-6 could be detected only when 
the total microsomal proteins were 6 µg, instead of the normally used 3 µg. 
 
Western Blot 3.5 shows the presence of CYP2E1, in the 55KDa region, in all yeast 
microsomal samples that contained the human CYP2E1protein. 
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 Table and Western Blot 3.5  CYP2E1.  
Lane P450 Promoters Reductase Strain Reference Other Information 
2 - - - YW41 Negative Control 
3 2E1 ADH2 ΔhRDM YAC67 LEU2 P450 reductase 
4 2E1 ADH2 yRD YAC72 LEU2 P450 reductase 
5 2E1 GAL1 ΔhRDM YAG41 LEU2 P450 reductase 
6 2E1 GAL1 yRD YAG25 LEU2 P450 reductase 
7 2E1 - - - Gentest Positive Control 
 
2          3             4          5            6           7  
The Figure shows Western blot of total proteins from microsomal samples. Lanes 3-6, yeast CYP2E1-
bearing microsomes; lane 2, the negative control (microsomes from an empty strain); lane 7, insect 
CYP2E1-bearing microsomes (obtained from Gentest). 
 
Western Blot 3.6 shows the presence of CYP3A4, in the 55KDa region, in all yeast 
microsomal samples that contained the human CYP3A4 protein. 
Table and Western Blot 3.6  CYP3A4.  
Lane P450 Promoters Reductase Strain Reference Other Information 
1 - - - - Marker 
2 - - - YW41 Negative Control 
3 3A4 ADH2 ΔhRDmyc YAC05 LEU2 P450 reductase 
4 3A4 ADH2 Yeast reductase YAC09 LEU2 P450 reductase 
5 3A4 GAL1 ΔhRDmyc YAG45 LEU2 P450 reductase 
6 3A4 GAL1 Yeast reductase YAG29 LEU2 P450 reductase 
7 3A4 - - - Gentest Positive Control 
 
2         3           4          5           6          7 
The Figure shows Western blot of total proteins from microsomal samples. Lanes 3-6, yeast CYP3A4-
bearing microsomes; lane 2, the negative control (microsomes from an empty strain); lane 7, insect 
CYP3A4-bearing microsomes (obtained from Gentest).  
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 3.5 Testing media components for optimal P450 expression 
 
3.5.1  Strain and clone background 
W303Matα, a haploid Saccharomyces cerevisiae strain, was used for CYP expression 
studies. It has five auxotrophic markers (ade2, his3, leu2, trp1, ura3) which were 
generated by knocking out dominant genes in biochemical pathways that lead to the 
synthesis of adenine, histidine, leucine, tryptophan and uracil (Sikorski & Hieter, 1989). 
A W303Matα derivative that expresses human CYP2C8 protein was selected for this 
study because the strain produced high levels of P450. This may allow effects on 
expression levels due to changes in specific components of the growth media to be more 
easily monitored.  
The yeast strain (LEU2::P450 reductase, TRP1::cytochrome b5), transformed with a 
URA3-bearing episomal plasmid encoding the human CYP2C8 gene and driven by the 
ADH2 promoter, is referred to as YAC16. The strain YAC16 requires additions of 
histidine and adenine for growth in minimal media. As the strain simultaneously 
expresses three heterologous proteins, CYP2C8, P450 reductase and b5, it was thought 
that optimisation of media conditions may be able to somewhat overcome the extra 
burden of tripartite expression and thereby benefit the levels of CYP2C8 expression. 
 
3.5.2  Growth Media 
 
Growing auxotrophic yeast cells in minimal media is not as simple as providing 
complex rich nutrients in excess in full media. In glucose (a carbon source), auxotrophic 
yeast grows via fermentation rather than respiration. This leads to reduction of 
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 mitochondrial activity, oxygen utilisation and growth rate. Nitrogen sources also impact 
growth and strain selection. Although a minimal ammonium salt media provides an 
environment for plasmid selection, it does not provide growth conditions for optimal 
expression of heterologous proteins. Complex and undefined media are nutrient rich and 
are conducive to optimisation of levels of protein production.  
Keeping the carbon source [1% (w/v) glucose] constant, alterations to the other 
components of complex media were investigated. 
Table 3.1 contains a breakdown of the components that were varied.  
Table 3.1  Breakdown of components, in the media, which were varied. 
Media Yeast extract g.l-1 
Peptone 
g.l-1 
Tryptone 
g.l-1 
Total 
g.l-1 
Peptone rich media 10 20 0 30 
Tryptone rich media 10 0 20 30 
Equal media 10 10 10 30 
Yeast extract rich media 20 10 0 30 
Yeast extract rich & Peptone 
rich media 20 20 0 40 
Exclusive yeast extract media 30 0 0 30 
Exclusive Peptone media 0 30 0 30 
Exclusive Tryptone media 0 0 30 30 
Exclusive Casamino acids 30 30 
Different complex media, where the components were varied, were used for testing for optimal 
production levels in an ADH2 promotor-driven expression of CYP2C8. The different media were given 
names to assist in their use. All media components were per litre of ultrapure water and autoclaved under 
a standard procedure, 121ºC for 20 min. The exclusive “casamino acids media” contained none of the 
other components.  
 
3.5.3  Dissection of the media components for optimal P450 activities 
 
CYP2C8-bearing microsomes were prepared after growth in each of the complex media 
in shake flasks (see Section 2.10). The activities of these samples were determined by 
fluorescent microplate assay. As each sample had its own specific P450 content (as 
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 measured according to the protocol detailed in Section 2.13), the volume of sample per 
well was adjusted to 4 pmol per microplate-well, Table 3.2. The results from the 
fluorescent microplate assay show that CYP2C8 prepared using different media gave a 
wide range of activities, Graph 3.1. 
Table 3.2  Volumes of microsomes, equating to 4 pmol of P450, that were 
used per well of a 96-well microtitre plate. 
 
Media Volume per reaction in µl 
Exclusive Casamino acids 13.0 
Exclusive Peptone media 3.7 
Exclusive Tryptone media 3.0 
Peptone rich media 2.7 
Equal media 2.4 
Tryptone rich media 2.1 
Yeast extract rich & Peptone rich media 2.6 
Exclusive yeast extract media 2.4 
Yeast extract rich media 0.9 
The CYP2C8-bearing yeast strain, YAC16, was initially grown on SD-Min media solid-agar plate 
(containing histidine and adenine) for 3 days at 30°C. A pre-culture was grown in SW6 (casamino acid) 
media, overnight at 30°C in shake flasks at 220 rpm. These cells were used to inoculate the different 
complex media types for expression of protein in 1% glucose; cells were grown overnight at 30°C in 
shake flasks at 220 rpm. The cells were harvested to produce microsomes using the mechanical cell 
disruption method and assayed for total protein content by Bradford assay and specific P450 content was 
derived from the CO-binding assay. These measurements provided the amounts of P450 (CYP2C8) that 
were added to different wells of the microtitre plate for the fluorescent-based activity assays.  
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 Graph 3.1 Graph showing the CYP2C8 activities obtained in different 
complex media.  
 
 
CYP2C8 activities obtained from different complex media. Bars show the changes in relative 
fluorescence units (RFLUs) that occurred over 1 min of assay. The activity was calculated from the linear 
part of the kinetic reaction that produces fluorescein from dibenzylfluorescein (DBF). The assay was 
performed, in quadruplicate, after shaking before each read in 96-well black microplates, at 30°C for 30 
minutes. Each well contained 4 pmol of CYP2C8 in a 100 mM phosphate buffer, pH7.4, [DBF] 1 µM. 
The components of the regenerating system used were at the standard concentration. Final reaction 
volume was 100 µl; water was used to make up the P450 volume differences. Fluorescence measurements 
were made at 485/538 nm. The error bars are +/- 1x standard deviations.  
 
Whilst the overall P450 activity was important, the activities in Graph 3.1 were 
observed with CYP2C8 enzymes which were made up in very different volumes to 
obtain 4 pmol of CYP2C8. These were then normalised for a fixed volume of CYP2C8 
(1µl), Table 3.3.  
  
0 1000 2000 3000 4000 5000
Exclusive Cas amino acids
Exclusive tryptone media
Exclusive peptone media
Equal media
Yeast extract rich & peptone rich media
Yeast extract rich media
Tryptone rich media
Exclusive yeast extract media
Peptone rich media
Slope, Δ Change In Fluorescent Light Units Over 1 Min of fluorescein 
production from DBF 
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 Table 3.3  Activities in Graph 3.1, normalized per microlitre of sample. 
# Media Activity per min per 1 µl of CYP2C8 
1 Exclusive Casamino acids 24.69 
2 Exclusive Tryptone media 574 
3 Exclusive Peptone media 602.73 
4 Equal media 1413.33 
5 Peptone rich media 1592.24 
6 Tryptone rich media 1886.59 
7 Yeast extract rich & Peptone rich media 2297.38 
8 Exclusive yeast extract media 3034.37 
9 Yeast extract rich media 4370.40 
Values of CYP2C8 activities were taken from Graph 3.1 and were divided by values in Table 3.2, i.e. the 
volumes of CYP2C8 enzymes, per 4 pmol, which were added per reaction for each media type. These 
new values gave an activity for a fixed 1µl volume of microsomes.  
From Table 3.3, one observes that the “Peptone rich media” (# 5) had 36.4% of the 
activity of the “Yeast extract rich media” (# 9), volume for volume, even though the 
reactions overall contained the same amount of P450. The two samples had similar 
protein concentrations but the specific activity from the “Peptone rich media” was 0.081 
nmol.mg-1 and from the “Yeast extract rich media” 0.161 nmol.mg-1, which is twice as 
much. This means that the “Yeast extract rich media” (# 9) produced about twice the 
P450 amount, without a corresponding doubling of the protein concentration. So the 
“Peptone rich media” (# 5) contained more non-P450 related protein per mole of P450 
than the “Yeast extract rich media” (# 9).  
 
3.5.4  Discussion of the dissection of media components for optimal 
P450 activities. 
 
Regarding the make-up of these media, Proteose Peptone was derived from meat treated 
with enzymes of pancreatic origin. The Tryptone was made from a pancreatic digest of 
casein. The Casamino acids were also produced from casein but with the use of 
hydrochloric acid causing a complete hydrolysis of all peptide bonds and giving rise to 
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 all the essential amino acids excepting tryptophan which is destroyed during acid-
hydrolysis (Mueller et al., 1941). Yeast extract contains B vitamins and these are 
immensely important for growth of yeast. Yeast requires thiamine (B1) as a cofactor for 
pyruvate decarboxylase that allows fermentation of pyruvate to ethanol (Dyda et al., 
1990). As yeast ferments at the start of expression due to glucose levels, presence of B 
vitamins may be a major advantage.   
“Normal” media contains 30 g of powder which is comprised of 10 g of yeast extract 
and 20 g of peptone per litre (a standard Becton Dickinson recipe). This media had been 
used by others for P450 production and the expression of many proteins in yeast (Yang 
et al., 2008 and Garcia-Ruiz et al., 2010). Equal quantities of yeast extract and peptone 
have also been used for production of proteins in shake flasks, including expression of 
P450s in yeast (Bellamine et al., 1998). The recipe mentions using 10 g.L-1 of yeast 
extract and peptone. Again during expression studies, McLellan et al (2000) used equal 
quantities of the two but at 20 g.L-1.  
There is no evidence that others have used media where the yeast extract content was 
greater than the peptone.  
The data shows that simple variations in the composition of the media alter the potency 
of CYP2C8 in CYP-bearing yeast microsomes. This observation can be useful. 
Obtaining greater P450 activity in smaller volumes is important for the miniaturisation 
of P450 assays in microplates and possibly microarrays. This would allow reduction of 
costs and time for screening of potential P450 substrates, inhibitors and metabolic 
conversion products. With a media that provides high activity of CYP enzymes, 
biotransformation reactions could also be carried out with superior efficiencies.   
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 Chapter 4  Large-scale Production of P450s 
 
4.1 The use of fermentation 
 
Production of large quantities of P450s is required to reduce batch to batch variations 
and produce quantities that may be of use for testing in a whole new variety of 
applications. Hence, attempts were made to have high yields of P450s with the help of 
fermentors. But with so many variables involved in fermentation, a starting point was 
required. Although there are published examples of P450s that have been produced in 
fermentors, using both bacterial and yeast cells, procedural information is limited.  
The aim of the experiments was to perform a feasibility study using small-scale 
fermentors with the hope that this would be a starting point for larger-scale production, 
if required, at a later date.   
 
4.2 Optimising of conditions for growth of yeast in a fermentor 
 
The temperature, to be used for fermentation, is perhaps directly transferable from 
growth of yeast in shake flasks to fermentors. Some papers cite 30ºC as the best 
temperature for growth (van Dijken et al., 2000 and Blatiak et al., 1987). However, 
other groups have grown P450 gene-bearing yeast in fermentors at a lower temperature, 
28ºC (US Patent 6117649, Denis Pompom’s laboratories) and 28.5ºC (McLellan et al., 
2000).   
Conditions for base input, gas-flow, agitation, amount of additions of specific reagents 
and timing of their additions would have to be optimised for growth of yeast in 
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 fermentors to see if yields of P450s could be increased from what was obtained in shake 
flasks. These parameters were tested and optimised using publications as starting points. 
 
4.3 Effects of dissolved oxygen (DO) on growth, during 
fermentation 
 
In the absence of a known oxygen concentration that could be used, a range of 
concentrations were tried using three different gas-flow rates and allowing agitation to 
vary so that a fixed dissolved oxygen concentration (DO) of 30%, 50% or 70% could be 
maintained throughout fermentation. The air flow rates were 1.0, 1.5 or 2.5 Litres per 
min. The OD600s were used to assess the differences in growth; see Graph 4.1.  
Graph 4.1  OD600 obtained during the ADH2 promoter-driven 
expression of CYP1A2 from a yeast strain, at fixed DO 
concentrations and gas-flow rates. 
 
 
Measurements of OD600 during fermentation of the strain YR42, in a one-litre ferrmentor. YR42 harbours 
a plasmid that bears an ADH2 promoter-driven CYP1A2 expression cassette. The strain was grown in 
non-selective YP media, containing 1% glucose, pH held at 6.6. Identical fermentations were performed 
with differing compressed air gas-flow rates. Agitation in impellor (via rpm) was allowed to 
automatically adjust the relative dissolved oxygen (DO) level to reach 30, 50 or 70% for the 
corresponding gas-flow rates. Despite the different oxygenation levels there was no impact to the optical 
density, OD600 (OD at 600 nm), values. 
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 The OD600s suggested that there were no differences in growth that occurred during the 
fermentations. After the fermentations, the cells were centrifuged and the pellets 
weighed. However, the wet weight pellets were unexpectedly not equal,  
(a) DO 30%, 1.0 L.min-1 was 30.5 g,  
(b) DO 50%, 1.5 L.min-1 was 46 g, and  
(c) DO 70%, 2.5 L.min-1 was 39.0 g.  
There was a mismatch in the results as changes in dissolved oxygen (DO) gave rise to a 
change in biomass but not in OD. However, wet weights are not as accurate as taking 
dry weights. Based on OD, clamping the fermentor DO seemed unnecessary.  
It was then decided that the cells should be left to take what they required during growth 
from a fixed agitation impellor rpm. It would be similar to growth in shake flasks where 
the cells also take what they require from a fixed agitation.   
 
4.4 Removal of dissolved oxygen (DO) control  
 
Fermentation without clamping of dissolved oxygen (DO) concentration whilst holding 
a fixed agitation at a particular rpm was then tested. The DO concentrations were 
measured; see Graph 4.2.  
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 Graph 4.2 Relative percentages of DO over a fermentation time 
course without controlling DO, during the ADH2 promoter-
driven expression of CYP1A2 from a yeast strain. 
 
 
Measurements of dissolved oxygen (DO) during fermentation of the strain YR42 in a one-litre ferrmentor. 
YR42 harbours a plasmid that bears an ADH2 promoter-driven CYP1A2 expression cassette. The strain 
was grown in non-selective YP media containing 1% glucose, pH held at 6.6. Agitation and compressed 
gas flow was fixed at 500 rpm and 0.5 L.min-1. At point A, there were few cells and the oxygenation 
levels were high. At point B, about 250 min, the cells underwent slight alteration of the rate at which 
oxygen was utilised. At point C, about 480 min, further glucose was added and this caused oxygen 
utilisation to reverse at point D, 600 min. At point E, at 1080 min, glycerol and ethanol were added which 
continued to complement the rate of oxygen utilisation. After point F at 1400 min the oxygen utilisation 
seemed to stabilise.  
 
It was clear that the cells had different oxygen requirements at different times of 
growth. As the glucose reduced, oxygen utilisation from the media increased and 
reversed upon addition of more glucose. The glycerol and ethanol addition did not 
reverse oxygen utilisation. This was expected as these carbon sources require oxygen. 
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 In the same way as shake flasks were used at a fixed speed throughout growth, it was 
found that the best approach was to keep both the gas flow rpm constant, simply 
allowing the yeast cells to utilise oxygen as they require it. 
 
4.5 Modifications of a published fermentation protocol  
 
Merely growing cells did not equate to successful expression of P450s. Optimisation 
was difficult since no P450s were produced.  
A paper from McLellan et al (2000) had described expression of P450s in yeast in 
fermentors, under the control of the GAL promoter. Having failed to obtain any 
measurable P450 from an ADH2-driven construct, attempts were made to express 
CYP1B1 from the GAL1 promoter. The yeast strain, YH50, had earlier produced 
CYP1B1 reliably, in shake flasks, from a GAL1 promoter-driven construct. Hence, the 
strain YH50 was used in fermenters in conjunction with the parameters published by 
McLellan et al (2000), with the hope that these parameters could offer a platform for 
further improvements. The YH50 strain was extensively tested in fermentors and 
modifications of the published protocol made until a successful method was found. In a 
one-litre fermentor, an OD600 of 96 and a wet weight pellet of 103.6 g were ultimately 
obtained; see Graph 4.3.  
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 Graph 4.3  OD600 obtained during the GAL1 promoter-driven 
expression of CYPB1 from a yeast strain 
 
 
The growth curve, during fermentation, of the strain YH50, in a one-litre ferrmentor. YH50 harbours a 
plasmid that bears a GAL1 promoter-driven CYPB1 expression cassette. The graph initially demonstrates 
a typical log-phase growth. This was followed by a gradual change to stationary phase. The optical 
densities became extremely high. Growth started from a 10 ml seed culture grown in selective media, in a 
shake flask, overnight at 30°C at 220 rpm. The selective media contained, 6.7 g.L-1 Yeast Nitrogen Base, 
1 g.L-1 Casamino acids, 20 g.L-1 Glucose, 8.3 ml.L-1 and 20 mg.L-1 of auxotrophic supplements. After 
seeding all 10 ml to the 1 litre fermentor, cells were grown in media that contained 16 g.600 ml-1 yeast 
extract, 16 g.600 ml-1 peptone, 32 ml of 50% (w/v) glucose, 12 ml of adenine 2.5 g.250ml-1, 13.5 ml of 
other auxotrophic supplements (1.8 g.250ml-1), together with 45 µl of antifoam and amounts of 5M 
NaOH so that pH 6.6 is attained. After 12h of fermentation, 24 ml of 50% (w/v) glucose and 24 ml of 
pure ethanol was added. The same amount of auxotrophic supplements, as above, was also added. After a 
further 9h of fermentation, 24 g of galactose powder suspended in 12 ml of ethanol and the required 
auxotrophic supplements were added in the same amounts as above. After a further 16h of induction, 
fermentation was halted by cooling the vessel to 4ºC. The culture from the fermentor was centrifuged and 
processed to prepare microsomes using the mechanical cell disruption method.  
 
This culture in the one-litre fermentor was able to produce P450, as seen on the CO-
difference assay spectra; see Graph 4.4. 80 units of P450 were produced, as calculated 
from the CO-binding assay.  
However, the total protein content in the microsomes was quite high, 49.2 µg.µl-1. The 
specific content of P450, CYP1B1, was calculated to be 0.119 nM.mg-1.  
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 Graph 4.4  CO-difference assay of CYP1B1, obtained from the strain 
YH50 (which harbours an episomal plasmid that bears a 
GAL1 promoter-driven CYPB1 expression cassette). 
 
 
The formation of a CO-P450 peak (position 1, on the spectra) obtained from the CYP1B1, produced in 
the strain YH50 (harbouring an episomal plasmid that bears a GAL1 promoter-driven CYPB1 expression 
cassette). The microsomes were prepared from the culture grown in a 1 litre fermentor (Graph 4.3). The 
spectral analysis was performed in a cuvette. 1.5 mg of microsomes were topped up to 1 ml with 100mM 
potassium phosphate buffer (pH 7.4,) containing 20% glycerol; 5 mg of sodium hydrosulphite was added 
and scanned from 400 to 500 nm (i.e. this is the ‘blank’). After bubbling at 1 bubble per second for 1 min 
with carbon monoxide (CO), the sample was re-scanned at 400 to 500 nm. The corresponding units were 
derived from the y-axis absorbance at 450 nm minus the absorbance at the base of the peak towards the 
490 nm reference position. There was minimal disturbance of the line at 420 to 430 nm which infers 
minimal formation of misfolded P450 protein during the production of microsomes.  
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 4.6 Summary  
 
The cells from a one-litre fermentor were easily accommodated by the centrifugation 
methods normally used for shake flasks. The microsomal pellet also had the correct 
appearance in colour and viscosity, based on previous experience. 
Fermentation was extremely successful in terms of biomass. The P450 content was also 
encouraging. However, the scale-up of the process of fermentation proved to be a 
bottleneck because it is not feasible to use  
 
(1) Gram quantities of lyticase to lyse large volumes of cells obtained from a 
fermentor, and 
(2) An ultracentrifuge to fractionate the large volumes of lysates obtained from the 
cells after fermentation.  
Therefore, a new protocol involving PEG precipitation was developed to avoid the use 
of lyticase, in Chapter 5, to help remediate this problem. 
The ability to demonstrate that the fermentation process could be scaled-up and 
downstream processing could be optimised would reduce optimisation time, if 
circumstances required much larger productions, in the future.  
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 Chapter 5 Down-stream processing 
 
5.1  Introduction 
 
The aim of this Chapter was to produce a downstream processing protocol that was 
cost-effective, user-friendly and suitable for larger-scale operations. This would avoid 
the two critical steps in the preparation of microsomes: 
(1) Lyticase treatment, lyticase being extremely expensive for lysis of a large 
volume of cells, and  
(2) Ultracentrifugation, which would be impossible to use with very large volumes 
of cell lysates.  
Although it is known that proteins, which are not bound to membranes, could be 
conveniently precipitated using a variety of methods, it was suspected that these 
methods may not be suitable for precipitation of microsomes because of their extremely 
fragile nature.  
 
5.2 An alternative to lyticase treatment 
 
For small scale expressions, up to a couple of litres of culture, it is possible to prepare 
microsomes using a yeast lytic enzyme (lyticase). Lyticase treatment is usually followed 
by:  
(a) A number of short bursts of sonication in a cold room,  
(b) High speed centrifugation, which is followed by 
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 (c) Ultracentrifugation.  
Use of yeast lytic enzyme is a problem because it is very expensive and the process of 
sonication could be lengthy when using large volumes. 
There are a wide range of physical and chemical methods that could be used for cell 
disruption. It was thought that a method, which allows mechanical cell disruption and 
would disrupt the yeast outer cell wall keeping the fragile microsomal membrane intact, 
would be preferred to the combined processes of lytication and sonication. 
Hence, attempts were made to use a mechanical cell disruptor in order to avoid lyticase 
treatment and sonication. The cell disruptor was kept chilled at +4ºC and was operated 
continually for large volumes of samples.  
 
5.3  An alternative to ultracentrifugation  
 
A straightforward alternative to ultracentrifugation would be to precipitate the 
membrane-bound P450s using calcium chloride (CaCl2). In order to precipitate proteins, 
different final CaCl2 concentrations, centrifugation speeds and run times for 
centrifugation have been suggested (Peyronneau et al., 1992; Scheller et al., 1996).  
PEG (6000 MW) precipitation of P450s from rabbit liver microsomes has also been 
known since 1974 (van der Hoeven et al.). However, the researchers had noted lack of 
activity and the P450s had to be reconstituted with lipids. Later, Sadler et al (1985) also 
attempted PEG precipitations of yeast-produced P450s with no great success.  
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 The published PEG procedures were modified. Precipitation of microsomal P450s was 
attempted with PEG-3350 (MW 3350) instead of PEGs with higher molecular weight.  
 
5.4 Results 
 
5.4.1 Results from testing an alternative to yeast lytic enzymes and 
sonication  
 
The lyticase incubation caused a time-dependent drop in OD600 (OD at 600 nm) that 
corresponded to the gradual destruction of the cell wall, over an hour, with a 79.9% 
drop in OD.  
In contrast, the drop in OD600, using mechanical cell disruption, averaged 44.4% for 
pressures between 15 and 30 KPSI. The cell disruptor is capable of being set at too high 
a pressure which would destroy all intracellular membranes. It was a case of finding the 
pressure that caused maximal disruption with minimal microsomal membrane damage.  
After sonication of the lyticase treated cells, the samples were processed first with high-
speed centrifugation and then ultracentrifugation.  
Active CYP1B1 enzymes were produced from CYP1B1-expressing cells (from yeast 
strain YH50) using 
(1) Lyticase/sonication treatment, and 
(2) Cell disruption (using a mechanical cell disruptor).  
The amounts of P450s obtained were assayed via P450 CO-difference spectroscopy; see 
Table 5.1. 
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Table 5.1  Levels of P450 produced from cell disruption (at different 
pressures) and lyticase treatment.  
 
Pressure setting in KPSI Specific P450 content in pmol.mg-1 of total protein 
15 29.2 
20.25 37.2 
21.75 51.9 
25.5 43.4 
30 31.7 
Lyticase 89.6 
Using mechanical cell disruption of YH50 cells that harbour an episomal plasmid bearing a GAL1 
promoter-driven CYP1B1 expression cassette, it was observed that there was an increase in the specific 
content of the P450 up to the point of 21.75 KPSI in the cell disruptor; extra pressure was not helpful. The 
mechanical cell disruption was not as successful as the lyticase treatment. However, lyticase treatment 
cannot be used for large-scale culture because of extraordinary high costs.  
 
Cells were grown in shake flasks at 30°C, 220 rpm in YP media overnight and the contents were 
combined to give a final OD600 of ~20. The cell culture was portioned off for lyticase treatment. 15 g of 
wet weight cells were re-suspended in 9 ml of sorbitol buffer B (containing sorbitol, Tris and EDTA); 
protease inhibitors and a reducing agent were added and then cells were incubated with 85 mg of lyticase. 
The cells were then sonicated. The remaining part of the culture was pelleted (31.8 g) and re-suspended in 
sorbitol buffer A (sorbitol, Tris and EDTA); 1 ml of buffer was used to re-suspend 1 g of cell pellet; to 
the re-suspended cells, protease inhibitors and a reducing agent were added before cell disruption. The 
cells were divided into 5 lots of 7.5 ml volumes and subjected to a range of different pressure settings in 
the cell disruptor: 15, 20.25, 21.75, 25.5 and 30 KPSI. Microsomes were prepared after all cell 
disruptions. 
 
Lyticase treatment gave the best specific content. However, the lyticase process is 
impossible to scale-up due to costs. So the best mechanical disruption pressure setting 
was considered to be an acceptable compromise with the view that the process could be 
scaled up to hundreds of litres. After mechanical cell disruption, a lot of undisrupted 
cells are unfortunately wasted. With the sonication technique, all undisrupted cells are 
collected for further sonication (i.e. cells that survive lyticase treatment are still 
challenged by further sonication).  
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5.4.2 Results from testing an alternative to ultracentrifugation  
 
After mechanical disruption of cells, microsomal P450s were precipitated using CaCl2 
and PEG-3350. Amounts of microsomal P450s, obtained from the two precipitations, 
were compared; see Table 5.2. 
Table 5.2  Amounts of P450 produced from two precipitation methods. 
 
Concentration method Specific P450 content in pmol.mg-1 of total protein 
Calcium Chloride 7.3 
PEG-3350 102.6 
Using two different reagents, microsomes were precipitated from YH50 cells that harbour an episomal 
plasmid bearing a GAL1 promoter-driven CYP1B1 expression cassette. It is observed that there is over 
ten-fold increase in the P450 specific content when PEG-3350 is used for precipitation.  
 
Cells were grown in shake flasks at 30°C, 220 rpm in YP media overnight and the contents of flasks were 
combined to give a final OD600 of ~21. The culture was pelleted and re-suspended sorbitol buffer A 
(sorbitol, Tris and EDTA buffer) which contained protease inhibitors and reducing agent; 1 ml of buffer 
was used to re-suspend 1 g of cell pellet; The re-suspended cells were used for cell disruption. The S9 
fraction was produced and split into two: (1) for calcium chloride precipitation and (2) for PEG 
precipitation.  
 
Microsomes were prepared from the S9 fraction as follows. 2 M CaCl2 stock was added to the S9 fraction 
for a final concentration of 18 mM and centrifuged at 16,000g for 15 min. The concentrations used were 
obtained from published sources. The CaCl2 concentration range which had been used before was 15 to 
20 mM. The centrifugation speed which was published was 14,000g for 10 min to 20,000g for 20 min 
(Peyronneau et al., 1992; Scheller et al., 1996).  
 
For the PEG precipitation, ice cold PEG-3350 50% (w/v) was added to a cold Tris, EDTA, sorbitol and 
sodium chloride buffer suspended S9 fraction. After 20 min, the viscous precipitate was centrifuged at 
12,000g at +4°C for 10 min; microsomal pellets were produced and gently re-suspended using glass 
homogenisers. The microsomal pellets were homogenised in buffer C (containing glycerol, Tris and 
EDTA). 
 
It was observed from the experiment that precipitation with calcium chloride yielded 
very little P450. Hence, the process was deemed unsuccessful.  
However, PEG precipitation gave very good P450 content and a classically shaped CO-
difference P450 spectrum; see Graph 5.1.   
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 Graph 5.1 CO spectra of CYP1B1-bearing microsomes, after PEG 
precipitation. 
 
 
The formation of a CO-P450 peak, at position 1 of the spectra, of CYP1B1 obtained from YH50 cells that 
harbour an episomal plasmid bearing a GAL1 promoter-driven CYP1B1 expression cassette. The spectral 
analysis was performed in a cuvette; 1.5 mg of microsomes were topped up to 1 ml with 100 mM 
potassium phosphate buffer (pH 7.4) which contained 20% glycerol; 5 mg of sodium hydrosulphite was 
added and a blank scan was run from 400 to 500 nm. After bubbling carbon monoxide (CO) at 1 bubble 
per second for 1 min, the sample was rescanned from 400 to 500 nm. There was minimal disturbance of 
the line at 420 to 430 nm which implies that minimal misfolded P450 was formed during preparation of 
the microsomes.  
 
5.5 Discussion 
 
It was expected that the mechanical cell disruption, at a certain pressure, would produce 
a large amount of cells that still remained undisrupted. But this was acceptable, since 
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 the process could conceivably deal with hundreds of litres in several hours. The process 
involving lyticase and sonication is definitely not an alternative because of its extremely 
high costs and also being so labour-intensive.  
The fact that the CaCl2 precipitation did not work was unexpected. It was disappointing 
as it would have been a very simple and cheap procedure.  
PEG precipitation is more involved than the CaCl2 procedure but it has proved to be 
very successful. Compared to the process that used ultracentrifugation, the PEG 
precipitation process has greatly reduced the overall time for making microsomes. It 
should be pointed out that maintenance of an ultracentrifuge (or multiple 
ultracentrifuges) would have been extremely costly. The ability to precipitate 
microsomes with PEG offers the potential of running multiple precipitations per day to 
process large amounts of S9 fractions obtained after mechanical cell disruption. With a 
continuous-flow centrifuge this process could even further be streamlined. 
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 Chapter 6  Stabilisation of P450s via lyophilisation 
 
6.0 Introduction 
 
During the processes of production and using microsomes for assaying, it was apparent 
that there are many ways of causing damage to the microsomes or the P450 enzymes 
themselves. This could be due to mechanical, thermal or chemical stresses. Different 
P450s would be expected to react similarly to these stresses. Despite their great genetic 
variation, they are essentially proteins with overall similar tertiary structures (Denisov 
et al., 2011).  
It has been demonstrated that there are two critical features that are essential for P450 
enzyme activity: 
(1) Association with membranes and  
(2) Retention of the haem group.  
P450s require interactions with lipids to place them in proximity with their typical 
exogenous and endogenous substrates. P450s also require access to water. It is 
intriguing that the lipids do not, in any way, inhibit movement of water towards the 
active site of P450s (Denisov et al., 2011).  
The lipids allow correct orientation of the P450 reductase and the P450 proteins, see 
Figure 6.1. Clearly, membrane-association of P450s and the co-activator protein P450 
reductase has both a functional as well as a structural role. 
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 Figure 6.1  A P450 Microsomal structure (Reed & Backes, 2012). 
 
 
The blue ovals represent the hydrophilic phospholipid heads that have arranged themselves into a 
spherical lipid bi-layer with their hydrophobic hydrocarbon black tails pointing inwards. The P450s, in 
this case 1A2, have an N-terminal lipid binding region. The rest of the P450 protein has access to the 
water soluble buffer partition. The cytochrome P450 reductase (CPR) is attached in the same way. 
Evidence points to the fact that the P450 and its reductase should be on the same microsomal membrane 
for proper P450 activity. It is important to think of a microsomal sample as a collection of these structures 
in solution. Each of these is likely to have a variable size and slightly different ratios of lipids, general 
microsomal proteins, P450, P450 reductase and b5 proteins (not shown). During an assay, the use of a 
representative sample size of this population would reduce sample to sample variation. The yeast 
microsomes provide the best representative state of a human P450, as if it was in its native environment 
bound to the smooth endoplasmic reticulum membranes.  
 
When considering stability of P450 activity the relationship between membrane, P450 
and P450 reductase (and/or b5) needs to be considered. The relationship with water in 
the active site, where the haem resides, is also important to form the inter-linked 
structure with a P450 as described in the Introduction (see Section 1.8). Water is 
required in the enzyme’s active site and also to allow formation of the three-
dimensional bilayer structure. 
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 Matejtschuk (2007) states that membrane-bound proteins have special problems during 
lyophilisation He also mentions that “intracellular membranes are prone to disruption 
during dehydration and structures will be at risk”.  
Heikal et al., (2009) researched P-glycoprotein, a cell membrane pump, overexpression 
of which causes resistance to anticancer drugs. The authors were interested in 
establishing a high-throughput screen. They noted that the protein is only stable for 
short periods at -80°C and required stabilisation to allow design of a high-throughput 
assay. The P-glycoprotein was purified and reconstituted onto artificial membranes. The 
paper states that the instability of membrane-bound proteins is well known. The authors 
also add that freeze-drying of liposomes is well documented but it is not applicable to 
membrane-bound microsomal proteins. Moreover, there has been no reported success in 
freeze-drying protein-embedded liposomes (i.e. proteo-liposomes).  
Like P450s, P-glycoprotein has a complex relationship with its lipid host. Heikal et al., 
(2009) found that the presence of either 20% trehalose or maltose allowed 60% of 
activity to be retained after 150 days, at 30 to 37°C. They also found glycerol to be very 
poor, allowing retention of less than 5% of the original activity. This is in contrast to 
commercial microsomes that are frozen in buffer containing glycerol for storage at 
minus 80°C.  
P450-bearing microsomes are shipped on dry ice and the product data sheets encourage 
minimal freeze-thawing events. One way to avoid the use of the cold chain is to 
lyophilise proteins. However, it was expected that this process, for the reasons detailed 
above, would destroy P450 activity. The use of sugars has been known to thermo-
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 stabilise P450s to prevent formation of apoprotein at up to 48°C. This was encouraging 
but only shown to preserve structure, activity had not been tested (Kuhm-Velten, 1997).  
 
6.1  Comparison of CYP2D6 activities, co-expressed with two 
different reductases, and lyophilised in the presence of two 
different cryopreservants  
 
It was investigated if there would be any differences in CYP2D6 activity when 
microsomal CYP2D6 (derived from both insect and yeast cells) was lyophilised in the 
presence of glycerol and sucrose (two different cryopreservants). Two different 
preparations of CYP2D6 were used for lyophilisation, one enzyme co-expressed with 
the yeast reductase (hRD) and the other co-expressed with ∆hRDM, a relatively low-
toxic variant of wild-type human P450 reductase (hRD). The aim was to see if relative 
reductase activities (hRD being slightly better in activity than ∆hRDM) would lead to 
differential loss of stability; see Graphs 6.1 to 6.2.  
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 Graph 6.1 Comparison of insect cell-derived CYP2D6 activity co-
expressed with hRD (prepared in-house), lyophilised in 
the presence of two different cryopreservants, and after 
keeping lyophilised samples for 40h at +21°C.  
 
 
2.5 pmol of insect cell-derived CYP2D6 (prepared in-house), co-expressed with wild type P450 reductase 
(hRD), was lyophilised after re-suspension in 100 mM potassium phosphate buffer (pH 7.6), in the 
presence of either 20% (w/v) sucrose or glycerol (two different cryopreservants), in wells of a microtitre 
plate. These were stored at +21°C for 40h before rehydration and testing. Activity was measured by 
kinetic analysis of AMMC turnover at Excitation wavelength 400 nm/Emission 460 nm in a 100 mM 
potassium phosphate pH 7.6 at 37°C. The regenerating system was the non-standard A* for use with 
AMMC. The kinetics demonstrates that glycerol was not effective as a P450 cryopreservant when the 
P450 was co-expressed with wild-type P450 reductase, hRD. The sucrose samples had 9.3 times more 
activity than the glycerol samples.  
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 Graph 6.2 Comparison of insect cell-derived CYP2D6 activity co-
expressed with ∆hRDM (prepared in-house), lyophilised in 
the presence of two different cryopreservants, and after 
keeping lyophilised samples for 40h at +21°C.  
 
 
2.5 pmol of insect cell-derived CYP2D6 (prepared in-house), co-expressed with the P450 reductase 
variant (∆hRDM), was lyophilised after re-suspension in 100 mM potassium phosphate buffer (pH 7.6), 
in the presence of either 20% (w/v) sucrose or glycerol (two different cryopreservants), in wells of a 
microtitre plate. These were stored at +21°C for 40h before rehydration and testing. Activity was 
measured by kinetic analysis of AMMC turnover at Excitation wavelength 400 nm/Emission 460 nm in a 
100 mM potassium phosphate pH 7.6 at 37°C. The regenerating system was the non-standard A* for use 
with AMMC. The kinetics demonstrates, once again, that glycerol was not effective as a P450 
cryopreservant when the P450 was co-expressed with the P450 reductase variant, ∆hRDM. The sucrose 
samples had 3.25 times more activity than the glycerol samples. The glycerol samples from both Graphs 
6.1 and 6.2 are nearly identical in rates of reaction. However, the sucrose samples of the wild type P450 
reductase (Graph 6.1) had a 2.9 times greater rate of reaction of the ∆hRDM (Graph 6.2).  
 
It was concluded that the glycerol buffer was much poorer than the sucrose buffer at 
retaining CYP2D6 activity after 40h at +21°C, post-lyophilisation. This was regardless 
of the P450 reductase co-expressed with CYP2D6, hRD (wild-type human P450 
reductase) or ∆hRM (the P450 reductase variant). 
After establishing that lyophilisation in the presence of sucrose was far better than in the 
presence of glycerol, lyophilized CYP2D6 enzyme, individually co-expressed with the 
Lyophilised, reductase variant (∆hRDM), glycerol 
Lyophilised, reductase variant (∆hRDM), sucrose 
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 two P450 reductases, were tested against the untreated samples which had been stored at 
-80°C; see Graphs 6.3 and 6.4.  
 
Graph 6.3  Comparison of activity of insect cell-derived CYP2D6 
enzyme, co-expressed with hRD (prepared in-house), 
before and after lyophilisation (in the presence of 
sucrose), after having kept the lyophilised samples for 40h 
at +21°C. 
 
 
2.5 pmol of insect cell-derived CYP2D6 (prepared in-house), co-expressed with the P450 reductase 
variant (hRD), was lyophilised after re-suspension in 100 mM potassium phosphate buffer (pH 7.6), in 
the presence of 20% (w/v) sucrose, in wells of a microtitre plate. These were stored at +21°C for 40h 
before rehydration and testing. The Control was the enzyme stored at -80°C which was also assayed for 
activity, in the presence of sucrose. Activity was measured by kinetic analysis of AMMC turnover at 
Excitation wavelength 400 nm/Emission 460 nm in a 100 mM potassium phosphate pH 7.6 at 37°C. The 
regenerating system was the non-standard A* for use with AMMC. The kinetics demonstrates that that 
sucrose was effective as a P450 cryopreservant when the P450 was co-expressed with the wild-type P450 
reductase, hRD. 
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 Graph 6.4  Comparison of activity of insect cell-derived CYP2D6 
enzyme, co-expressed with ∆hRDM (prepared in-house), 
before and after lyophilisation (in the presence of 
sucrose), after having kept the lyophilised samples for 40h 
at +21°C. 
 
2.5 pmol of insect cell-derived CYP2D6 (prepared in-house), co-expressed with the P450 reductase 
variant (∆hRDM), was lyophilised after re-suspension in 100 mM potassium phosphate buffer (pH 7.6), 
in the presence of 20% (w/v) sucrose, in wells of a microtitre plate. These were stored at +21°C for 40h 
before rehydration and testing. The Control was the enzyme stored at -80°C which was also assayed for 
activity, in the presence of sucrose. Activity was measured by kinetic analysis of AMMC turnover at 
Excitation wavelength 400 nm/Emission 460 nm in a 100 mM potassium phosphate pH 7.6 at 37°C. The 
regenerating system was the non-standard A* for use with AMMC. The kinetics demonstrates that that 
sucrose was effective as a P450 cryopreservant when the P450 was co-expressed with the P450 reductase 
variant, ∆hRDM.  
 
The activity of CYP2D6, co-expressed with the wild type human P450 reductase (hRD) 
or the human P450 reductase variant (∆hRDM), 40h after keeping at +21°C post-
lyophilisation, compared with untreated –80°C stock samples (i.e. enzymes that had 
been stored at –80°C) show that lyophilsation does not have any effect on CYP2D6 
microsomal activity.  
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 6.2 Conclusions from experiments that compared the impact of 
two different cryopreservants on CYPs, co-expressed with 
two different reductases 
 
The experiments in Section 6.1 show that the product obtained after lyophilisation in the 
presence of 20% (v/v) concentration of glycerol was clearly much inferior to that 
obtained after lyophilisation in the presence of 20% (w/v) sucrose. Neither P450 
reductase had an advantage over the other regarding post-lyophilisation activities. The 
human P450 reductase variant, ∆hRDM, had been shown earlier in our group to be far 
less toxic than the wild type reductase, hRD during yeast expression. However, in these 
insect cell microsomes the reverse seemed to occur.  
The ratios of CYP2D6 activity loss between sucrose and glycerol were not equal for 
both types of reductase. The difference was that the sucrose was 9.3 times more 
CYP2D6 active than the glycerol samples with the wild type P450 reductase. For the 
∆hRDM P450 reductase the sucrose samples were 3.25 times more active with CYP2D6 
than the glycerol samples. The glycerol samples for both P450s reductases had nearly 
identical CYP2D6 activities.   
The results would indicate that:  
(a) Reductase type plays no role in the stability of P450 enzyme activity during the 
process of lyophilisation;  
(b) More importantly, the lyophilised samples retained the activities seen in 
untreated enzymes that had been stored at -80°C; 
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 (c) As the wild type P450 reductase and the ∆hRDM were both reduced to nearly 
identical CYP2D6 activities (and in light of point (a) above), the loss of 
CYP2D6 activity to a basal level was due to the use of glycerol rather than 
specific to P450 reductase type. It was just the case that the wild type P450 
reductase produced 2.9 times more CYP2D6 activity that the ∆hRDM. 
(d) The process works with Insect cell expressed P450s.   
 
6.3  Experiments to determine if the ‘stabilisation of 
microsomes’ was specific to the P450-bearing microsomes, 
produced in yeast and insect cells at De Montfort University  
 
There are many different ways of preparing recombinant microsomal P450 enzymes. 
Depending on the organism in which the enzymes are produced, the downstream 
production techniques vary. Often the reagents used during the process of isolation of 
microsomal enzymes are different. Moreover, each commercial producer has their 
unique buffers to re-suspend their microsomes. Hence, it would be apt to consider if the 
outcome of lyophilisation would be altered if lyophilisation was performed with 
microsomal P450s obtained from different sources, for example, with the enzymes 
obtained commercially from the leading P450 manufacturers, 
(a) BD-Gentest, 
(b) Invitrogen, and  
(c) Cypex. 
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 The comparative analysis was performed on enzymes that had been kept for 24h at 
21°C, after lyophilisation.  
After 24h at +21°C, the activity of the lyophilised Gentest CYP2C8 enzyme was 
preserved, implying that the activity of the lyophilised enzyme remained unchanged 
from the enzyme that had continuously been stored at -80°C; see Graph 6.5.  
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 Graph 6.5  Comparison of lyophilised BD-Gentest’s CYP2C8 enzyme, 
kept for 24h at +21˚C, with enzyme stored at -80°C. 
 
4 pmol of BD-Gentest’s CYP2C8 microsomal enzyme (produced from insect cells; also referred to as 
‘Supersomes’) was first diluted in a 100mM potassium phosphate buffer (pH 7.6) which contained 20% 
(w/v) sucrose, and then aliquoted into wells of a 96-well microtitre plate. The contents of the plate were 
lyophilised. After lyophilisation, the plate was stored at +21°C for 24h before rehydration and testing 
against Gentest’s CYP2C8 microsomal sample that had been stored at -80°C. Activity was measured by 
kinetic analysis of DBF turnover at Excitation wavelength 530 nm/Emission wavelength 590 nm in a 
100mM potassium phosphate (pH 7.6) at 37°C. The regenerating system was the standard A.  
 
The kinetics in Graph 6.5 demonstrates that sucrose was effective in preserving activity 
post-lyophilisation of a BD Gentest’s microsomal P450 which had been isolated from 
insect cells. 
Graph 6.6 shows that, similar to the preservation of BD Gentest’s microsomal P450 
enzyme after lyophilisation, Cypex’s CYP2C8 activity could also be preserved after 
keeping the lyophilised plate for 24h at +21°C.  
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 Graph 6.6  Comparison of lyophilised Cypex’s CYP2C8 enzyme, kept 
for 24h at +21˚C, with enzyme stored at -80°C. 
 
4 pmol of Cypex’s CYP2C8 microsomal enzyme (produced from bacterial cells; also referred to as 
‘Bactosomes’) was first diluted in a 100mM potassium phosphate buffer (pH 7.6) which contained 20% 
(w/v) sucrose, and then aliquoted into wells of a 96-well microtitre plate. The contents of the plate were 
lyophilised. After lyophilisation, the plate was stored at +21°C for 24h before rehydration and testing 
against Cypex’s CYP2C8 microsomal sample that had been stored at -80°C. Activity was measured by 
kinetic analysis of DBF turnover at Excitation wavelength 530 nm/Emission wavelength 590 nm in a 100 
mM potassium phosphate (pH 7.6) at 37°C. The regenerating system was the standard A.  
 
Graph 6.7 shows that, after keeping 24h at +21°C, the activity of lyophilised CYP2C8-
bearing microsomes (prepared in-house) surprisingly increased when compared with the 
control which is the CYP2C8 enzyme that had been stored at -80°C.  
 
  
140 
 
 Graph 6.7  Comparison of lyophilised yeast-derived CYP2C8 enzyme 
(prepared in-house), kept for 24h at +21˚C, with enzyme 
stored at -80°C.  
 
 
4 pmol of in-house CYP2C8 microsomal enzyme (produced from yeast cells; also referred to as 
‘Sacchrosomes’) was first diluted in a 100 mM potassium phosphate buffer (pH 7.6) which contained 
20% (w/v) sucrose, and then aliquoted into wells of a 96-well microtitre plate. The contents of the plate 
were lyophilised. After lyophilisation, the plate was stored at +21°C for 24h before rehydration and 
testing against yeast-CYP2C8 microsomal sample that had been stored at -80°C. Activity was measured 
by kinetic analysis of DBF turnover at Excitation wavelength 530 nm/Emission wavelength 590 nm in a 
100 mM potassium phosphate (pH 7.6) at 37°C. The regenerating system was the standard A.  
 
Graph 6.8 shows that, after 24h at +21°C, the activity of the sucrose-treated and 
lyophilised CYP2D6, obtained from Invitrogen, had similar activity to that of the 
untreated -80°C control. 
 
 
 
 
Lyophilised in-house yeast-CYP2C8  
-80°C control, in-house yeast-CYP2C8  
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Graph 6.8  Comparison of lyophilised Invitrogen’s CYP2D6 enzyme, 
kept for 24h at +21˚C, with enzyme stored at -80°C. 
 
2.5 pmol of Invitrogen CYP2D6 microsomal enzyme (produced from insect cells; also referred to as 
‘Baculosomes’) was first diluted in a 100mM potassium phosphate buffer (pH 7.6) which contained 20% 
(w/v) sucrose, and then aliquoted into wells of a 96-well microtitre plate. The contents of the plate were 
lyophilised. After lyophilisation, the plate was stored at +21°C for 24h before rehydration and testing 
against Invitrogen’s CYP2D6 microsomal sample that had been stored at -80°C. Activity was measured 
by kinetic analysis of AMMC turnover at Excitation wavelength 400 nm/Emission wavelength 460 nm in 
a 100mM potassium phosphate (pH 7.6) at 37°C. The regenerating system was the non-standard A* for 
use with AMMC.  
The kinetics in Graph 6.8 demonstrated once again that sucrose was as effective as a 
P450 cryopreservant with Invitrogen’s CYP2D6 as it had been with CYP2C8 
microsomal samples, obtained from three different sources. 
 
6.4  Conclusions from experiments that determined if the 
‘stabilisation of microsomes’ was specific to yeast and insect 
cell-produced microsomes prepared at De Montfort 
University 
 
The most obvious feature of the data obtained above was that the in-house yeast and 
insect derived CYP-bearing microsomes were not unique. Activity could be maintained 
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 after lyophilisation of all microsomal samples, whatever their source (bacteria, insect or 
yeast cells). Different expression systems could have yielded different levels of 
recovery. This would be because of:  
(1) The tensile strength of intra- and outer-cellular membranes in different 
organisms, very likely, is different.  
(2) The proteins that constitute the microsomes in different organisms are definitely 
different.  
(3) Moreover, the physico-chemical properties of different reagents used in the 
isolation of microsomes from different organisms are also different.  
All these could have affected recovery of P450 activity after lyophilisation.  
Two of the commercial microsomes (from BD-Gentest and Invitrogen) are produced 
from insect cells whereas the Cypex enzymes are derived from a bacterial expression 
system. Insect cell microsomes are similar to yeast cell microsomes in that they both 
belong to the intracellular environment of eukaryotic cells. It would be reasonable to 
expect that the architecture of microsomes derived from all eukaryotic cells would be 
similar although the numbers and the functions of the proteins contained in the 
microsomes could be very diverse.  
Bacterial cells, being prokaryotic, are quite different from eukaryotes in the sense that 
bacteria do not contain intra-cellular compartments. Since they do not contain the 
endoplasmic reticular membranes, the P450s (with reductases and b5) are usually 
purified from the cell and reconstituted as membrane-bound proteins using artificial 
membranes.  
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 A difference between yeast and insect cells is that membrane fluidity in the two types of 
cells is modified by ergosterol and cholesterol, respectively. Further research should be 
able to determine if alteration of these sterols influence membrane fluidity and whether 
these alterations affect the process of lyophilisation (Chen, et al., 2010). Normally, the 
endoplasmic reticulum does not contain these sterols. They are mostly outer cell 
membrane agents. However, cholesterol is often found in the preparation of microsomes 
(Brenner, 1990). There seems to be no clear cut difference between retention and loss of 
activities between the in-house yeast and commercial insect cell-derived microsomes 
post-lyophilisation. This is probably because the endogenous levels of sterols in the 
microsomes are too low.  
The storage buffers, used in different commercial preparations, are all variations on a 
similar theme. However, there are some differences in the concentrations of the 
components of the buffers (see Table 6.1):  
• Three of the four microsome producers use glycerol at 20% (v/v). The other uses 
sucrose in its place at 250 mM which is 8.6 % (w/v).   
• All use Tris buffer but there is a five-fold difference between concentrations 
used, 10 mM to 50 mM, with little pH variance (usually between 7.4 and 7.6). 
• The buffers have a range of EDTA concentrations of between 0.1 mM and 1 
mM, a ten-fold difference. 
It was also a surprise that various suppliers recommend very specific buffers for 
individual CYP-specific activity assays.  
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 Table 6.1.  Components of buffers used by 3 commercial suppliers for re-
suspension of their microsomes compared to that used in the 
preparation of in-house yeast microsomes. 
 
Reagent Invitrogen Cypex BD Gentest In-house yeast 
Glycerol 20% 0 20% 20% 
Sucrose 0 8.6%  (250 mM) 0 0 
Potassium Phosphate 100 mM  (pH 7.5) 0 0 0 
Tris 0 50 mM  (pH 7.6) 
10 mM  
(pH 7.4) 
100 mM  
(pH 7.5) 
EDTA 0.1 mM 0.25 mM 1 mM 0 
DTT 1 mM 0 0 0 
A range of similar buffers are used by different manufacturers for re-suspension of their microsomes 
before supplied as frozen samples, on dry ice, before their use. This has been sourced from supplier-
provided product data sheets.  
 
In order to obtain optimal levels of activities for each P450, a manufacturer re-suspends 
a P450 in buffers where the volumes of different components differ, sometimes greatly, 
depending on a particular P450. Hence, there are differences in the buffer contents used 
for re-suspension of P450s by the three suppliers which may get carried over into the 
final lyophilised product.  
Some P450s received less added cryopreservants and contained more of the formulation 
buffer, respectively, in the following order CYP3A4, CYP2D6 and CYP2C8. The 
specific numbers for this may be seen in Table 6.2 which depicts the “differences in the 
assay well contents due to the nature of the microsome samples and differences in assay 
optimisation”. 
145 
 
 It could be argued that certain samples may recover activity better than others. Since 
there are only subtle variances in the buffer types, mixtures and concentrations, it is 
difficult to envisage that there would be a sudden disastrous loss of activity. This may 
suggest three things:  
(1) The formulation buffers that the microsomes are supplied in may contribute little 
to lyophilisation.  
(2) CYP2C8 data implies that the ratios of P450 to sugar are more or less 
appropriate.  
(3) Since the Invitrogen microsomes and the yeast-derived microsomes, prepared 
in-house, use the same buffers it cannot clearly be stated that there are 
endogenous factors that provide advantages towards lyophilisation of either the 
insect or yeast microsomes.  
Table 6.2.  Differences in the assay well content due to the nature of the 
microsome samples and differences in assay optimisations. 
Sample 
CYPs 
Ratio of 
microsome 
volume to  
sucrose  
buffer 
% 
microsome 
to sucrose 
buffer 
µg of 
sucrose 
per 
well 
[Protein] 
in 
mg.ml-1 
P450 
specific 
content in 
nmol.mg-
1 
Ratio 
of 
protein 
to 
sucrose 
Ratio of 
sucrose 
to 
specific 
content 
Ratio 
of 
sucrose 
to pmol 
of P450 
2D6 
Invitrogen 0.4 27.8 1440 4.2 0.22 345.3 6666.7 576 
2C8 
Gentest 0.7 40 1200 3.5 0.29 342.9 4200.0 300 
2C8 
Cypex 0.8 44 1100 6.0 0.15 186.7 7383.0 280 
In-house 
2C8 ̶  
yeast 
0.7 40 1200 4.1 0.24 292.7 4926.1 300 
These values represent the final formulation of the named reagents in the microplate well for the P450 
activity assays. There was a lot of variability in the different components of these microplates and this 
was because of the nature of the product formulations. 
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 6.5  Experiments to analyse P450 activities in lyophilised yeast 
microsomal samples, prepared in-house, after keeping the 
lyophilised products over longer periods of time at +21˚C 
 
After 24 days at +21°C, the sucrose-treated, lyophilised yeast CYP1A1 demonstrated 
25% loss of activity compared to the untreated -80°C control; Graph 6.9. 
Graph 6.9  Analysis of sucrose-treated, lyophilised CYP1A1, after 24 
days at +21°C. 
 
 
1.5 pmol of yeast CYP1A1 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.6), which 
contained 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 24 days before 
rehydration and testing against the same untreated samples which had been stored at -80°C. Activity was 
measured by kinetic analysis of EROD turnover at Ex 530 nm/Em 590 nm in 100 mM potassium 
phosphate (pH 7.6), at 37°C. The regenerating system was the standard A. The rates of reactions are 
shown and demonstrate that sucrose was quite effective as a P450 cryopreservant when compared with 
the untreated -80°C control, taking into account the error bars, +/- 1x standard deviations. However, the 
mean loss in activity was approximately 25%. 
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After 24 days at +21°C, the sucrose-treated, lyophilised yeast CYP1A2 demonstrated 
40% loss of activity compared to the untreated -80°C control; Graph 6.10. 
Graph 6.10  Analysis of sucrose-treated, lyophilised CYP1A2, after 24 
days at +21°C. 
 
 
1 pmol of yeast CYP1A2 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.6), which 
contained 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 24 days before 
rehydration and testing against the same untreated samples which had been stored at -80°C. Activity was 
measured by kinetic analysis of CEC turnover at Ex 400 nm/Em 460 nm in 100 mM potassium phosphate 
(pH 7.6), at 37°C. The regenerating system was the standard A. The rates of reactions are shown and 
demonstrate that lyophilisation in the presence of sucrose, as a P450 cryopreservant, lost about 40% 
activity compared to untreated -80°C control. Error bars are +/- 1x standard deviation.  
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After 24 days at +21°C, the sucrose-treated, lyophilised yeast CYP1B1 demonstrated 
30% loss of activity compared to the untreated -80°C control; Graph 6.11.  
Graph 6.11  Analysis of sucrose-treated, lyophilised CYP1B1, after 24 
days at +21°C. 
 
 
1.5 pmol of yeast CYP1B1 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.6), which 
contained 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 24 days before 
rehydration and testing against the same untreated samples which had been stored at -80°C. Activity was 
measured by kinetic analysis of EROD turnover at Ex 530 nm/Em 590 nm in 100 mM potassium 
phosphate (pH 7.6), at 37°C. The regenerating system was the standard A. The rates of reactions are 
shown and demonstrate that sucrose was mostly effective as a P450 cryopreservant when compared with 
the untreated -80°C control, taking into account the error bars are +/- 1x standard deviations. However, 
the mean loss in activity was approximately 30%. 
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After 24 days at +21°C, the sucrose-treated, lyophilised yeast CYP2A6 demonstrated 
30% ‘increase’ of activity compared to the untreated -80°C control; Graph 6.12. 
Graph 6.12.  Analysis of sucrose-treated, lyophilised CYP2A6, 
after 24 days at +21°C.  
 
 
1 pmol of yeast CYP2A6 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.6), which 
contained 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 24 days before 
rehydration and testing against the same untreated samples which had been stored at -80°C. Activity was 
measured by kinetic analysis of Coumarin turnover at Ex 400 nm/Em 460 nm in 100 mM potassium 
phosphate (pH 7.6), at 37°C. The regenerating system was the non-standard A*. The rates of reactions are 
shown and demonstrate that sucrose was very effective as a P450 cryopreservant when compared with the 
untreated -80°C control, error bars are +/- 1x standard deviations. The mean gain in activity was 
approximately 30%. 
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After 24 days at +21°C, the sucrose-treated, lyophilised yeast CYP2C8 a poor retention 
of activity, losing approximately 75% of activity compared to the untreated -80°C 
control; Graph 6.13. 
Graph 6.13.  Analysis of sucrose-treated, lyophilised CYP2C8, 
after 24 days at +21°C.  
 
 
4 pmol of yeast CYP2C8 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.6), which 
contained 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 24 days before 
rehydration and testing against the same untreated samples which had been stored at -80°C. Activity was 
measured by kinetic analysis of DBF turnover at Ex 485 nm/Em 530 nm in 100 mM potassium phosphate 
(pH 7.6), at 37°C. The regenerating system was the standard A. The rates of reactions are shown and 
demonstrate that sucrose was not effective as a P450 cryopreservant when compared with the untreated -
80°C control, error bars are +/- 1x standard deviations. The mean value loss in activity was approximately 
75%.  
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After 24 days at +21°C, the sucrose-treated, lyophilised yeast CYP2D6 demonstrated 
minimal loss of activity against the untreated -80°C control; Graph 6.14. 
Graph 6.14  Analysis of sucrose-treated, lyophilised CYP2D6, after 24 
days at +21°C.  
 
 
2.5 pmol of yeast CYP2D6 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.6), which 
contained 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 24 days before 
rehydration and testing against the same untreated samples which had been stored at -80°C. Activity was 
measured by kinetic analysis of AMMC turnover at Ex 485 nm/Em 530 nm in 100 mM potassium 
phosphate (pH 7.6), at 37°C. The regenerating system was the non-standard A*. The rates of reactions are 
shown and demonstrate that sucrose was effective as a P450 cryopreservant when compared with the 
untreated -80°C control, error bars are +/- 1x standard deviations. The mean loss in activity was 
approximately 10%.  
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After 24 days at +21°C, the treated and lyophilised yeast CYP2E1 demonstrated a loss 
of about one third the activity compared to the untreated -80°C control; Graph 6.15. 
Graph 6.15  Analysis of sucrose-treated, lyophilised CYP2E1, after 24 
days at +21°C. 
 
 
2.5 pmol of yeast CYP2E1 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.6), which 
contained 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 24 days before 
rehydration and testing against the same untreated samples which had been stored at -80°C. Activity was 
measured by kinetic analysis of EOMCC turnover at Ex 400 nm/Em 460 in 100 mM potassium phosphate 
(pH 7.6), at 37°C. The regenerating system was the standard A. The rates of reactions are shown and 
demonstrated that sucrose was not effective as a P450 cryopreservant when compared with the untreated -
80°C control, error bars are +/- 1x standard deviations. The mean value loss in activity was approximately 
35%.  
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After 24 days at +21°C, the treated and lyophilised yeast CYP3A4 demonstrated a loss 
of about one sixth of activity against the untreated -80°C control, Graph 6.16. 
Graph 6.16  Analysis of sucrose-treated, lyophilised CYP3A4, after 24 
days at +21°C. 
 
 
1 pmol of yeast CYP3A4 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.6), which 
contained 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 24 days before 
rehydration and testing against the same untreated samples which had been stored at -80°C. Activity was 
measured by kinetic analysis of DBOMF turnover at Ex 400 nm/Em 460 in 100 mM potassium phosphate 
(pH 7.6), at 37°C. The regenerating system was the non-standard A. The rates of reactions are shown and 
demonstrated that sucrose was effective as a P450 cryopreservant when compared with the untreated -
80°C control, error bars are +/- 1x standard deviations. The mean loss in activity was approximately 15%. 
 
6.6  Experimental Conclusions: analysis of in-house yeast-
produced P450-bearing microsomes, lyophilised, and kept 
for 24 days +21˚C 
 
It was noticed that certain P450s had retained activities better than others. Between each 
sample there was a great variance in the protein compositions; Table 6.3.    
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 Table 6.3.  Measurable parameters of the in-house yeast P450s.  
 
Sample Total Microsomal Protein content, mg.ml-1 
Specific P450 content, 
nmol.mg-1 
1A1 10.5 95 
1A2 8.62 116 
1B1 15.2 65.7 
2A6 16.1 44 
2C8 4.1 243.6 
2D6 8.4 119 
2E1 9.1 109.8 
3A4 21.8 42 
The total microsomal protein content of the different P450s had a range of over 4-fold. The specific P450 
content is a measure of the amount of P450 relative to the total protein content had a range of over 5-fold. 
It is possible that these parameters assist the stability after lyophilisation. 
 
CYP3A4 had an unusually high protein content, more than double the mean of all the 
other samples used. It also had a very low specific content and it may be the case that 
extra levels of proteins assist the sucrose in stabilising the P450s after lyophilisation. 
CYP2C8, which showed poorest stability, had the lowest protein content and the highest 
P450-specific content.  
CYP2A6 had an unusual ability to greatly increase its activity after lyophilisation by 
approximately a quarter. Looking at its parameters, it also had the second highest 
protein content and the second lowest P450-specific content. During production, the last 
step of the process creates a gelatinous mass that must manually be homogenised. This 
step is temperature and perhaps time-sensitive. The quality of homogenisation is a 
trade-off against denaturation due to physical stresses. It may be the case that 
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 lyophilisation, in the case of CYP2A6, gave rise to an advantageous reorganisation of 
the microsomes.  
 
6.7 Use of nine cryopreservants, mostly simple carbohydrates, 
in the stabilisation of Cypex’s CYP1A2 
 
The agents used were selected on the basis that they were sugars or that they had been 
used previously in protocols for manufacture of microsomes and, hence, not known to 
be harmful to microsomes.  
All prospective cryopreservants were added to either warm phosphate or Tris buffer 
both at 100 mM, and filter sterilised. The use of phosphate buffer in lyophilisation 
potentially could be a problem. Tris was therefore tested, as Matejtschuk (2007) states 
that for lyophilisation, “phosphate buffers are a no because of pH change and so Tris is 
preferred”. The trial of Tris was considered important as BD-Gentest recommends its 
use with certain P450s. Tris inhibits certain enzymes but there is documented use of 
P450s with Tris (Ghalanbor et al., 2008). Using EDTA as an alternative was not 
considered to be worthwhile since the P450 regeneration system contained the enzyme 
glucose-6-phosphate dehydrogenase, which requires magnesium cations for improved 
activity (Lendzian 1978).  
Cypex’s microsomes from bacteria-expressed P450s were used to investigate the use of 
reconstituted microsomes, so there were no (non-P450 related) proteins upon these 
microsomes. These microsomes should have been far more uniform in production so 
that any effect of the sugar should be more apparent. 
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CYP1A2 obtained from Cypex was lyophilised in the presence of different sugars, 
stored for 12 days at +21˚C; see Graph 6.17. There was a large range of activities 
recovered but it was clear that the samples that contained Tris and also glycerol 
performed badly. 
Graph 6.17  Cypex’s CYP1A2 lyophilised in the presence of different 
sugars, stored at room temperature (+21˚C) for 12 days. 
 
1 pmol of Cypex CYP1A2 was lyophilised in either 100 mM potassium phosphate (pH 7.6) or 100 mM 
Tris. The 50% Tris sample is 50 mM Tris together with 50 mM phosphate buffer. A range of sugars and 
other molecules was used, at 20% (w/v). The microsomes, together with different sugars, were 
lyophilised in microplate wells. These were stored at +21°C for 12 days before rehydration and testing 
against the same untreated samples stored at -80°C. Activity was measured by kinetic analysis of CEC 
turnover at Ex 400 nm/Em 460 nm in 100 mM potassium phosphate (pH 7.6) at 37°C. The regenerating 
system was the standard A. The rates of reactions are shown and demonstrate that glucose, trehalose and 
mannose were better than sucrose. It was also the case that Tris was not better than potassium phosphate. 
Error bars are +/- 1x standard. 
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6.8 Experimental Conclusions from the use of nine 
cryopreservants, mostly simple carbohydrates, for the 
lyophilisation of Cypex’s CYP1A2 
 
The major observation was that Tris did not allow as much recovery of P450 activity as 
the phosphate buffer regardless of the sugar used. Also, glycerol functioned poorly 
regardless as to whether Tris or phosphate buffer was used.  
The use of Cypex’s artificial membrane microsomes meant that it was less likely that 
unusual background reactions may have occurred that may have interfered with the 
outcome.  
In optical assays, sugars can also scatter light (Dreux and Lafosse, 1995). It is feasible 
that some of the lyophilisation agents used interact with the P450s under assay 
conditions. This is not documented in the scientific literature but as water resides in the 
active site of P450s (Section 1.8), it is possible that solutes may interfere with the way 
water binds and releases to the active site.  
The carbohydrates used were 20% (w/v) but upon rehydration usually formed a 
maximum of 9 µl per 100 µl reaction. Therefore, the final maximum reaction 
concentration was just under 2% (w/v) but was still quite high for a component that 
really has no function after rehydration. As percentages were used for comparisons it 
should be noted that, due to their different molecular weights, the reagents used for 
lyophilisation are not all equal in the numbers of molecules per reaction. 
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 Trehalose was interesting as it is the main sugar in the fluids of many insects and 
protects them from freezing and gives rise to protein stabilisation from thermal and 
osmotic stresses (Nelson-Thompson, 2003). Saccharomyces cerevisiae is an industrial 
source of trehalose. It can be forced to produce up to 20% of dry cell weight (Schiraldi 
et al., 2002). It may be logical then to suspect that yeast proteins may be tolerant to high 
levels of trehalose than perhaps other lyophilisation agents. In S. cerevisiae, trehalose 
regulation is so important that trehalose is present at all stages of growth (Souza and 
Panek, 1967).   
 
6.9  To determine if lyophilised P450s could be used for drug 
metabolism studies  
 
Thanks to Dr Jacob Biboy for mass spectrometry guidance.  
While fluorescent P450 assays are very useful for cheap and rapid screening of P450 
inhibitors, they are limited in their ability to detect what may be occurring at a 
molecular level when a P450 reacts with a chemical substrate (i.e. when a P450 reacts 
with a chemical compound, acting as a substrate, to form a metabolite).  
For drug metabolism studies, mass spectrometry is preferred. Therefore, it was 
important to consider if the lyophilisation process would interfere in any way with the 
use of P450s in HPLC/Mass Spectrometric analysis.  
The experiment was performed using in-house CYP2D6-bearing yeast microsomes. The 
lyophilised CYP2D6 samples were produced by lyophilisation in the presence of 20% 
trehalose or mannose. The lyophilised samples were left at 21°C for 72h before 
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 rehydration and testing against the untreated –80ºC CYP2D6 control. The substrate used 
was dextromethorphan hydrobromide which converts to dextromethorphan via a 
dextromethorphan O-demethylase reaction, mediated by CYP2D6.  
Reactions were carried out for 10, 20 and 30 min, and then stopped.  
The CYP2D6 mass spectrometry data, using the enzymes lyophilised in the presence of 
sugars, trehalose and mannose, was formed from the individual time-points of the 
reactions, stopped at 10, 20 and 30 min. The reaction measured conversion of 
dextromethorphan hydrobromide to dextromethorphan by a dextromethorphan O-
demethylase reaction (see Sections 2.22, 2.23). Graph 6.18 depicts the results obtained.  
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 Graph 6.18  A discontinuous composition from data run over three 
time periods; mass spectrometry using in-house yeast 
CYP2D6, lyophilised with two different sugars, and having 
stored at +21˚C for 72h. The substrate for CYP2D6-
mediated reaction was dextromethorphan. 
 
 
3 pmol of yeast CYP2D6 was lyophilised in 100mM potassium phosphate buffer (pH 7.6), containing 
either 20% (w/v) trehalose or mannose in microplate wells. These were stored at +21°C for 72h before 
rehydration and testing against the same untreated samples stored at -80°C. Activity was measured, by 
mass spectrometry, via kinetic turnover of dextromethorphan (MW 370.3) to dextrorphan (MW 356.3) 
through a dextromethorphan O-demethylase reaction (removal of –CH2). Dextromethorphan elutes from 
the column with a retention time of ~8.5 min, whereas the product’s retention time is ~7 min. The 
indivdual reactions were stopped at defined time points after incubation for 10, 20, 30min at 37°C. The 
data was compiled to form a discontinous kinetic curve. The kinetics showed formation of product, in 
nM, and demonstrated that the P450 cryopreservants trehalose and mannose had similar turnovers. There 
was a slight loss of activity in the lyophilised samples against the untreated -80˚C controls, except in the 
case of the mannose control. The results were indicative rather than absolute as small amounts of 
substrate and product binding were a concern. Each mass spectrometry sample run took about 20 min and 
it was a concern that the samples may have either precipitated, bound to the vial or that the product was 
unstable or degraded. This was exacerbated by producing samples in triplicate.  
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6.10  Conclusions from the experiment that determined if 
lyophilised P450s could be used for drug metabolism 
studies 
 
The most interesting phenomenon from the calculated rates of activity was that the 
lyophilised mannose sample gained about 60% more activity than the –80ºC sample. 
However, in the case of trehalose, the –80ºC control with trehalose had an increase of 
25% over the lyophilised sample. Superficially, mannose seemed to be the better 
cryopreservant. However, the –80ºC control with mannose had the least activity and the 
–80ºC control with trehalose seemed to have the best activity.  
Since the –80ºC control with trehalose had better activity than the –80ºC control with no 
sugars, perhaps trehalose may have somehow interfered with the assay itself. This 
would indicate that any increase in activity may not be due to the physical optical 
properties of light being altered by the sugar. It may be intrinsic to the biochemistry of 
the microsomes/P450s which appeared to be influenced by a specific sugar.  
 
6.11  Does the presence of sugar in lyophilised CYP samples alter 
IC50 values? 
 
P450s are widely used for screening chemical libraries for CYP inhibition properties. It 
was important to not just to show stability of the lyophilised P450s with their substrates 
but also that they were not altered in their ability to be inhibited.  
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 The effect of sucrose on P450 active sites, after lyophilisation, was tested in IC50 assays, 
using known inhibitors. Three P450s used for these studies were CYP1A2, CYP2D6 
and CYP3A4 since they are the most important CYP enzymes for drug developmental 
studies. In-house yeast P450s were lyophilised and stored at 21°C for 21 days. The 
lyophilised enzymes were compared, in IC50 determination assays, with the untreated -
80°C in-house yeast samples. Gentest untreated -80°C P450s were used as another 
control.  
 
Graphs 6.19 IC50 values of CYP2D6 inhibition by quinidine: 
comparison of yeast-lyophilised, untreated yeast and 
Gentest enzymes 
2 pmol of yeast-CYP2D6 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.4), containing 
20% (w/v) sucrose in microplate wells. These were stored at +21°C for 21 days before rehydration and 
testing against the same yeast and untreated Gentest samples which had been stored at -80°C. Activity 
was measured by an endpoint reaction after 10 min of EOMCC turnover at Ex 400 nm/Em 460 nm in 100 
mM potassium phosphate (pH 7.4) at 30°C. The enzymes were tested in the presence of the inhibitor 
quinidine at concentrations ranging from 3.4 to 0.00017 µm. The regenerating system was the standard A. 
The endpoint values were scaled against positive and negative control samples. The data was analysed 
using GraphPad Prism which calculated the IC50 values. The IC50 values demonstrated that not only that 
yeast lyophilised P450s (c) had fidelity with the -80°C yeast samples (b) but also with the -80°C Gentest 
P450 (a). The published IC50 of quinidine is < 0.3 µM in human liver microsomes (Donato et al., 2004). 
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Graphs 6.20 IC50 values of CYP3A4 inhibition by ketoconazole: 
comparison of yeast-lyophilised, untreated yeast and 
Gentest enzymes 
 
 
1 pmol of yeast-CYP3A4 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.4), containing 
20% (w/v) sucrose in microplate wells. These were stored at +21°C for 21 days before rehydration and 
testing against the same yeast and untreated Gentest samples which had been stored at -80°C. Activity 
was measured by an endpoint reaction after 10 min of DBF turnover at Ex 485 nm/Em 538 nm in 100 
mM potassium phosphate (pH 7.4) at 30°C. The enzymes were tested in the presence of the inhibitor 
ketoconazole at concentrations ranging from 1.95 to 0.061 µm. The regenerating system was the standard 
A. The endpoint values were scaled against positive and negative control samples. The data was analysed 
using GraphPad Prism which calculated the IC50 values. The IC50 values demonstrated that not only yeast 
lyophilised P450s (c) had fidelity with the -80°C yeast samples (b) but also with the -80°C Gentest P450 
(a). The published IC50 value of ketoconazole is < 0.3 µM in human liver microsomes (Donato et al., 
2004). 
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 Graphs 6.21 IC50 values of CYP1A2 inhibition by furafylline: 
comparison of yeast-lyophilised, untreated yeast and 
Gentest enzymes 
 
 
1 pmol of yeast-CYP1A2 was lyophilised in a 100 mM potassium phosphate buffer (pH 7.4), containing 
20% (w/v) sucrose buffer in microplate wells. These were stored at +21°C for 21 days before rehydration 
and testing against the same yeast and untreated Gentest samples which had been stored at -80°C. 
Activity was measured by an endpoint reaction after 10 min of CEC turnover at Ex 409 nm/Em 460 nm in 
100 mM potassium phosphate (pH 7.4) at 30°C. The enzymes were tested in the presence of the inhibitor 
furafylline at concentrations ranging from 31.25 to 0.0305 µm. The regenerating system was the standard 
A. The endpoint values were scaled against positive and negative control samples. The data was analysed 
using GraphPad Prism which calculated the IC50 values. The IC50 values demonstrated not only that yeast 
lyophilised P450s (c) had fidelity with their -80°C yeast samples (b) but also with the -80°C Gentest P450 
(a). The published IC50 of Furafylline is 6.2 µM in human liver microsomes (Donato et al., 2004). 
 
  
IC50 of Furafylline using yeast stabilised CYP1A2 after 21 days at 21°C 
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 6.12  Conclusions from the experiment that attempted to answer 
the question, does the presence of sugar in lyophilised CYP 
samples alter IC50 values? 
 
With the CYP2D6, CYP3A4 and CYP1A2, the IC50 values in all the untreated yeast 
minus 80°C enzymes were very close to the yeast P450 enzymes that had been 
lyophilised and stored at 21°C for 21 days. The IC50 values in untreated minus 80°C 
Gentest CYPs 2D6, 3A4 and 1A2 enzymes were close to the values obtained using both 
treated and untreated yeast P450 enzymes. This experiment was very important to 
demonstrate that the nature of the lyophilised P450s was not altered in a way that would 
change their relationship with their inhibitors.   
 
6.13  Does lyophilisation affect the use of different substrates for 
enzyme activity studies? 
 
Up to this point, the enzyme CYP2D6 has been used together with BD-Gentest’s 
substrate, AMMC. Invitrogen’s EOMCC substrate may also be used for CYP2D6 
fluorescent microplate assays. Invitrogen do not offer structural details for EOMCC. 
AMMC is a coumarin derivative, 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-
methoxy-4-methylcoumarin (Chauret, 2001). EOMCC may not be a coumarin-based 
molecule. This experiment was to test if lyophilisation had an effect on the ability of a 
P450 to interact with different substrates.  
There were two important observations in the experiment where CYP2D6 activity was 
tested, using AMMC as a substrate.  
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 (1) For both the in-house yeast and BD-Gentest CYP2D6 the presence of sucrose 
did not seem to alter the activities between the untreated control –80˚C and the 
lyophilised sample; see Graph 6.22.  
(2) Gentest’s CYP2D6 had much more activity than the in-house yeast CYP2D6. 
Graph 6.22  CYP2D6 enzyme activities using AMMC as a substrate.  
 
 
2.5 pmol of yeast and Gentest CYP2D6 was lyophilised in 100 mM potassium phosphate buffer (pH 7.6), 
containing 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 7 days before 
rehydration and testing against the same untreated samples stored at -80°C. Activity was measured by 
kinetic analysis of AMMC turnover at Ex 485 nm/Em 530 nm in a100 mM potassium phosphate (pH 
7.6), at 37°C. The regenerating system was the non-standard A*. The rates of reactions are shown and 
they demonstrate that sucrose was effective as a P450 cryopreservant when compared with the untreated 
control (i.e. enzymes which had been stored at -80°C), error bars are +/- 1x standard deviations.  
 
Using EOMCC, the above trend holds implying that the untreated –80˚C control and 
lyophilised samples do not differ much in their activities. Also there was much less 
variance between the in-house yeast and BD Gentest samples; see Graph 6.23.  
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 Graph 6.23  CYP2D6 enzyme acitivities using EOMCC as a substrate. 
 
 
2.5 pmol of yeast and Gentest CYP2D6 was lyophilised in a 100 mM potassium phosphate buffer (pH 
7.6), containing 20% (w/v) sucrose, in microplate wells. These were stored at +21°C for 7 days before 
rehydration and testing against the same untreated samples stored at -80°C. Activity was measured by 
kinetic analysis of EOMCC turnover at Ex 400 nm/Em 460 nm in 100 mM potassium phosphate (pH 7.6), 
at 37°C. The regenerating system was the standard A. The rates of reactions are shown and again 
demonstrate that sucrose was effective as a P450 cryopreservant against the untreated -80°C control, error 
bars are +/- 1x standard deviations. Like AMMC, EOMCC did not demonstrate any diffrences between 
the untreated -80˚C controls and the lyophilised samples. This was the case for both sets of microsomes, 
one originating from yeast and the other from insect cells.  
 
6.14  Conclusions from the experiment that attempted to answer 
the question, does lyophilisation affect the use of different 
substrates during specific enzyme activity studies? 
 
The use of two substrates AMMC (chemical structure known) and EOMCC (chemical 
structure known) in assessing the activities of CYP2D6 enzyme, lyophilised in the 
presence of a sugar, indicate that there is no obvious augmentation or reduction of 
activity specifically towards one substrate.  
The differing activities between in-house yeast and BD Gentest using AMMC may 
possibly be explained by the fact that BD Gentest had a patent for AMMC 
(WO/2000/004008) and published a paper on its use (Chauret, 2001). It may be that 
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 BD-Gentest used chemical-biological techniques to optimise for the best activity of 
CYP2D6 using the specific substrate, AMMC.  
 
6.15  Determination of the effects of escalating concentrations of 
sugars on the activities of lyophilised CYP3A4 
 
20% (w/v) of sugars had been successful in preserving P450-bearing microsomes after 
lyophilsation for some periods of time. But the validity of this amount of sugar that was 
used for lyophilisation required further testing.  
Escalating amounts of cryopreservants were tested to check if enhancement of the 
amounts of sugars used for the process of lyophilisation would provide greater stability 
of P450s. For this experiment, samples of CYP3A4 (produced in-house) were chosen. 
They were lyophilised in the presence of increasing doses of sucrose and mannose, 
followed by storage for 72h at ambient temperature (+21°C). 
Graph 6.24 shows that:  
(a) Increasing concentrations of sucrose did not seem to cause much variation in 
activity in untreated –80ºC control CYP3A4 enzymes, and  
(b) A concentration of sucrose between 4 and 9% (w/v) was sufficient to maintain 
activity in lyophilised CYP3A4 sample; adding a higher concentration of 
sucrose was not of great benefit.  
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 Graph 6.24  Measurement of activity of CYP3A4 samples, lyophilised in 
the presence of escalating concentrations of sucrose, and 
then keeping for 72h at 21°C. 
1 pmol of yeast CYP3A4 was lyophilised in 100 mM potassium phosphate buffers (pH 7.6), containing 
increasing concentrations of sucrose, in microplate wells. The lyophilised samples were stored at +21°C 
for 72h before rehydration and testing against the same untreated CYP3A4 samples stored at -80°C. 
Activity was measured by kinetic analysis of DBOMF turnover at Ex 485 nm/Em 530 nm in 100 mM 
potassium phosphate (pH 7.6) at 37°C. The regenerating system was the non-standard A. The rates of 
reactions are shown and demonstrate that sucrose was effective as a P450 cryopreservant when compared 
with the untreated -80°C controls and sucrose levels above 9% did not add much value. Error bars are +/- 
1x standard deviations. 
 
Graph 6.25 shows that:  
(a) Although different concentrations of mannose have very little effect on untreated 
–80ºC CYP3A4 control enzymes,  
(b) Lyophilised samples lost a significant amount of activity in the presence of 
mannose; however, it appeared that activities increased with increasing 
concentrations of mannose.  
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 Graph 6.25. Measurement of activity of CYP3A4 samples, lyophilised in 
the presence of escalating concentrations of mannose, and 
then keeping for 72h at 21°C.  
 
 
1 pmol of yeast CYP3A4 was lyophilised in 100 mM potassium phosphate buffers (pH 7.6), containing 
increasing concentrations of mannose, in microplate wells. These were stored at +21°C for 72h before 
rehydration and testing against the same untreated CYP3A4 samples stored at -80°C. Activity was 
measured by kinetic analysis of DBOMF turnover at Ex 485 nm/Em 530 nm in 100 mM potassium 
phosphate (pH 7.6) at 37°C. The regenerating system was the non-standard A. The rates of reactions are 
shown and demonstrate that extra mannose only caused rates to decrease compares to the untreated -80°C 
control CYP3A4 samples, irrespective of the concentrations of mannose. Error bars are +/- 1x standard 
deviations. 
 
6.16  Conclusions from the experiment that determined the 
effects of escalating concentrations of sugars (sucrose and 
mannose) on the activities of lyophilised CYP3A4 
 
(1) CYP3A4 enzyme samples required 36% or higher mannose levels to recover a 
useful level of activity.  
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 (2) Levels of sucrose of around 9% appeared to be enough to preserve most 
CYP3A4activity after lyophilisation.  
It was concluded that the sugar, sucrose, consistently performed as a cryopreservant and 
that it would not be worthwhile going forward with mannose, as a cryopreservant, any 
further.  
 
6.17  Long-term storage at +21°C and shipping of lyophilised 
P450s, without dry ice 
 
CYP1A2 was tested for long-term stability at ambient laboratory temperature, 21°C, in-
house. For comparison’s sake, a lyophilised CYP1A2-containing microplate was sent to 
a large biopharmaceutical company who had experience in using P450 assays. 
Alongside, a frozen sample of un-lyophilised CYP1A2 was shipped on dry ice. Both 
packages were sent by aeroplane to the USA and then from the airport by road, for the 
remainder of the journey. Both CYP1A2 samples were in phosphate buffer that 
contained 20% (w/v) sucrose.  
It was found that in the lyophilised sample, CYP1A2 activity was maintained even after 
95 days of storage. This was considered a very successful outcome. Graph 6.26 shows 
the results.  
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 Graph 6.26  Activity of CYP1A2, lyophilised in the presence of sucrose, 
and kept for 95 days at ambient temperature +21˚C; tested 
in-house. 
 
 
1 pmol of yeast CYP1A2 was lyophilised in 100 mM potassium phosphate buffer (pH 7.6), containing 
20% (w/v) sucrose, in microplate wells. The plate was stored at +21°C for 95 days before rehydration and 
testing against the same untreated CYP1A2 samples, stored at -80°C. Activity was measured by kinetic 
analysis of CEC turnover at Ex 400 nm/Em 460 nm in 100 mM potassium phosphate (pH 7.6), at 37°C. 
The regenerating system was the standard A. The lyophilised CYP1A2 samples retained most of their 
activity over 95 days when compared with the untreated CYP1A2 control enzyme which had been stored 
at-80°C. Error bars are +/- 1x standard deviation. 
 
For the transit test, CYP1A2 sucrose microplates were made and sent to the third party 
by air frieght and tested in their laboratory against untreated control CYP1A2 sent on 
dry ice. Both samples showed similar activities, with standard deviations, Graph 6.27. 
The third party’s report stated that the P450 activity of the lyophilised CYP1A1 was 
“slightly less” than the untreated –80ºC control after international shipment at ambient 
temperature and several weeks in their laboratory at ambient temperature.  
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 Graph 6.27  Activity of CYP1A2, lyophilised in the presence of sucrose, 
and kept for 95 days at ambient temperature +21˚C; tested 
by third-party (a multi-national biopharma). 
 
 
1 pmol of yeast CYP1A2 was lyophilised in 100 mM potassium phosphate (pH 7.6), containing 20% 
(w/v) sucrose, in microplate wells. After 4 weeks the plates were shipped by air and road to the USA at 
varying ambient temperatures and stored at +21°C for 2 months before rehydration and tested against the 
same untreated CYP1A2 samples that had been stored at -80°C. Activity was measured by kinetic 
analysis of CEC turnover at Ex 400 nm/Em 460 nm in 100 mM potassium phosphate (pH 7.6), at 37°C. 
The regenerating system was the standard A. The lyophilised CYP1A2 samples retained most of their 
mean activities when compared with control untreated CYP1A2 enzyme that had been stored at -80°C 
over the same period. Using the error bars (+/- 1x standard deviation) the activities look similar. 
 
6.18  Conclusions from the long-term storage experiment where 
CYP1A2 samples had been stored at +21C or kept at varying 
ambient temperatures, over a period of 95 days, after 
lyophilsation 
 
The fact that the activity was maintained after 95 days at an ambient laboratory 
temperature (+21°C) confirms that lyophilisation is a pivotal step towards the wider 
global use of P450 microsomal enzymes which are highly temperature labile. The 
results emphasised that lyophilised P450 enzymes:  
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 (1) Can be kept at varying ambient temperatures during inter-continental shipment, 
and 
(2) Could be used by different people and with pieces of equipment remote from the 
ones that were used for development of the P450 assay at De Montfort 
University.  
 
6.19  Chapter Summary: Conclusions 
 
The work described above forms a solid proof of principle or feasibility study towards 
establishing a process that would allow fragile P450-bearing microsomal enzymes to be 
routinely lyophilised in a way that enzyme activity could be maintained even after 
keeping the enzymes at ambient temperatures for long periods of time (i.e. up to 95 
days). This work also demonstrates that there is scope for further studies that may allow 
the formulation of a product that has significantly longer lifespan, at sensible ambient 
temperatures. Since  
(a) The P450 enzymes are structurally quite complex and  
(b) There are varieties of lyophilised P450 products that could be envisaged for 
different uses,  
there are still a lot of possible variables to test.  
While the concept of P450 lyophilisation may be there in the literature, all published 
work refer to lyophilisation of ‘inactive’ purified P450 proteins (i.e. shorn of 
membranes). The work done in this thesis is unique, since it is the first to lyophilise 
fragile P450 microsomal complexes as viable, active enzymes.  
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 Some relevant papers, which have previously described P450 lyophilisation, are 
individually discussed below. The last few examples are noted briefly as they are less 
relevant.  
Lotlikar et al., (1976) have described the need for phospholipids for correct function of 
the P450s. Lyophilisation was used to remove water from membrane-less P450s before 
solvents were used to extract purified P450 proteins; see Table 6.4.  
Table 6.4.  Differences between current work and Lotlikar et al (1976) 
Parameter Lotlikarr’s work Current work Important Difference(s) 
Material used Hamster liver microsomes. 
Recombinant yeast P450 
microsomes (also from 
other expression 
sources, but to a lesser 
degree). 
The large amount of junk 
protein content in hamster 
liver microsomes perhaps 
protects them? 
Cryopreservant None; used only water. 
Used various agents 
mostly sugars. Self-explanatory. 
Freeze drying Dried to powder. Dried to thick gel (film) 
No real detail of method 
in the paper. 
Sample storage -15°C Ambient lab temp, 21°C. Self-explanatory. 
Stability 
1 to 2 weeks, 
for purified 
inactive 
protein. 
Many months. Self-explanatory. 
 
Mulligan (2008) published a paper with a description of products offered by Codexis 
Inc; see Table 6.5.  
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 Table 6.5. Differences between current work and Mulligan (2008). 
Parameter Mulligan’s work Current work Important difference(s) 
Material 
Recombinant 
lyophilised P450 
powder. Only 
mentions bacterial 
enzymes, not 
microsomes. 
Use of bacterial fusion 
enzyme of P450 & 
P450 reductase. 
Recombinant yeast 
P450 microsomes (also 
from other expression 
sources, but to a lesser 
degree). 
Use of separate 
proteins. 
Microsomes contain a 
sugar for proper P450 
function. 
Fusion proteins, 
produced in yeast, may 
provide the same data 
as separate P450 and 
P450 reductase. 
Use No mention of storage or stability. 
Characterised storage 
& stability. Self-explanatory. 
 
There is a patent that describes plant P450s in the context of lyophilisation 
[International patent application WO2008/047112 A1 (Casey & Hughes, 2008)]; main 
relevant pages are: 15, 16, 43, 44, 45, 53 and 54; comparative results described in Table 
6.6. 
Table 6.6.  Differences between current work and patent application 
WO2008/047112 A1. 
Parameter Patent’s claims Current work Difference 
Material 
Plant P450s enzymes, 
specifically CYP74, 
includes purification of 
protein as His-tags, not 
as microsomes 
Recombinant yeast 
P450 microsomes 
(also from other 
expression sources, 
but to a lesser degree).  
Plants have very 
different membrane 
structures from yeast 
cells; examples in 
patent does not use 
microsomes 
Detergents 
Requirement of 
detergents for 
hydration, to obtain 
activity 
No detergents used Self-explanatory 
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 Aikawa et al (1976) used lyophilised S9 fractions which are intermediates in the process 
of producing microsomes; see Table 6.7. 
Table 6.7.  Differences between current work and Akawa et al (1976) 
Parameter Aikawa’s work Current work Important Difference(s) 
Material 
Liver S9 fractions 
from rat, mouse, 
guinea pig, rabbit 
and dog; not 
microsomes. 
Recombinant yeast 
P450 microsomes 
(also from other 
expression sources, 
but to a lesser degree). 
The massive 
amount of junk 
protein content in 
animal liver 
microsomes 
perhaps have a 
protective effect. 
Stability 
No activity change 
after lyophilisation 
for one month at  
-20ºC. 
Stored over one 
month at ambient lab 
temperature, ~21°C. 
Self-explanatory. 
Cryopreservation 
No mention of 
cryopreservation 
agents. 
Use of 
cryopreservation 
agents. 
Self-explanatory. 
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 Kamataki and Kitagawa (1974) published their paper on storage of rat liver 
microsomes; see Table 6.8.  
Table 6.8. Differences between current work and Kamataki and Kitagawa, 
(1974). 
Parameter Kamataki and Kitagawa’s work Current work 
Important 
Difference (s) 
Material 
Rat liver 
microsomes (but 
also S9 fractions 
and microsome 
supernatants). 
Recombinant yeast P450 
microsomes (also from other 
expression sources, but to a 
lesser degree).  
The massive 
amount of junk 
protein content in 
animal liver 
microsomes 
perhaps has a 
protective effect. 
Storage Storage at –20ºC. Stored at ambient lab temperature, ~+21°C. Self-explanatory. 
Stability 
Quote from paper 
“S9 fractions 
were more stably 
stored than 
microsomes”. 
Used microsomes. 
It is a common 
perception that 
soluble proteins 
are easy to 
lyophilise but 
microsomes are 
not easy. 
 
Leibman (1983) worked on storage of liver and lung preparations, Table 6.9. 
Table 6.9.  Differences between current work and Leibman, (1983). 
Parameter Leibman’s work Current work Important difference(s) 
Material Rat liver and lungs. 
Recombinant yeast P450 
microsomes (Also other 
expression sources to a 
lesser degree). 
The massive amount of 
junk protein content in 
animal microsomes 
perhaps protects them. 
Storage –15°C. 
Stored at ambient lab 
temperature approx 
+21°C. 
Self-explanatory. 
Stability 
Only recommend 
several weeks’ storage 
before activity loss 
becomes a problem. 
Characterised longer than 
several weeks. Self-explanatory. 
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Iwata et al (1996) freeze-dried isolated mouse liver microsomes for purification of 
proteins from the microsomes for non-active protein studies. Oddly enough, the paper 
describes large-scale preparation of microsomes with a low speed centrifuge. It does not 
discuss the use of cryopreservants and does not mention any activity of microsomal 
enzymes.  
Chefson et al (2007) described in their paper (“His-select P450 with a nickel affinity 
gel”) purification of histidine-tagged P450 proteins, not microsomes.  
A paper by Nakhgevany et al (1996) is about P450 proteins purified from rabbit 
microsomes. 
On the basis of a lack of publications in the specific area of research that has been 
described in this Chapter of the thesis, it was decided to file for a patent application so 
that the work could be protected to explore further new applications of lyophilised 
microsomal P450 enzymes [Stabilisation, WO 2010010343 A1, Chaudhuri, et al., 
(2008)].   
 
6.20 ABSTRACT of the filed Patent Application from De Montfort 
University 
 
A dried composition comprising a membrane-associated recombinant cytochrome P450 
(CYP) enzyme, wherein the CYP enzyme is stable at 21°C for a period of at least 10 
days, and preferably for at least 3 months. A method of storing a recombinant 
membrane-associated CYP enzyme, the method comprising providing a recombinant 
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 membrane-associated CYP enzyme, freeze-drying the CYP enzyme, and storing the 
dried CYP enzyme at room temperature.  
 
6.21 Future work 
 
Development of lyophilised products also involves experimenting simultaneously with 
many different variables. The main problem faced was that some procedures could be 
quite involved, costly and required a lot of set-up and waiting time periods.  
The lyophilisation work was done with a very basic machine that had no changeable 
settings. As the machine did not have cooled shelves, the risk of the product thawing 
before lyophilisation was a worry. With a more sophisticated machine the shelves can 
keep the samples frozen before lyophilisation, the temperature ramping and vacuum 
strength could be changed, and a secondary drying process could be performed. More 
sophisticated lyophilisation equipment, than what has been used here, should be able to 
optimise the procedure and produce more consistent results.  
The use of electron microscopy may be useful for testing different sugars and methods, 
providing an insight to the specific structural changes that occurs in the presence of 
sugars which, in turn, could be correlated to more successful long-term stability. This 
may also allow prediction of the outcome with the use of new sugars without waiting 
for months for results. 
All new applications of stabilised P450s would implicitly involve ease of use. A simple 
application, which has been considered for drug metabolism studies, is providing a 
P450 or multiple P450s on a microtitre plate which could directly be used for assaying 
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 just by the addition of water and test candidates. This would greatly benefit a laboratory 
user with limited experience and equipment.  
With the proven ability to produce thermostable P450s, diverse P450s could be 
stabilised for use as kits that could be used in the field by persons testing samples in 
adverse conditions. For example, kits could be created for testing of:  
(a) The quality of water following chemical spills,  
(b) Chemical weapon agents in war zones, and  
(c) Toxic agents in developing countries for routine toxicological testing.  
These would require developing colorimetric metabolites and inhibition profiles of key 
enzymes. Toxic compounds, as either competitive or non-competitive inhibitors, would 
prevent formation of a colour. Smart phone camera applications would be able to assess 
colours and then could be used to quantify the outcome, for example, results obtained 
by Choodum et al (2013).  
The work done by Maves and Sligar (2001) which attempted to understand what makes 
the P450s function in hotter climates could be applied to create fully thermostable 
lyophilised P450s for use in very hot places.  
Ideally, the formulation of insoluble lyophilisation agents could be used to encapsulate 
P450s. This would allow P450s to be used for bioremediation and biotransformations. 
These encapsulated P450s could be packed into columns and used to perform cleaning 
operations or chemical transformations and allow the products to be quickly and easily 
separated. Finally, P450s stabilised onto microarray chips could be used to form highly 
sophisticated screens of drug candidates and medical toxicology samples.  
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